Anti-malarial drug
By developing compounds targeting plasmepsin X and IX, the problem of drug resistance in existing malaria treatments was solved, and effective inhibition of Plasmodium falciparum and therapeutic effects of malaria were achieved.
Patent Information
- Application Number
- CN202280091113.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-08-12
- Filing Date
- 2022-12-05
- Publication Date
- 2024-11-08
Smart Images

Figure CN118922422A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in treating Plasmodium infection. More specifically, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in treating Plasmodium infection, especially for treating malaria. Background Art
[0002] Malaria is a major disease in humans, infecting hundreds of millions of people and killing over 450,000 people each year. The most lethal form of malaria is caused by Plasmodium falciparum. This protozoan parasite is responsible for nearly all malaria deaths, most of which occur in Africa. Plasmodium falciparum has a complex life cycle, beginning with the Anopheles mosquito vector, which injects its sporozoite form into the human host during a blood meal. These sporozoites migrate to the liver and invade hepatocytes, where they develop into thousands of hepatic merozoites. These merozoites then enter the bloodstream and invade red blood cells, beginning the parasite's asexual cycle and causing the symptoms of malaria. The parasite develops within the protected environment of the red blood cell, producing 16-32 merozoites. Once mature, they escape from the host cell and invade new red blood cells. Some of these parasites differentiate into gametocytes, the parasite's sexual form. These gametocytes are ingested by mosquitoes, where they form male and female gametes within the extracellular matrix of the mosquito's midgut, fuse, and differentiate into oocysts. Sporozoites form within the oocysts, escape, and migrate to the salivary glands to be passed to the next host during a mosquito blood meal, thus enabling the continuation and survival of the parasite.
[0003] Other forms of malaria include relapsing forms of malaria caused by Plasmodium vivax, which is a cause of significant morbidity, can cause virulent and sometimes fatal disease, and is endemic primarily outside of Africa. Plasmodium knowlesi is a zoonotic parasite found in Southeast Asia that typically infects long-tailed macaques but has been shown to infect humans in Malaysian Borneo.
[0004] Artemisinins combined with paired drugs have become the mainstay of malaria treatment and control. However, due to the increasing threat of resistance to artemisinin-based combination therapies (ACTs), the development of new antimalarial drugs with novel targets that inhibit multiple steps in the parasite life cycle has become a top priority for malaria control. These new antimalarials, whether used as monotherapy or in ACT pairs, hold promise for progress toward malaria elimination by reducing the likelihood of pre-existing drug-resistant mutants in parasite populations.
[0005] Currently, aspartic proteases are the main targets for drug development: HIV aspartic proteases have been successfully targeted with clinically used drugs; inhibitors targeting human renin, BACE1 and γ-secretase have been or are in clinical development. In the field of antimalarial drugs, the aspartic proteases plasmepsin X and IX (PMX and PMIX) of Plasmodium falciparum have been identified as potential targets because inhibitors can block the parasite's escape and invasion of host cells and prevent the maturation of some rhoptry and microneme proteins required for this process (Pino P, Caldelari R, Mukherjee B, Vahokoski J, Klages N, Maco B et al. A multistage antimalarial targets the plasmepsins IX and X essential for invasion and egress. Science. 2017; 358(6362): 522-8). Summary of the Invention
[0006] The present invention relates to compounds of formula (I):
[0007]
[0008] Among them A, X, V, Y, Z, R a , R b , R 3 , R 4 , R 12 , R 13 , R 15 , m and p are as follows.
[0009] The present invention also describes a method for treating a Plasmodium infection, comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need of such treatment. The present invention also describes a method for treating a Plasmodium infection, comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier to a subject in need of such treatment.
[0010] The present invention also describes a method of treating malaria comprising administering to a subject in need of such treatment a compound of formula (I) or a pharmaceutically acceptable salt thereof.
[0011] The present invention also provides for the use of compositions for treating malaria, including pharmaceutical compositions comprising one or more compounds of the invention (e.g., a compound of the invention), or a tautomer thereof, or a pharmaceutically acceptable salt or solvate of the compound and / or the tautomer, optionally together with one or more additional therapeutic agents, optionally in an acceptable (e.g., pharmaceutically acceptable) carrier or diluent.
[0012] In addition, the present invention provides methods for treating Plasmodium infections, treating malaria, inhibiting plasmepsin X, or dually inhibiting plasmepsin X and plasmepsin IX using pharmaceutical compositions comprising one or more of the compounds (in free form or in pharmaceutically acceptable salt form) and one or more conventional pharmaceutical excipients. The present invention also provides methods for using a combination of the compounds or salts of the present invention in combination with one or more additional pharmaceutically active agents.
[0013] The present invention also provides methods for inhibiting plasmepsin X, or dually inhibiting the activity of plasmepsin X and plasmepsin IX, and treating, preventing, ameliorating and / or delaying the onset of a disease or condition (e.g., malaria), wherein the inhibition of plasmepsin X and / or plasmepsin IX has or may have a therapeutic effect.
[0014] The present invention also provides a method for inhibiting Plasmodium falciparum aspartic protease. The present invention also provides a method for blocking the growth of Plasmodium falciparum by inhibiting plasmepsin X. The present invention also provides a method for blocking the growth of Plasmodium falciparum by dual inhibition of PMX and plasmepsin IX.
[0015] The present invention also provides a method for treating malaria by inhibiting plasmepsin X. The present invention also provides a method for treating malaria by dual inhibition of PMX and plasmepsin IX.
[0016] These and other embodiments of the invention, which are described in detail below or which become apparent to those skilled in the art, are within the scope of the present invention. DETAILED DESCRIPTION
[0017] Described herein are compounds having structural formula (I):
[0018]
[0019] Where A is a straight chain or branched chain, saturated or unsaturated (C3-C 10 ) alkylene, phenyl (C3-C10 ) alkylene or cycloalkyl (C3-C 10 ) alkylene, comprising at least one -CH2- group, wherein one or more additional -CH2- groups in A are optionally and independently replaced by a moiety selected from O, S, NR, CONR, NRCO, SO2 and SO2NR, and one or more hydrogen atoms along A may be independently selected from hydroxy, halogen and C 1-3 group substitution of haloalkyl groups;
[0020] X is a bond, C(R 14 )2, O, S, SO, SO2 or NH;
[0021] Y is CR 9 or N, where when Y is N, Z is CR 11 And V is CR 10 ;
[0022] V is CR 10 or N, where when V is N, Z is CR 11 And Y is CR 9 ;
[0023] Z is CR 11 or N, where when Z is N, V is CR 10 And Y is CR 9 ;
[0024] R is hydrogen, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, COC1-C6 alkyl or COOC1-C6 alkyl;
[0025] R a is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhalogenated C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 ), or when combined with R bWhen taken together, they form a C3-C6 cycloalkyl or heterocycloalkyl group, wherein the C3-C6 cycloalkyl or heterocycloalkyl group is unsubstituted or substituted with one or two substituents selected from the group consisting of halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhaloC1-C6 alkyl, haloC1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) and C1-C6 alkyl N(R 7 )(R 8 );
[0026] R b is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhalogenated C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 ), or when combined with R a When taken together, they form a C3-C6 cycloalkyl or heterocycloalkyl group, wherein the C3-C6 cycloalkyl or heterocycloalkyl group is unsubstituted or substituted with one or three substituents selected from the group consisting of halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhaloC1-C6 alkyl, haloC1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) and C1-C6 alkyl N(R 7 )(R 8 );
[0027] R 3 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 )、C1-C6 alkyl N(R 7 )(R 8 ), C1-C6 alkyl (OCH2CH2) n N(R 7 )(R 8 ) or C1-C6 alkyl O halo C1-C6 alkyl, or when with R 4 When taken together, they form a C3-C6 cycloalkyl group or a C3-C6 heterocycloalkyl group;
[0028] R 4 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 )、C1-C6 alkyl N(R 7 )(R 8 ), C1-C6 alkyl (OCH2CH2) n N(R 7 )(R 8 ) or C1-C6 alkyl O halo C1-C6 alkyl, or when with R 3 When taken together, they form a C3-C6 cycloalkyl group or a C3-C6 heterocycloalkyl group;
[0029] R 7 is hydrogen, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, COC1-C6 alkyl or COOC1-C6 alkyl;
[0030] R 8 is hydrogen, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, COC1-C6 alkyl or COOC1-C6 alkyl;
[0031] R9 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 ).
[0032] R 10 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 );
[0033] R 11 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 );
[0034] R 12 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 );
[0035] R 13is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 );
[0036] R 14 Each occurrence of is independently selected from the group consisting of hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) and C1-C6 alkyl N(R 7 )(R 8 );
[0037] R 15 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 );
[0038] R 16 Each occurrence of is independently selected from the group consisting of hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) and C1-C6 alkyl N(R 7 )(R 8 );
[0039] m is 0 or 1;
[0040] n is 1, 2, 3 or 4; and
[0041] p is 0 or 1.
[0042] In the embodiments described herein, X is a bond, C(R 14 )2, O, S, SO, SO2 or NH. In certain embodiments described herein, X is a bond. In certain embodiments, X is C(R 14 )2, where R 14 As discussed in further detail below. In certain embodiments, X is a bond, CH2, CH(CH3), C(CH3)2, O, CH(OCH3), SO2, or CF2. In other embodiments, X is CH2, O, S, SO, SO2, or NH. In certain embodiments, X is CH2. In the embodiments described herein, X is O. In certain embodiments described herein, X is S. In certain embodiments described herein, X is SO. In other embodiments described herein, X is SO2. In certain embodiments described herein, X is NH.
[0043] In the embodiments described herein, Y is CR 9 Or N. In certain embodiments, Y is CR 9 , where R 9 This will be discussed in detail below. In certain embodiments, Y is N. In certain embodiments, Y is CH. In certain embodiments, when Y is N, Z is CR 11 And V is CR 10 .
[0044] In the embodiments described herein, V is CR 10 or N. In certain embodiments, V is CR 10 , where R 10 This will be discussed in detail below. In certain embodiments, V is N. In certain embodiments, V is CH. In certain embodiments, when V is N, Z is CR 11 And Y is CR 9 .
[0045] In the embodiments described herein, Z is CR 11 or N. In certain embodiments, Z is CR 11 , where R 11 This will be discussed in detail below. In certain embodiments, Z is CH. In certain embodiments, Z is N. In certain embodiments, when Z is N, V is CR 10 And Y is CR 9 .
[0046] In certain embodiments, X is O, Y and V are each CH, and Z is N. In certain embodiments, X is O, Y and Z are each CH, and V is N. In certain embodiments, X is O, and V, Y, and Z are all CH.
[0047] In the compounds described herein, R a is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylO C1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhalogenated C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 ) or when with R b together to form a C3-C6 cycloalkyl or heterocycloalkyl, wherein the C3-C6 cycloalkyl or heterocycloalkyl may be unsubstituted or substituted by one or two substituents selected from the group consisting of halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylO C1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhaloC1-C6 alkyl, haloC1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) and C1-C6 alkyl N(R 7 )(R 8 ).
[0048] In certain embodiments described herein, R a For hydrogen.
[0049] In certain embodiments, R a Examples of suitable halogens include chlorine, bromine, fluorine and iodine.
[0050] In certain embodiments, R a For CN.
[0051] In certain embodiments, R a For OH.
[0052] In certain embodiments, R a Suitable alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy and n-butoxy.
[0053] In certain embodiments, R a It is a C1-C6 alkyl group or an OC1-C6 alkyl group.
[0054] In certain embodiments, R a It is a C1-C6 alkyl COOH.
[0055] In certain embodiments, R a is COOH.
[0056] In certain embodiments, R a It is an oxo group.
[0057] In certain embodiments, R a It is a COOC1-C6 alkyl group.
[0058] In certain embodiments, R a It is C1-C6 alkyl, COOC1-C6 alkyl.
[0059] In certain embodiments, R a is a C3-C6 cycloalkyl group. Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
[0060] In certain embodiments, R a is C1-C6 alkyl C3-C6 cycloalkyl. Suitable cycloalkyl examples include but are not limited to
[0061] In certain embodiments, R a C1-C6 alkyl. Examples of C1-C6 alkyl may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R a It is a methyl group.
[0062] In certain embodiments, R ais C1-C6 alkyl O halo C1-C6 alkyl. Suitable examples of C1-C6 alkyl O halo C1-C6 alkyl include but are not limited to
[0063] In certain embodiments, R a is a halogenated C1-C6 alkyl group. Suitable examples of the halogenated alkyl group include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl.
[0064] In certain embodiments, R a Suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol.
[0065] In certain embodiments, R a CON(R 7 )(R 8 In certain embodiments, R a N(R 7 )(R 8 In certain embodiments, R a C1-C6 alkyl N(R 7 )(R 8 ), where R 7 and R 8 This will be described in detail below.
[0066] In certain embodiments, the compounds described herein have Formula (II):
[0067]
[0068] In certain embodiments, when R a With R b together to form a C3-C6 cycloalkyl or heterocycloalkyl, wherein the C3-C6 cycloalkyl or heterocycloalkyl is unsubstituted or substituted by one or two substituents selected from the group consisting of halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhaloC1-C6 alkyl, haloC1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) and C1-C6 alkyl N(R 7 )(R 8 ).
[0069] Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0070] In certain embodiments, cycloalkyl is unsubstituted. In certain embodiments, heterocycloalkyl is substituted by one or two substituents selected from the group consisting of halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkyl C3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhaloC1-C6 alkyl, haloC1-C6 alkyl, C1-C6 alkylOH, CON(R) 7 )(R 8 )、N(R 7 )(R 8 ) and C1-C6 alkyl N(R 7 )(R 8 ).
[0071] In certain embodiments, the cycloalkyl group is substituted with a substituent selected from the group consisting of halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhaloC1-C6 alkyl, haloC1-C6 alkyl, C1-C6 alkylOH, CON(R) 7 )(R 8 )、N(R 7 )(R 8 ) and C1-C6 alkyl N(R 7 )(R 8 ).
[0072] In certain embodiments, the cycloalkyl group is substituted with two substituents selected from the group consisting of halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhaloC1-C6 alkyl, haloC1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R8 ) and C1-C6 alkyl N(R 7 )(R 8 ).
[0073] In certain embodiments, the cycloalkyl group is substituted with OH.
[0074] In certain embodiments, when R a With R b together to form a heterocycloalkyl group, wherein the heterocycloalkyl group is unsubstituted or substituted with one or two substituents selected from the group consisting of halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhaloC1-C6 alkyl, haloC1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) and C1-C6 alkyl N(R 7 )(R 8 ).
[0075] Non-limiting examples of monocyclic heterocycloalkyl groups include piperidinyl, oxetanyl, pyrrolyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, β-lactam, γ-lactam, δ-lactam, β-lactone, γ-lactone, δ-lactone, and pyrrolidone and oxides thereof. Non-limiting examples of heterocycloalkyl groups include, but are not limited to:
[0076]
[0077] Non-limiting examples of bicyclic heterocycloalkyls include, but are not limited to:
[0078]
[0079] In certain embodiments, when R a With R b Together they form:
[0080]
[0081] In certain embodiments, heterocycloalkyl is unsubstituted. In certain embodiments, heterocycloalkyl is substituted by one or two substituents selected from the group consisting of halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkyl C3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhaloC1-C6 alkyl, haloC1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) and C1-C6 alkyl N(R 7 )(R 8 ).
[0082] In certain embodiments, the heterocycloalkyl group is substituted with a substituent selected from the group consisting of halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhaloC1-C6 alkyl, haloC1-C6 alkyl, C1-C6 alkylOH, CON(R) 7 )(R 8 )、N(R 7 )(R 8 ) and C1-C6 alkyl N(R 7 )(R 8 ).
[0083] In certain embodiments, the heterocycloalkyl group is substituted with two substituents selected from the group consisting of halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhaloC1-C6 alkyl, haloC1-C6 alkyl, C1-C6 alkylOH, CON(R) 7 )(R 8 )、N(R 7 )(R 8 ) and C1-C6 alkyl N(R 7 )(R 8 ).
[0084] In certain embodiments, the heterocycloalkyl is substituted with two substituents selected from the group consisting of: C1-C6 alkyl.
[0085] In the compounds described herein, R b is halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhalogenated C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 ), or when combined with R a together to form a C3-C6 cycloalkyl or heterocycloalkyl, wherein the C3-C6 cycloalkyl or heterocycloalkyl is unsubstituted or substituted by one or two substituents selected from the group consisting of halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhaloC1-C6 alkyl, haloC1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 ).
[0086] In certain embodiments described herein, R b It's hydrogen.
[0087] In certain embodiments, R b is a halogen. Examples of suitable halogens include chlorine, bromine, fluorine and iodine.
[0088] In certain embodiments, R b It is CN.
[0089] In certain embodiments, R b It's OH.
[0090] In certain embodiments, R bSuitable alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy.
[0091] In certain embodiments, R b It is C1-C6 alkyl OC1-C6 alkyl.
[0092] In certain embodiments, R b It is a C1-C6 alkyl COOH.
[0093] In certain embodiments, R b It is COOH.
[0094] In certain embodiments, R b It is an oxo group.
[0095] In certain embodiments, R b It is COOC1-C6 alkyl.
[0096] In certain embodiments, R b It is C1-C6 alkylCOOC1-C6 alkyl.
[0097] In certain embodiments, R b is a C3-C6 cycloalkyl group. Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0098] In certain embodiments, R b is C1-C6 alkyl C3-C6 cycloalkyl. Suitable cycloalkyl examples include but are not limited to
[0099] In certain embodiments, R b is C1-C6 alkyl. Examples of C1-C6 alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R b It's methyl.
[0100] In certain embodiments, R b It is C1-C6 alkyl O halo C1-C6 alkyl. Suitable C1-C6 alkyl O halo C1-C6 alkyl include but are not limited to
[0101] In certain embodiments, R b is a halogenated C1-C6 alkyl group. Examples of suitable halogenated alkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl.
[0102] In certain embodiments, R b Suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol.
[0103] In certain embodiments, R b It is CON(R 7 )(R 8 In certain embodiments, R b It is N(R 7 )(R 8 In certain embodiments, R b Is C1-C6 alkyl N (R 7 )(R 8 ), where R 7 and R 8 This will be described in detail below.
[0104] In certain embodiments, when R b With R a together to form a cycloalkyl or heterocycloalkyl group, wherein the cycloalkyl or heterocycloalkyl group is unsubstituted or substituted with one or two substituents selected from the group consisting of halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOO C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhaloC1-C6 alkyl, haloC1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) and C1-C6 alkyl N(R 7 )(R 8 ).
[0105] In certain embodiments, when R b With R atogether to form a cycloalkyl group, wherein the cycloalkyl group is unsubstituted or substituted with one or two substituents selected from the group consisting of halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhaloC1-C6 alkyl, haloC1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) and C1-C6 alkyl N(R 7 )(R 8 ).
[0106] Examples of suitable cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0107] In certain embodiments, cycloalkyl is unsubstituted. In certain embodiments, heterocycloalkyl is substituted by one or two substituents selected from the group consisting of halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkyl C3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhaloC1-C6 alkyl, haloC1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) and C1-C6 alkyl N(R 7 )(R 8 ).
[0108] In certain embodiments, the cycloalkyl group is substituted with a substituent selected from the group consisting of halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhaloC1-C6 alkyl, haloC1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8) and C1-C6 alkyl N(R 7 )(R 8 ).
[0109] In certain embodiments, the cycloalkyl group is substituted with two substituents selected from the group consisting of halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhaloC1-C6 alkyl, haloC1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) and C1-C6 alkyl N(R 7 )(R 8 ).
[0110] In certain embodiments, the cycloalkyl group is substituted with OH.
[0111] In certain embodiments, when R b With R a together to form a heterocycloalkyl group, wherein the heterocycloalkyl group is unsubstituted or substituted by one or two substituents selected from the group consisting of halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhaloC1-C6 alkyl, haloC1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) and C1-C6 alkyl N(R 7 )(R 8 ).
[0112] Non-limiting examples of monocyclic heterocycloalkyl groups include piperidinyl, oxetanyl, pyrrolyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, β-lactam, γ-lactam, δ-lactam, β-lactone, γ-lactone, δ-lactone, and pyrrolidone, and oxides thereof.
[0113] Non-limiting examples of heterocycloalkyl groups include, but are not limited to:
[0114]
[0115] Non-limiting examples of bicyclic heterocycloalkyls include, but are not limited to:
[0116]
[0117] In certain embodiments, when R b With R a Together they form:
[0118]
[0119] In certain embodiments, cycloalkyl or heterocycloalkyl is unsubstituted. In certain embodiments, cycloalkyl or heterocycloalkyl is substituted by one or two substituents selected from the group consisting of halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkyl C3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhaloC1-C6 alkyl, haloC1-C6 alkyl, C1-C6 alkylOH, CON(R) 7 )(R 8 )、N(R 7 )(R 8 ) and C1-C6 alkyl N(R 7 )(R 8 In certain embodiments, the cycloalkyl or heterocycloalkyl group is substituted with a substituent selected from the group consisting of halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhaloC1-C6 alkyl, haloC1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) and C1-C6 alkyl N(R 7 )(R 8In certain embodiments, the cycloalkyl or heterocycloalkyl group is substituted with two substituents selected from the group consisting of halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhaloC1-C6 alkyl, haloC1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) and C1-C6 alkyl N(R 7 )(R 8 ).
[0120] In certain embodiments, heterocycloalkyl is substituted with two substituents selected from the group consisting of C1-C6 alkyl. In certain embodiments, cycloalkyl is substituted with two substituents selected from the group consisting of C1-C6 alkyl. In certain embodiments, cycloalkyl is unsubstituted.
[0121] In the embodiments described herein, R 3 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 )、C1-C6 alkyl N(R 7 )(R 8 ), C1-C6 alkyl (OCH2CH2) n N(R 7 )(R 8 ) or C1-C6 alkyl O halo C1-C6 alkyl or when with R 4 When taken together, they form a C3-C6 cycloalkyl group or a C3-C6 heterocycloalkyl group.
[0122] In certain embodiments of the compounds described herein, R 3 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl O C1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8)、N(R 7 )(R 8 )、C1-C6 alkyl N(R 7 )(R 8 ), C1-C6 alkyl (OCH2CH2) n N(R 7 )(R 8 ) or C1-C6 alkyl O halo C1-C6 alkyl or when with R 4 Together, they form a C3-C6 cycloalkyl or a C3-C6 heterocycloalkyl. In certain embodiments, R 3 is hydrogen. In certain embodiments, R 3 is a halogen. Suitable halogens include fluorine, chlorine, bromine and iodine. In certain embodiments, R 3 In certain embodiments, R 3 It's OH.
[0123] In certain embodiments, R 3 is C1-C6 alkoxy. Suitable alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy. In certain embodiments, R 3 is C1-C6 alkyl OC1-C6 alkyl. In certain embodiments, R 3 In certain embodiments, R 3 is C1-C6 alkylCOOH. In certain embodiments, R 3 is a C3-C6 cycloalkyl group. Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, R 3 is a C1-C6 alkyl group. Examples of C1-C6 alkyl groups may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R 3 is a haloalkyl group. Suitable examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl. 3 is a C1-C6 alkyl OH. Examples of suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol. In certain embodiments, R 3It is CON(R 7 )(R 8 ). N(R 7 )(R 8 Suitable examples of ) include, but are not limited to, CONH2 and CON(CH3)2. In certain embodiments, R 3 It is N(R 7 )(R 8 ). N(R 7 )(R 8 ) include, but are not limited to, NH2 and N(CH3)2. In certain embodiments, R 3 Is C1-C6 alkyl N (R 7 )(R 8 ). C1-C6 alkyl N(R 7 )(R 8 Suitable examples of ) include, but are not limited to R 7 and R 8 This will be discussed in further detail below.
[0124] In certain embodiments, R 3 is C1-C6 alkyl or halo C1-C6 alkyl. Suitable examples of haloalkyl include but are not limited to
[0125] In certain embodiments, R 3 Is a C1-C6 alkyl group (OCH2CH2) n N(R 7 )(R 8 ). R 7 、R 8 and n will be discussed in detail below. C1-C6 alkyl (OCH2CH2) n N(R 7 )(R 8 Suitable examples of ) include, but are not limited to
[0126] With respect to the compounds described herein, n is 1, 2, 3, or 4. In certain embodiments, n is 1. In certain embodiments, n is 2. In certain embodiments, n is 3. In certain embodiments, n is 4.
[0127] In certain embodiments, when R 3 With R 4 When taken together, they form a C3-C6 cycloalkyl group or a C3-C6 heterocycloalkyl group. In certain embodiments, when R 3 With R 4When taken together, they form a C3-C6 cycloalkyl group. Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, when R 3 With R 4 When taken together, they form a C3-C6 heterocycloalkyl. Suitable examples of heterocycloalkyl include, but are not limited to, piperidinyl, oxetanyl, pyrrolyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, β-lactam, γ-lactam, δ-lactam, β-lactone, γ-lactone, δ-lactone, and pyrrolidone, and oxides thereof.
[0128] In certain embodiments, R 3 is hydrogen, fluorine, methyl, ethyl, OH, methoxy,
[0129]
[0130] In certain embodiments, R 3 is hydrogen, methyl, ethyl or
[0131] In certain embodiments, when R 3 With R 4 Together they form an oxetane group.
[0132] In certain embodiments described herein, R 4 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 )、C1-C6 alkyl N(R 7 )(R 8 ), C1-C6 alkyl (OCH2CH2) n N(R 7 )(R 8 ) or C1-C6 alkyl O halo C1-C6 alkyl, or when with R 3 Together they form a C3-C6 cycloalkyl or C3-C6 heterocycloalkyl. In certain embodiments of the compounds described herein, R 4 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8)、N(R 7 )(R 8 )、C1-C6 alkyl N(R 7 )(R 8 ), or when combined with R 3 Together they form a C3-C6 cycloalkyl or a C3-C6 heterocycloalkyl. In certain embodiments, R 4 is hydrogen. In certain embodiments, R 4 is halogen. Suitable halogens include fluorine, chlorine, bromine or iodine. In certain embodiments, R 4 In certain embodiments, R 4 It's OH.
[0133] In certain embodiments, R 4 is C1-C6 alkoxy. Suitable alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy. In certain embodiments, R 4 is C1-C6 alkyl OC1-C6 alkyl. In certain embodiments, R 4 In certain embodiments, R 4 is C1-C6 alkylCOOH. In certain embodiments, R 4 is a C3-C6 cycloalkyl group. Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, R 4 is C1-C6 alkyl. Examples of C1-C6 alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R 4 is a haloalkyl group. Suitable examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl. 4 is a C1-C6 alkyl OH. Examples of suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol. In certain embodiments, R 4 It is CON(R 7 )(R 8 ). N(R 7 )(R 8Suitable examples of ) include, but are not limited to, CONH2 and CON(CH3)2. In certain embodiments, R 4 It is N(R 7 )(R 8 ). N(R 7 )(R 8 ) include, but are not limited to, NH2 and N(CH3)2. In certain embodiments, R 4 Is C1-C6 alkyl N (R 7 )(R 8 ). C1-C6 alkyl N(R 7 )(R 8 Suitable examples of ) include, but are not limited to R 7 and R 8 This will be discussed in further detail below.
[0134] In certain embodiments, R 4 is C1-C6 alkyl or halo C1-C6 alkyl. Suitable examples of haloalkyl include but are not limited to
[0135] In certain embodiments, R 4 Is a C1-C6 alkyl group (OCH2CH2) n N(R 7 )(R 8 ). R 7 、R 8 See below for a detailed discussion of n, and above for a discussion of C1-C6 alkyl (OCH2CH2) n N(R 7 )(R 8 Suitable examples of ) include, but are not limited to
[0136] In certain embodiments, when R 4 With R 3 When taken together, they form a C3-C6 cycloalkyl group or a C3-C6 heterocycloalkyl group. In certain embodiments, when R 4 With R 3 When taken together, they form a C3-C6 cycloalkyl group. Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, when R 4 With R 3When taken together, they form a C3-C6 heterocycloalkyl. Suitable examples of heterocycloalkyl include, but are not limited to, piperidinyl, oxetanyl, pyrrolyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, β-lactam, γ-lactam, δ-lactam, β-lactone, γ-lactone, δ-lactone, and pyrrolidone, and oxides thereof.
[0137] In certain embodiments, R 4 is hydrogen or methyl. In certain embodiments, R 4 is hydrogen, methyl, ethyl or In certain embodiments, when R 4 With R 3 In certain embodiments, R 3 and R 4 All are hydrogen, methyl or ethyl.
[0138] In certain embodiments, R 3 is hydrogen and R 4 It's hydrogen.
[0139] In certain embodiments, R 3 and R 4 are halogen, wherein halogen is selected from fluorine, chlorine, bromine and iodine. In certain embodiments, R 3 and R 4 All are fluorine.
[0140] In the embodiments described herein, R 5 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhalogenated C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 ).
[0141] In certain embodiments described herein, R 5 It's hydrogen.
[0142] In certain embodiments, R 5 is a halogen. Examples of suitable halogens include chlorine, bromine, fluorine and iodine.
[0143] In certain embodiments, R 5 It is CN.
[0144] In certain embodiments, R 5 It's OH.
[0145] In certain embodiments, R 5 Suitable alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy.
[0146] In certain embodiments, R 5 It is C1-C6 alkyl OC1-C6 alkyl.
[0147] In certain embodiments, R 5 It is a C1-C6 alkyl COOH.
[0148] In certain embodiments, R 5 It is COOH.
[0149] In certain embodiments, R 5 It is an oxo group.
[0150] In certain embodiments, R 5 It is COOC1-C6 alkyl.
[0151] In certain embodiments, R 5 It is C1-C6 alkylCOOC1-C6 alkyl.
[0152] In certain embodiments, R 5 is a C3-C6 cycloalkyl group. Examples of suitable cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0153] In certain embodiments, R 5 is a C1-C6 alkyl C3-C6 cycloalkyl. Examples of suitable cycloalkyl groups include, but are not limited to
[0154] In certain embodiments, R 5is a C1-C6 alkyl group. Examples of C1-C6 alkyl groups may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R 5 It's methyl.
[0155] In certain embodiments, R 5 is C1-C6 alkyl O halo C1-C6 alkyl. Suitable examples of C1-C6 alkyl O halo C1-C6 alkyl include but are not limited to
[0156] In certain embodiments, R 5 is a halogenated C1-C6 alkyl group. Suitable examples of the halogenated alkyl group include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl.
[0157] In certain embodiments, R 5 Suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol.
[0158] In certain embodiments, R 5 It is CON(R 7 )(R 8 In certain embodiments, R 1 It is N(R 7 )(R 8 In certain embodiments, R 5 Is C1-C6 alkyl N (R 7 )(R 8 ), where R 7 and R 8 This will be described in detail below.
[0159] In certain embodiments, R 5 is hydrogen, methyl, ethyl or tert-butyl.
[0160] In the embodiments described herein, R 6is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhalogenated C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 ).
[0161] In certain embodiments described herein, R 6 It's hydrogen.
[0162] In certain embodiments, R 6 is a halogen. Examples of suitable halogens include chlorine, bromine, fluorine and iodine.
[0163] In certain embodiments, R 6 It is CN.
[0164] In certain embodiments, R 6 It's OH.
[0165] In certain embodiments, R 6 Suitable alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy.
[0166] In certain embodiments, R 6 It is C1-C6 alkyl OC1-C6 alkyl.
[0167] In certain embodiments, R 6 It is a C1-C6 alkyl COOH.
[0168] In certain embodiments, R 6 It is COOH.
[0169] In certain embodiments, R 6 It is an oxo group.
[0170] In certain embodiments, R 6 It is COOC1-C6 alkyl.
[0171] In certain embodiments, R 6 It is C1-C6 alkylCOOC1-C6 alkyl.
[0172] In certain embodiments, R 6 is a C3-C6 cycloalkyl group. Examples of suitable cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0173] In certain embodiments, R 6 is a C1-C6 alkyl C3-C6 cycloalkyl. Examples of suitable cycloalkyl groups include, but are not limited to
[0174] In certain embodiments, R 6 is a C1-C6 alkyl group. Examples of C1-C6 alkyl groups may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R 6 It's methyl.
[0175] In certain embodiments, R 6 is C1-C6 alkyl O halo C1-C6 alkyl. Suitable examples of C1-C6 alkyl O halo C1-C6 alkyl include but are not limited to
[0176] In certain embodiments, R 6 is a halogenated C1-C6 alkyl group. Suitable examples of the halogenated alkyl group include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl.
[0177] In certain embodiments, R 6 Suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol.
[0178] In certain embodiments, R 6 It is CON(R 7 )(R 8 In certain embodiments, R 6 It is N(R 7 )(R 8 In certain embodiments, R 6 Is C1-C6 alkyl N (R 7 )(R 8 ), where R 7 and R 8This will be described in detail below.
[0179] In certain embodiments, R 6 is hydrogen, methyl, ethyl or tert-butyl.
[0180] In the embodiments described herein, R 7 is hydrogen, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, COC1-C6 alkyl or COOC1-C6 alkyl. In certain embodiments, R 7 It is hydrogen, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl or C1-C6 alkylOH.
[0181] In certain embodiments, R 7 is hydrogen. In certain embodiments, R 7 is C1-C6 alkylCOOH. In certain embodiments, R 7 In certain embodiments, R 7 is a C3-C6 cycloalkyl group. Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, R 7 is a C1-C6 alkyl group. Examples of C1-C6 alkyl groups may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R 7 is a haloalkyl group. Suitable examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl. 7 is a C1-C6 alkyl OH. Examples of suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol.
[0182] In certain embodiments, R 7 is COC1-C6 alkyl. Suitable examples include, but are not limited to, COCH3. In certain embodiments, R 7 is COOC1-C6 alkyl. Suitable examples include, but are not limited to, COOCH3.
[0183] In the embodiments described herein, R 8 is hydrogen, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, COC1-C6 alkyl or COOC1-C6 alkyl. In certain embodiments, R 8 It is hydrogen, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl or C1-C6 alkylOH.
[0184] In certain embodiments, R 8 is hydrogen. In certain embodiments, R 8 is C1-C6 alkylCOOH. In certain embodiments, R 8 In certain embodiments, R 8 is a C3-C6 cycloalkyl group. Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, R 8 is a C1-C6 alkyl group. Examples of C1-C6 alkyl groups may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R 8 is a haloalkyl group. Suitable examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl. 8 is a C1-C6 alkyl OH. Examples of suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol.
[0185] In certain embodiments, R 8 is COC1-C6 alkyl. Suitable examples include, but are not limited to, COCH3. In certain embodiments, R 8 is COOC1-C6 alkyl. Suitable examples include, but are not limited to, COOCH3.
[0186] In the embodiments described herein, R 9is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 ) and N(R 7 )(R 8 ). In certain embodiments described herein, R 9 is hydrogen. In certain embodiments, R 9 is a halogen. Examples of suitable halogens include chlorine, bromine, fluorine, and iodine. In certain embodiments, R 9 In certain embodiments, R 9 It's OH.
[0187] In certain embodiments, R 9 is C1-C6 alkoxy. Suitable alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy. In certain embodiments, R 9 is C1-C6 alkyl OC1-C6 alkyl. In certain embodiments, R 9 In certain embodiments, R 9 is C1-C6 alkylCOOH. In certain embodiments, R 9 is a C3-C6 cycloalkyl group. Examples of suitable cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, R 9 is a C1-C6 alkyl group. Examples of C1-C6 alkyl groups may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R 9 is a haloalkyl group. Suitable examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl. 9 is a C1-C6 alkyl OH. Suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol. In certain embodiments, R 9 It is CON(R 7 )(R 8In certain embodiments, R 9 It is N(R 7 )(R 8 In certain embodiments, R 9 Is C1-C6 alkyl N (R 7 )(R 8 ).
[0188] With respect to the compounds described herein, R 10 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 ) and N(R 7 )(R 8 In certain embodiments, R 10 is hydrogen. In certain embodiments, R 10 is a halogen. Suitable halogens include fluorine, chlorine, bromine and iodine. In certain embodiments, R 10 In certain embodiments, R 10 It's OH.
[0189] In certain embodiments, R 10 is C1-C6 alkoxy. Suitable alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy. In certain embodiments, R 10 is C1-C6 alkyl OC1-C6 alkyl. In certain embodiments, R 10 In certain embodiments, R 10 is C1-C6 alkylCOOH. In certain embodiments, R 10 is a C3-C6 cycloalkyl group. Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, R 10 is a C1-C6 alkyl group. Examples of C1-C6 alkyl groups may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R 10is a haloalkyl group. Suitable examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl. 10 is a C1-C6 alkyl OH. Examples of suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol. In certain embodiments, R 10 It is CON(R 7 )(R 8 In certain embodiments, R 10 It is N(R 7 )(R 8 In certain embodiments, R 10 Is C1-C6 alkyl N (R 7 )(R 8 ).
[0190] In the embodiments described herein, R 11 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 ) and N(R 7 )(R 8 In certain embodiments, R 11 is hydrogen. In certain embodiments, R 11 is a halogen. Suitable halogens include fluorine, chlorine, bromine and iodine. In certain embodiments, R 11 In certain embodiments, R 11 It's OH.
[0191] In certain embodiments, R 11 is C1-C6 alkoxy. Suitable alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy. In certain embodiments, R 11 is C1-C6 alkyl OC1-C6 alkyl. In certain embodiments, R 11 In certain embodiments, R 11 is C1-C6 alkylCOOH. In certain embodiments, R 11 is a C3-C6 cycloalkyl group. Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, R 11is a C1-C6 alkyl group. Examples of C1-C6 alkyl groups may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R 11 is a haloalkyl group. Suitable examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl. 11 is a C1-C6 alkyl OH. Examples of suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol. In certain embodiments, R 11 It is CON(R 7 )(R 8 In certain embodiments, R 11 It is N(R 7 )(R 8 In certain embodiments, R 11 Is C1-C6 alkyl N (R 7 )(R 8 ).
[0192] In the embodiments described herein, R 12 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 In certain embodiments, R 12 is hydrogen. In certain embodiments, R 12 is a halogen. Suitable halogens include fluorine, chlorine, bromine and iodine. In certain embodiments, R 12 In certain embodiments, R 12 It's OH.
[0193] In certain embodiments, R 12is C1-C6 alkoxy. Suitable alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy. In certain embodiments, R 12 is C1-C6 alkyl OC1-C6 alkyl. In certain embodiments, R 12 In certain embodiments, R 12 is C1-C6 alkylCOOH. In certain embodiments, R 12 is a C3-C6 cycloalkyl group. Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, R 12 is a C1-C6 alkyl group. Examples of C1-C6 alkyl groups may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R 12 is a haloalkyl group. Suitable examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl. 12 is a C1-C6 alkyl OH. Examples of suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol. In certain embodiments, R 12 It is CON(R 7 )(R 8 In certain embodiments, R 12 It is N(R 7 )(R 8 In certain embodiments, R 12 Is C1-C6 alkyl N (R 7 )(R 8 ).
[0194] In certain embodiments, R 12 is hydrogen, methyl, ethyl, methoxy, OH or
[0195] In certain embodiments, R 12 is hydrogen or
[0196] In the embodiments described herein, R 13is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 In certain embodiments, R 13 is hydrogen. In certain embodiments, R 13 is a halogen. Suitable halogens include fluorine, chlorine, bromine and iodine. In certain embodiments, R 13 In certain embodiments, R 13 It's OH.
[0197] In certain embodiments, R 13 is C1-C6 alkoxy. Suitable alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy. In certain embodiments, R 13 is C1-C6 alkyl OC1-C6 alkyl. In certain embodiments, R 13 In certain embodiments, R 13 is C1-C6 alkylCOOH. In certain embodiments, R 13 is a C3-C6 cycloalkyl group. Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, R 13 is a C1-C6 alkyl group. Examples of C1-C6 alkyl groups may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R 13 is a haloalkyl group. Suitable examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl. 13 is a C1-C6 alkyl OH. Examples of suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol. In certain embodiments, R 13It is CON(R 7 )(R 8 In certain embodiments, R 13 It is N(R 7 )(R 8 In certain embodiments, R 13 Is C1-C6 alkyl N (R 7 )(R 8 ).
[0198] In certain embodiments, R 13 is hydrogen, methyl, ethyl, methoxy, OH or
[0199] In certain embodiments, R 13 is hydrogen or
[0200] In certain embodiments, R 12 and R 13 Independently selected from the group consisting of hydrogen, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkyl.
[0201] In the embodiments described herein, R 14 Each occurrence of is independently selected from the group consisting of hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 In certain embodiments, R 14 is hydrogen. In certain embodiments, R 14 is a halogen. Suitable halogens include fluorine, chlorine, bromine and iodine. In certain embodiments, R 14 In certain embodiments, R 14 It's OH.
[0202] In certain embodiments, R 14 is C1-C6 alkoxy. Suitable alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy. In certain embodiments, R 14 is C1-C6 alkyl OC1-C6 alkyl. In certain embodiments, R 14 In certain embodiments, R 14is C1-C6 alkylCOOH. In certain embodiments, R 14 is a C3-C6 cycloalkyl group. Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, R 14 is a C1-C6 alkyl group. Examples of C1-C6 alkyl groups may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R 14 is a haloalkyl group. Suitable examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl. 14 is a C1-C6 alkyl OH. Examples of suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol. In certain embodiments, R 14 It is CON(R 7 )(R 8 In certain embodiments, R 14 It is N(R 7 )(R 8 In certain embodiments, R 14 Is C1-C6 alkyl N (R 7 )(R 8 ).
[0203] In certain embodiments, wherein X is C(R 14 )2,R 14 Independently selected from the group consisting of hydrogen, halogen, OH, C1-C6 alkylOH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl and C1-C6 alkyl.
[0204] In certain embodiments, R 14 is hydrogen, methyl, ethyl, methoxy, OH or
[0205] In the embodiments described herein, R 15is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 ) and N(R 7 )(R 8 In certain embodiments, R 15 is hydrogen. In certain embodiments, R 15 is a halogen. Suitable halogens include fluorine, chlorine, bromine and iodine. In certain embodiments, R 15 In certain embodiments, R 15 It's OH.
[0206] In certain embodiments, R 15 is C1-C6 alkoxy. Suitable alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy. In certain embodiments, R 15 is C1-C6 alkyl OC1-C6 alkyl. In certain embodiments, R 15 In certain embodiments, R 15 is C1-C6 alkylCOOH. In certain embodiments, R 15 is a C3-C6 cycloalkyl group. Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, R 15 is a C1-C6 alkyl group. Examples of C1-C6 alkyl groups may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R 15 It's ethyl.
[0207] In certain embodiments, R 15 is a haloalkyl group. Suitable examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl. 15 is a C1-C6 alkyl OH. Examples of suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol. In certain embodiments, R15 It is CON(R 7 )(R 8 In certain embodiments, R 15 It is N(R 7 )(R 8 In certain embodiments, R 15 Is C1-C6 alkyl N (R 7 )(R 8 ).
[0208] In certain embodiments, R 15 It is a methyl or ethyl group.
[0209] In the embodiments described herein, R 16 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 ) and N(R 7 )(R 8 In certain embodiments, R 16 is hydrogen. In certain embodiments, R 16 is a halogen. Suitable halogens include fluorine, chlorine, bromine and iodine. In certain embodiments, R 16 In certain embodiments, R 16 It's OH.
[0210] In certain embodiments, R 16 is C1-C6 alkoxy. Suitable alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy. In certain embodiments, R 16 is C1-C6 alkyl OC1-C6 alkyl. In certain embodiments, R 16 In certain embodiments, R 16 is C1-C6 alkylCOOH. In certain embodiments, R 16 is a C3-C6 cycloalkyl group. Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, R 16is a C1-C6 alkyl group. Examples of C1-C6 alkyl groups may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R 16 is a haloalkyl group. Suitable examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl. 16 is a C1-C6 alkyl OH. Examples of suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol. In certain embodiments, R 16 It is CON(R 7 )(R 8 In certain embodiments, R 16 It is N(R 7 )(R 8 In certain embodiments, R 16 Is C1-C6 alkyl N (R 7 )(R 8 ).
[0211] In the compound embodiments described herein, m is 0 or 1. In certain embodiments, m is 0. In certain embodiments, m is 1.
[0212] In the compound embodiments described herein, p is 0 or 1. In certain embodiments, p is 0. In certain embodiments, p is 1.
[0213] In the embodiments described herein, A is a linear or branched, saturated or unsaturated (C3-C 10 ) alkylene, phenyl (C3-C 10 ) alkylene or cycloalkyl (C3-C 10 )alkylene, and contains at least one -CH2- group, wherein one or more additional -CH2- groups in A may be optionally and independently substituted with a group selected from the group consisting of: O, S, NR, CONR, NRCO, SO2 and SO2NR, and one or more hydrogens in A may be independently substituted with a group selected from the group consisting of: hydroxy, halogen and C 1-3In certain embodiments, A is a linear or branched, saturated or unsaturated (C3-C 10 ) alkylene or cycloalkyl (C3-C 10 )alkylene, wherein one or more -CH2- groups in A may be optionally and independently substituted with a group selected from the group consisting of O, S, and NH. In certain embodiments, A will always contain at least one -CH2- group.
[0214] In certain embodiments, A is a linear (C3-C 10 ) alkylene. Straight chain C3-C 10 ) Examples of alkylene groups include,
[0215]
[0216] In certain embodiments, A is a branched (C3-C 10 ) alkylene. Suitable branched chain (C3-C 10 ) Alkylene includes but is not limited to:
[0217]
[0218] In certain embodiments, A is saturated (C3-C 10 )alkylene. Examples include:
[0219]
[0220] In certain embodiments, A is unsaturated (C3-C 10 ) alkylene. Suitable unsaturated (C3-C 10 ) alkylene includes any saturated (C3-C 10 )alkylene, wherein hydrogen has been removed and one or more double or triple bonds exist between adjacent carbon atoms. Unsaturated (C3-C 10 ) Examples of alkylene groups include, but are not limited to:
[0221]
[0222] In other embodiments, A is a straight chain cycloalkyl (C3-C 10 Suitable straight chain cycloalkyl (C3-C 10 ) alkylene includes two carbon atoms in the chain contained in a (C3-C 10 ) Cycloalkyl in cycloalkyl (C3-C 10 ) alkylene. Straight chain cycloalkyl (C3-C 10 ) Examples of alkylene groups include, but are not limited to:
[0223]
[0224] In certain embodiments, A is a branched cycloalkyl (C3-C 10 Suitable branched cycloalkyl (C3-C 10 ) alkylene includes two carbon atoms in the chain contained in a (C3-C 10 ) Branched chain in cycloalkyl (C3-C 10 ) alkylene. Cycloalkyl (C3-C 10 ) Examples of alkylene groups include, but are not limited to:
[0225]
[0226] In certain embodiments, A is a saturated cycloalkyl (C3-C 10 ) alkylene. Saturated cycloalkyl (C3-C 10 ) Examples of alkylene groups include, but are not limited to:
[0227]
[0228] In certain embodiments, A is an unsaturated cycloalkyl (C3-C 10 ) alkylene. Unsaturated ring (C3-C 10 ) Examples of alkylene groups include, but are not limited to:
[0229]
[0230] In certain embodiments, A is an unsaturated or saturated phenyl group (C3-C 10 ) alkylene. Unsaturated and saturated phenyl (C3-C 10 ) Examples of alkylene groups include, but are not limited to:
[0231]
[0232] In other embodiments, one or more -CH2- groups in A may be optionally and independently substituted with a group selected from the group consisting of O, S, NR, CONR, NRCO, SO2, and SO2NR. In other embodiments, one or more -CH2- groups in A may be optionally and independently substituted with a group selected from the group consisting of O, S, and NH. In other embodiments, one or more -CH2- groups in A may be optionally and independently substituted with O. In other embodiments, one or more -CH2- groups in A may be optionally and independently substituted with S. In other embodiments, one or more -CH2- groups in A may be optionally and independently substituted with NR. In other embodiments, one or more -CH2- groups in A may be optionally and independently substituted with CONR. In other embodiments, one or more -CH2- groups in A may be optionally and independently substituted with NRCO. In other embodiments, one or more -CH2- groups in A may be optionally and independently substituted with SO2. In other embodiments, one or more -CH2- groups in A may be optionally and independently substituted with SO2NR. R will be described in further detail below.
[0233] In the embodiments described herein, R is hydrogen, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halo-C1-C6 alkyl, C1-C6 alkylOH, COC1-C6 alkyl, or COOC1-C6 alkyl. In certain embodiments, R is hydrogen, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halo-C1-C6 alkyl, or C1-C6 alkylOH.
[0234] In certain embodiments, R is hydrogen. In certain embodiments, R is C1-C6 alkyl, COOH. In certain embodiments, R is COOH. In certain embodiments, R is C3-C6 cycloalkyl. Suitable examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, R is C1-C6 alkyl. The example of C1-C6 alkyl can include but is not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl and 1-ethyl-1-methylpropyl. In certain embodiments, R is a halo C1-C6 alkyl. Suitable examples of haloalkyl include but are not limited to fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl and 2,2-difluoroethyl. In certain embodiments, R is a C1-C6 alkyl OH. Examples of suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol.
[0235] In certain embodiments, R is COC1-C6 alkyl. Suitable examples include, but are not limited to, COCH3. In certain embodiments, R is COOC1-C6 alkyl. Suitable examples include, but are not limited to, COOCH3.
[0236] Examples of such implementations include, but are not limited to:
[0237]
[0238] In certain embodiments, A is:
[0239]
[0240] In certain embodiments, one or more hydrogen atoms on A may be substituted with a group independently selected from the group consisting of hydroxyl, halogen, and C 1-3 Examples of suitable halogens include chlorine, bromine, fluorine, and iodine. In certain embodiments, A is:
[0241]
[0242] Also described herein are compounds having structural formula (III):
[0243]
[0244] Wherein, A is a linear or branched, saturated or unsaturated (C3-C 10 ) alkylene, phenyl (C3-C 10 ) alkylene or cycloalkyl (C3-C 10 ) alkylene, which contains at least one -CH2- group, wherein one or more additional -CH2- groups in A may be optionally and independently substituted with a group selected from the group consisting of: O, S, NR, CONR, NRCO, SO2 and SO2NR, and one or more hydrogens in A may be independently substituted with a group selected from the group consisting of: hydroxy, halogen and C 1-3 alkyl halide;
[0245] Q is C(R 16 )2, O, S, SO, SO2 or NH;
[0246] X is a bond, C(R 14 )2, O, S, SO, SO2 or NH;
[0247] Y is CR 9 or N, when Y is N, Z is CR 11 And V is CR 10 ;
[0248] V is CR 10 or N, when V is N, Z is CR 11 And Y is CR 9 ;
[0249] Z is CR 11 or N, when Z is N, V is CR 10 And Y is CR 9 ;
[0250] R is hydrogen, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, COC1-C6 alkyl or COOC1-C6 alkyl;
[0251] R 1 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhalogenated C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8) or C1-C6 alkyl N(R 7 )(R 8 );
[0252] R 2 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhalogenated C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 );
[0253] R 3 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 )、C1-C6 alkyl N(R 7 )(R 8 ), C1-C6 alkyl (OCH2CH2) n N(R 7 )(R 8 ) or C1-C6 alkyl O halo C1-C6 alkyl or when with R 4 When taken together, they form a C3-C6 cycloalkyl group or a C3-C6 heterocycloalkyl group;
[0254] R 4 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 )、C1-C6 alkyl N(R 7 )(R 8 ), C1-C6 alkyl (OCH2CH2) n N(R 7)(R 8 ) or C1-C6 alkyl O halo C1-C6 alkyl or when with R 3 When taken together, they form a C3-C6 cycloalkyl group or a C3-C6 heterocycloalkyl group;
[0255] R 5 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 );
[0256] R 6 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 );
[0257] R 7 is hydrogen, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, COC1-C6 alkyl or COOC1-C6 alkyl;
[0258] R 7 is hydrogen, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, COC1-C6 alkyl or COOC1-C6 alkyl;
[0259] R 9 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8) or C1-C6 alkyl N(R 7 )(R 8 );
[0260] R 10 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 );
[0261] R 11 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 );
[0262] R 12 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 );
[0263] R 13 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R8 );
[0264] R 14 Each occurrence of is independently selected from the group consisting of hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halo-C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) and C1-C6 alkyl N(R 7 )(R 8 );
[0265] R 15 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 );
[0266] R 16 Each occurrence of is independently selected from the group consisting of hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) and C1-C6 alkyl N(R 7 )(R 8 );
[0267] l is 0 or 1;
[0268] m is 0 or 1;
[0269] n is 1, 2, 3, or 4;
[0270] p is 0 or 1.
[0271] In the embodiments described herein, Q is C(R 16 )2, O, S, SO, SO2 or NH. In certain embodiments, Q is C(R16 )2, where R 16 As will be discussed in further detail below. In certain embodiments, Q is CH2, CH(CH3), C(CH3)2, O, CH(OCH3), SO2, or CF2. In other embodiments, Q is CH2, O, S, SO, SO2, or NH. In certain embodiments, Q is CH2. In certain embodiments described herein, Q is O. In certain embodiments described herein, Q is S. In other embodiments described herein, Q is SO. In other embodiments described herein, Q is SO2. In certain embodiments described herein, Q is NH. In other embodiments described herein, Q is O or SO2. In other embodiments described herein, Q is O or CH2.
[0272] In the embodiments described herein, X is a bond, C(R 14 )2, O, S, SO, SO2 or NH. In certain embodiments described herein, X is a bond. In certain embodiments described herein, X is C(R 14 )2, where R 14 As will be discussed in further detail below. In certain embodiments described herein, X is a bond, CH2, CH(CH3), C(CH3)2, O, CH(OCH3), SO2, or CF2. In other embodiments, X is CH2, O, S, SO, SO2, or NH. In certain embodiments described herein, X is CH2. In certain embodiments described herein, X is O. In certain embodiments described herein, X is S. In certain embodiments described herein, X is SO. In other embodiments described herein, X is SO2. In certain embodiments described herein, X is NH.
[0273] In the embodiments described herein, Y is CR 9 Or N. In certain embodiments, Y is CR 9 , where R 9 This will be discussed in detail below. In certain embodiments, Y is N. In certain embodiments, Y is CH. In certain embodiments, when Y is N, Z is CR 11 And V is CR 10 .
[0274] In the embodiments described herein, V is CR 10 Or N. In certain embodiments, V is CR 10 , where R 10 This will be discussed in detail below. In certain embodiments, V is N. In certain embodiments, V is CH. In certain embodiments, when V is N, Z is CR11 And Y is CR 9 .
[0275] In the embodiments described herein, Z is CR 11 or N. In certain embodiments, Z is CR 11 , where R 11 This will be discussed in detail below. In certain embodiments, Z is CH. In certain embodiments, Z is N. In certain embodiments, when Z is N, V is CR 10 And Y is CR 9 .
[0276] In certain embodiments, X is O, Y and V are each CH, and Z is N. In certain embodiments, X is O, Y and Z are each CH, and V is N. In certain embodiments, X is O, and V, Y, and Z are all CH.
[0277] In certain embodiments, X is a bond, Y and V are each CH, and Z is N. In certain embodiments, X is a bond, Y and Z are each CH, and V is N. In certain embodiments, X is a bond, and V, Y, and Z are all simultaneously CH.
[0278] Also described herein are compounds of Formula III represented by structural formula (IIIA):
[0279]
[0280] where R 1 、R 2 、R 3 、R 4 、R 5 、R 6 、R 15 , A and Q are as described herein. 1 、R 2 、R 3 、R 4 、R 5 、R 6 、R 15 When R 3 and R 4 Another embodiment of Formula IIIA is achieved when all R 3 and R 4When Q is CH2, CH(CH3), C(CH3)2, O, CH(OCH3), SO2 or CF2, another embodiment of Formula IIIA is realized. In other embodiments described herein, Q in Formula IIIA is O or SO2. In other embodiments described herein, Q in Formula IIIA is O or CH2. When A is a linear or branched, saturated or unsaturated (C3-C 10 )alkylene, comprising at least one -CH2- group, and one or more additional -CH2- groups in A may be independently and optionally substituted with a group selected from the group consisting of O, S, NR, CONR, NRCO, SO2 and SO2NR, and one or more hydrogen atoms in A may be independently substituted with a group selected from the group consisting of hydroxy, halogen and C1-3 haloalkyl, another embodiment of Formula IIIA is realized.
[0281] Also described herein are compounds of Formula III represented by structural formula (IIIB):
[0282]
[0283] where R 1 、R 2 、R 3 、R 4 、R 5 、R 6 、R 15 , A and Q are as described herein. 1 、R 2 、R 3 、R 4 、R 5 、R 6 、R 15 When R 3 and R 4 Another embodiment of Formula IIIB is achieved when all of R 3 and R 4 When Q is CH2, CH(CH3), C(CH3)2, O, CH(OCH3), SO2 or CF2, another embodiment of Formula IIIB is realized. In other embodiments described herein, Q in Formula IIIB is O or SO2. In other embodiments described herein, Q in Formula IIIB is O or CH2. When A is a linear or branched, saturated or unsaturated (C3-C 10)alkylene, comprising at least one -CH2- group, and one or more additional -CH2- groups in A may be independently and optionally substituted with a group selected from the group consisting of O, S, NR, CONR, NRCO, SO2 and SO2NR, and one or more hydrogen atoms in A may be independently substituted with a group selected from the group consisting of hydroxy, halogen and C1-3 haloalkyl, another embodiment of Formula IIIB is realized.
[0284] Certain embodiments are represented by Formula IV-VI:
[0285]
[0286] In the embodiments described herein, R 1 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhalogenated C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 ).
[0287] In certain embodiments described herein, R 1 It's hydrogen.
[0288] In certain embodiments, R 1 is a halogen. Examples of suitable halogens include chlorine, bromine, fluorine and iodine.
[0289] In certain embodiments, R 1 It is CN.
[0290] In certain embodiments, R 1 It's OH.
[0291] In certain embodiments, R 1 Suitable alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy.
[0292] In certain embodiments, R 1 It is a C1-C6 alkyl group.
[0293] In certain embodiments, R1 It is a C1-C6 alkyl COOH.
[0294] In certain embodiments, R 1 It is COOH.
[0295] In certain embodiments, R 1 It is an oxo group.
[0296] In certain embodiments, R 1 It is COOC1-C6 alkyl.
[0297] In certain embodiments, R 1 It is C1-C6 alkylCOOC1-C6 alkyl.
[0298] In certain embodiments, R 1 is a C3-C6 cycloalkyl group. Examples of suitable cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0299] In certain embodiments, R 1 is a C1-C6 alkyl C3-C6 cycloalkyl. Examples of suitable cycloalkyl groups include, but are not limited to
[0300] In certain embodiments, R 1 is a C1-C6 alkyl group. Examples of C1-C6 alkyl groups may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl.
[0301] In certain embodiments, R 1 is C1-C6 alkyl O halo C1-C6 alkyl. Suitable examples of C1-C6 alkyl O halo C1-C6 alkyl include but are not limited to
[0302] In certain embodiments, R 1 is a halogenated C1-C6 alkyl group. Suitable examples of the halogenated alkyl group include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl.
[0303] In certain embodiments, R 1Suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol.
[0304] In certain embodiments, R 1 It is CON(R 7 )(R 8 In certain embodiments, R 1 It is N(R 7 )(R 8 In certain embodiments, R 1 Is C1-C6 alkyl N (R 7 )(R 8 ), where R 7 and R 8 This will be described in detail below.
[0305] In certain embodiments, R 1 is hydrogen, bromine, fluorine, chlorine, methyl, OH, halogen, CN, oxo, methoxymethyl, COOCH2CH3 or trifluoromethyl.
[0306] In the embodiments described herein, R 2 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhalogenated C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 ).
[0307] In certain embodiments described herein, R 2 It's hydrogen.
[0308] In certain embodiments, R 2 is a halogen. Examples of suitable halogens include chlorine, bromine, fluorine and iodine.
[0309] In certain embodiments, R 2 It is CN.
[0310] In certain embodiments, R 2 It's OH.
[0311] In certain embodiments, R 2Suitable alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy.
[0312] In certain embodiments, R 2 It is a C1-C6 alkyl group.
[0313] In certain embodiments, R 2 It is a C1-C6 alkyl COOH.
[0314] In certain embodiments, R 2 It is COOH.
[0315] In certain embodiments, R 2 It is an oxo group.
[0316] In certain embodiments, R 2 It is COOC1-C6 alkyl.
[0317] In certain embodiments, R 2 It is C1-C6 alkylCOOC1-C6 alkyl.
[0318] In certain embodiments, R 2 is a C3-C6 cycloalkyl group. Examples of suitable cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0319] In certain embodiments, R 2 is a C1-C6 alkyl C3-C6 cycloalkyl. Examples of suitable cycloalkyl groups include, but are not limited to
[0320] In certain embodiments, R 2 is a C1-C6 alkyl group. Examples of C1-C6 alkyl groups may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl.
[0321] In certain embodiments, R 2 is C1-C6 alkyl O halo C1-C6 alkyl. Suitable examples of C1-C6 alkyl O halo C1-C6 alkyl include but are not limited to
[0322] In certain embodiments, R 2 is a halogenated C1-C6 alkyl group. Suitable examples of the halogenated alkyl group include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl.
[0323] In certain embodiments, R 2 Suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol.
[0324] In certain embodiments, R 2 It is CON(R 7 )(R 8 In certain embodiments, R 2 It is N(R 7 )(R 8 In certain embodiments, R 2 Is C1-C6 alkyl N (R 7 )(R 8 ), where R 7 and R 8 This will be described in detail below.
[0325] In certain embodiments, R 2 is hydrogen, bromine, fluorine, chlorine, methyl, OH, halogen, CN, oxo, methoxymethyl, COOCH2CH3 or trifluoromethyl.
[0326] In certain embodiments, R 1 and R 2 In certain embodiments, R 1 is OH, and R 2 For hydrogen.
[0327] In the embodiments described herein, R 3 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 )、C1-C6 alkyl N(R 7 )(R 8 ), C1-C6 alkyl (OCH2CH2) n N(R 7 )(R 8 ) or C1-C6 alkyl O halo C1-C6 alkyl or when with R 4When taken together, they form a C3-C6 cycloalkyl group or a C3-C6 heterocycloalkyl group.
[0328] In certain embodiments of the compounds described herein, R 3 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 )、C1-C6 alkyl N(R 7 )(R 8 ) or when with R 4 Together, they form a C3-C6 cycloalkyl or a C3-C6 heterocycloalkyl. In certain embodiments, R 3 is hydrogen. In certain embodiments, R 3 is a halogen. Suitable halogens include fluorine, chlorine, bromine and iodine. In certain embodiments, R 3 In certain embodiments, R 3 It's OH.
[0329] In certain embodiments, R 3 is C1-C6 alkoxy. Suitable alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy. In certain embodiments, R 3 is C1-C6 alkyl OC1-C6 alkyl. In certain embodiments, R 3 In certain embodiments, R 3 is C1-C6 alkylCOOH. In certain embodiments, R 3 is a C3-C6 cycloalkyl group. Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, R 3 is a C1-C6 alkyl group. Examples of C1-C6 alkyl groups may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R 3is a haloalkyl group. Suitable examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl. 3 is a C1-C6 alkyl OH. Examples of suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol. In certain embodiments, R 3 It is CON(R 7 )(R 8 ). N(R 7 )(R 8 Suitable examples of ) include, but are not limited to, CONH2 and CON(CH3)2. In certain embodiments, R 3 It is N(R 7 )(R 8 ). N(R 7 )(R 8 ) include, but are not limited to, NH2 and N(CH3)2. In certain embodiments, R 3 Is C1-C6 alkyl N (R 7 )(R 8 ). C1-C6 alkyl N(R 7 )(R 8 Suitable examples of ) include, but are not limited to R 7 and R 8 This will be discussed in further detail below.
[0330] In certain embodiments, R 3 is C1-C6 alkyl or halo C1-C6 alkyl. Suitable examples of haloalkyl include but are not limited to
[0331] In certain embodiments, R 3 Is a C1-C6 alkyl group (OCH2CH2) n N(R 7 )(R 8 ). R 7 、R 8 and n will be discussed in detail below. C1-C6 alkyl (OCH2CH2) n N(R 7 )(R 8 Suitable examples of ) include, but are not limited to
[0332] With respect to the compounds described herein, n is 1, 2, 3, or 4. In certain embodiments, n is 1. In certain embodiments, n is 2. In certain embodiments, n is 3. In certain embodiments, n is 4.
[0333] In certain embodiments, when R 3 With R 4 When taken together, they form a C3-C6 cycloalkyl group or a C3-C6 heterocycloalkyl group. In certain embodiments, when R 3 With R 4 When taken together, they form a C3-C6 cycloalkyl group. Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, when R 3 With R 4 When taken together, they form a C3-C6 heterocycloalkyl. Suitable examples of heterocycloalkyl include, but are not limited to, piperidinyl, oxetanyl, pyrrolyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, β-lactam, γ-lactam, δ-lactam, β-lactone, γ-lactone, δ-lactone, and pyrrolidone, and oxides thereof.
[0334] In certain embodiments, R 3 is hydrogen, fluorine, methyl, ethyl, OH, methoxy, CON(CH3)2,
[0335] In certain embodiments, R 3 is hydrogen, methyl, ethyl or
[0336] In certain embodiments, when R 3 With R 4 Together they form an oxetane group.
[0337] In certain embodiments described herein, R 4 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 )、C1-C6 alkyl N(R 7 )(R 8 ), C1-C6 alkyl (OCH2CH2) n N(R 7 )(R 8 ) or C1-C6 alkyl O halo C1-C6 alkyl, or when with R 3 Together they form a C3-C6 cycloalkyl or C3-C6 heterocycloalkyl. In certain embodiments of the compounds described herein, R4 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 )、C1-C6 alkyl N(R 7 )(R 8 ), or when combined with R 3 Together they form a C3-C6 cycloalkyl or a C3-C6 heterocycloalkyl. In certain embodiments, R 4 is hydrogen. In certain embodiments, R 4 is halogen. Suitable halogens include fluorine, chlorine, bromine or iodine. In certain embodiments, R 4 In certain embodiments, R 4 It's OH.
[0338] In certain embodiments, R 4 is C1-C6 alkoxy. Suitable alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy. In certain embodiments, R 4 is C1-C6 alkyl OC1-C6 alkyl. In certain embodiments, R 4 In certain embodiments, R 4 is C1-C6 alkylCOOH. In certain embodiments, R 4 is a C3-C6 cycloalkyl group. Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, R 4 is C1-C6 alkyl. Examples of C1-C6 alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R 4 is a haloalkyl group. Suitable examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl. 4is a C1-C6 alkyl OH. Examples of suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol. In certain embodiments, R 4 It is CON(R 7 )(R 8 ). N(R 7 )(R 8 Suitable examples of ) include, but are not limited to, CONH2 and CON(CH3)2. In certain embodiments, R 4 It is N(R 7 )(R 8 ). N(R 7 )(R 8 ) include, but are not limited to, NH2 and N(CH3)2. In certain embodiments, R 4 Is C1-C6 alkyl N (R 7 )(R 8 ). C1-C6 alkyl N(R 7 )(R 8 Suitable examples of ) include, but are not limited to R 7 and R 8 This will be discussed in further detail below.
[0339] In certain embodiments, R 4 is C1-C6 alkyl or halo C1-C6 alkyl. Suitable examples of haloalkyl include but are not limited to
[0340] In certain embodiments, R 4 Is a C1-C6 alkyl group (OCH2CH2) n N(R 7 )(R 8 ). R 7 、R 8 See below for a detailed discussion of n, and above for a discussion of C1-C6 alkyl (OCH2CH2) n N(R 7 )(R 8 Suitable examples of ) include, but are not limited to
[0341] In certain embodiments, when R 4 With R 3 When taken together, they form a C3-C6 cycloalkyl group or a C3-C6 heterocycloalkyl group. In certain embodiments, when R 4 With R 3 When taken together, they form a C3-C6 cycloalkyl group. Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, when R 4 With R3 When taken together, they form a C3-C6 heterocycloalkyl. Suitable examples of heterocycloalkyl include, but are not limited to, piperidinyl, oxetanyl, pyrrolyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, β-lactam, γ-lactam, δ-lactam, β-lactone, γ-lactone, δ-lactone, and pyrrolidone, and oxides thereof.
[0342] In certain embodiments, R 4 is hydrogen or methyl. In certain embodiments, R 4 is hydrogen, methyl, ethyl or
[0343] In certain embodiments, when R 4 With R 3 In certain embodiments, R 3 and R 4 All are hydrogen, methyl or ethyl.
[0344] In certain embodiments, R 3 is hydrogen and R 4 It's hydrogen.
[0345] In the embodiments described herein, R 5 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhalogenated C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 ).
[0346] In certain embodiments described herein, R 5 It's hydrogen.
[0347] In certain embodiments, R 5 is a halogen. Examples of suitable halogens include chlorine, bromine, fluorine and iodine.
[0348] In certain embodiments, R 5 It is CN.
[0349] In certain embodiments, R 5 It's OH.
[0350] In certain embodiments, R 5 Suitable alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy.
[0351] In certain embodiments, R 5 It is C1-C6 alkyl OC1-C6 alkyl.
[0352] In certain embodiments, R 5 It is a C1-C6 alkyl COOH.
[0353] In certain embodiments, R 5 It is COOH.
[0354] In certain embodiments, R 5 It is an oxo group.
[0355] In certain embodiments, R 5 It is COOC1-C6 alkyl.
[0356] In certain embodiments, R 5 It is C1-C6 alkylCOOC1-C6 alkyl.
[0357] In certain embodiments, R 5 is a C3-C6 cycloalkyl group. Examples of suitable cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0358] In certain embodiments, R 5 is a C1-C6 alkyl C3-C6 cycloalkyl. Examples of suitable cycloalkyl groups include, but are not limited to
[0359] In certain embodiments, R 5 is a C1-C6 alkyl group. Examples of C1-C6 alkyl groups may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R 5 It's methyl.
[0360] In certain embodiments, R 5is C1-C6 alkyl O halo C1-C6 alkyl. Suitable examples of C1-C6 alkyl O halo C1-C6 alkyl include but are not limited to
[0361] In certain embodiments, R 5 is a halogenated C1-C6 alkyl group. Suitable examples of the halogenated alkyl group include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl.
[0362] In certain embodiments, R 5 Suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol.
[0363] In certain embodiments, R 5 It is CON(R 7 )(R 8 In certain embodiments, R 1 It is N(R 7 )(R 8 In certain embodiments, R 5 Is C1-C6 alkyl N (R 7 )(R 8 ), where R 7 and R 8 This will be described in detail below.
[0364] In certain embodiments, R 5 is hydrogen, methyl, ethyl or tert-butyl.
[0365] In the embodiments described herein, R 6 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl, C1-C6 alkylCOOH, COOH, oxo, COOC1-C6 alkyl, C1-C6 alkylCOOC1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylC3-C6 cycloalkyl, C1-C6 alkyl, -C1-C6 alkylOhalogenated C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 ).
[0366] In certain embodiments described herein, R 6 It's hydrogen.
[0367] In certain embodiments, R 6is a halogen. Examples of suitable halogens include chlorine, bromine, fluorine and iodine.
[0368] In certain embodiments, R 6 It is CN.
[0369] In certain embodiments, R 6 It's OH.
[0370] In certain embodiments, R 6 Suitable alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy.
[0371] In certain embodiments, R 6 It is C1-C6 alkyl OC1-C6 alkyl.
[0372] In certain embodiments, R 6 It is a C1-C6 alkyl COOH.
[0373] In certain embodiments, R 6 It is COOH.
[0374] In certain embodiments, R 6 It is an oxo group.
[0375] In certain embodiments, R 6 It is COOC1-C6 alkyl.
[0376] In certain embodiments, R 6 It is C1-C6 alkylCOOC1-C6 alkyl.
[0377] In certain embodiments, R 6 is a C3-C6 cycloalkyl group. Examples of suitable cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0378] In certain embodiments, R 6 is a C1-C6 alkyl C3-C6 cycloalkyl. Examples of suitable cycloalkyl groups include, but are not limited to
[0379] In certain embodiments, R 6is a C1-C6 alkyl group. Examples of C1-C6 alkyl groups may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R 6 It's methyl.
[0380] In certain embodiments, R 6 is C1-C6 alkyl O halo C1-C6 alkyl. Suitable examples of C1-C6 alkyl O halo C1-C6 alkyl include but are not limited to
[0381] In certain embodiments, R 6 is a halogenated C1-C6 alkyl group. Suitable examples of the halogenated alkyl group include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl.
[0382] In certain embodiments, R 6 Suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol.
[0383] In certain embodiments, R 6 It is CON(R 7 )(R 8 In certain embodiments, R 6 It is N(R 7 )(R 8 In certain embodiments, R 6 Is C1-C6 alkyl N (R 7 )(R 8 ), where R 7 and R 8 This will be described in detail below.
[0384] In certain embodiments, R 6 is hydrogen, methyl, ethyl or tert-butyl.
[0385] In the embodiments described herein, R 7is hydrogen, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, COC1-C6 alkyl or COOC1-C6 alkyl. In certain embodiments, R 7 It is hydrogen, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl or C1-C6 alkylOH.
[0386] In certain embodiments, R 7 is hydrogen. In certain embodiments, R 7 is C1-C6 alkylCOOH. In certain embodiments, R 7 In certain embodiments, R 7 is a C3-C6 cycloalkyl group. Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, R 7 is a C1-C6 alkyl group. Examples of C1-C6 alkyl groups may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R 7 is a haloalkyl group. Suitable examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl. 7 is a C1-C6 alkyl OH. Examples of suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol.
[0387] In certain embodiments, R 7 is COC1-C6 alkyl. Suitable examples include, but are not limited to, COCH3. In certain embodiments, R 7 is COOC1-C6 alkyl. Suitable examples include, but are not limited to, COOCH3.
[0388] In the embodiments described herein, R 8 is hydrogen, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, COC1-C6 alkyl or COOC1-C6 alkyl. In certain embodiments, R8 It is hydrogen, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl or C1-C6 alkylOH.
[0389] In certain embodiments, R 8 is hydrogen. In certain embodiments, R 8 is C1-C6 alkylCOOH. In certain embodiments, R 8 In certain embodiments, R 8 is a C3-C6 cycloalkyl group. Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, R 8 is a C1-C6 alkyl group. Examples of C1-C6 alkyl groups may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R 8 is a haloalkyl group. Suitable examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl. 8 is a C1-C6 alkyl OH. Examples of suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol.
[0390] In certain embodiments, R 8 is COC1-C6 alkyl. Suitable examples include, but are not limited to, COCH3. In certain embodiments, R 8 is COOC1-C6 alkyl. Suitable examples include, but are not limited to, COOCH3.
[0391] In the embodiments described herein, R 9 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 ) and N(R 7 )(R 8 ). In certain embodiments described herein, R9 is hydrogen. In certain embodiments, R 9 is a halogen. Examples of suitable halogens include chlorine, bromine, fluorine and iodine.
[0392] In certain embodiments, R 9 In certain embodiments, R 9 It's OH.
[0393] In certain embodiments, R 9 is C1-C6 alkoxy. Suitable alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy. In certain embodiments, R 9 is C1-C6 alkyl OC1-C6 alkyl. In certain embodiments, R 9 In certain embodiments, R 9 is C1-C6 alkylCOOH. In certain embodiments, R 9 is a C3-C6 cycloalkyl group. Examples of suitable cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, R 9 is a C1-C6 alkyl group. Examples of C1-C6 alkyl groups may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R 9 is a haloalkyl group. Suitable examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl. 9 is a C1-C6 alkyl OH. Suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol. In certain embodiments, R 9 It is CON(R 7 )(R 8 In certain embodiments, R 9 It is N(R 7 )(R 8 In certain embodiments, R 9 Is C1-C6 alkyl N (R 7 )(R 8 ).
[0394] With respect to the compounds described herein, R 10 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 ) and N(R 7 )(R 8 In certain embodiments, R 10 is hydrogen. In certain embodiments, R 10 is a halogen. Suitable halogens include fluorine, chlorine, bromine and iodine. In certain embodiments, R 10 In certain embodiments, R 10 It's OH.
[0395] In certain embodiments, R 10 is C1-C6 alkoxy. Suitable alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy. In certain embodiments, R 10 is C1-C6 alkyl OC1-C6 alkyl. In certain embodiments, R 10 In certain embodiments, R 10 is C1-C6 alkylCOOH. In certain embodiments, R 10 is a C3-C6 cycloalkyl group. Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, R 10 is a C1-C6 alkyl group. Examples of C1-C6 alkyl groups may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R 10 is a haloalkyl group. Suitable examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl. 10 is a C1-C6 alkyl OH. Examples of suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol. In certain embodiments, R 10 It is CON(R7 )(R 8 In certain embodiments, R 10 It is N(R 7 )(R 8 In certain embodiments, R 10 Is C1-C6 alkyl N (R 7 )(R 8 ).
[0396] In the embodiments described herein, R 11 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 ) and N(R 7 )(R 8 In certain embodiments, R 11 is hydrogen. In certain embodiments, R 11 is a halogen. Suitable halogens include fluorine, chlorine, bromine and iodine. In certain embodiments, R 11 In certain embodiments, R 11 It's OH.
[0397] In certain embodiments, R 11 is C1-C6 alkoxy. Suitable alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy. In certain embodiments, R 11 is C1-C6 alkyl OC1-C6 alkyl. In certain embodiments, R 11 In certain embodiments, R 11 is C1-C6 alkylCOOH. In certain embodiments, R 11 is a C3-C6 cycloalkyl group. Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, R 11is a C1-C6 alkyl group. Examples of C1-C6 alkyl groups may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R 11 is a haloalkyl group. Suitable examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl. 11 is a C1-C6 alkyl OH. Examples of suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol. In certain embodiments, R 11 It is CON(R 7 )(R 8 In certain embodiments, R 11 It is N(R 7 )(R 8 In certain embodiments, R 11 Is C1-C6 alkyl N (R 7 )(R 8 ).
[0398] In the embodiments described herein, R 12 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 In certain embodiments, R 12 is hydrogen. In certain embodiments, R 12 is a halogen. Suitable halogens include fluorine, chlorine, bromine and iodine. In certain embodiments, R 12 In certain embodiments, R 12 It's OH.
[0399] In certain embodiments, R 12is C1-C6 alkoxy. Suitable alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy. In certain embodiments, R 12 is C1-C6 alkyl OC1-C6 alkyl. In certain embodiments, R 12 In certain embodiments, R 12 is C1-C6 alkylCOOH. In certain embodiments, R 12 is a C3-C6 cycloalkyl group. Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, R 12 is a C1-C6 alkyl group. Examples of C1-C6 alkyl groups may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R 12 is a haloalkyl group. Suitable examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl. 12 is a C1-C6 alkyl OH. Examples of suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol. In certain embodiments, R 12 It is CON(R 7 )(R 8 In certain embodiments, R 12 It is N(R 7 )(R 8 In certain embodiments, R 12 Is C1-C6 alkyl N (R 7 )(R 8 ).
[0400] In certain embodiments, R 12 is hydrogen, methyl, ethyl, methoxy, OH or
[0401] In certain embodiments, R 12 is hydrogen or
[0402] In the embodiments described herein, R 13is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 In certain embodiments, R 13 is hydrogen. In certain embodiments, R 13 is a halogen. Suitable halogens include fluorine, chlorine, bromine and iodine. In certain embodiments, R 13 In certain embodiments, R 13 It's OH.
[0403] In certain embodiments, R 13 is C1-C6 alkoxy. Suitable alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy. In certain embodiments, R 13 is C1-C6 alkyl OC1-C6 alkyl. In certain embodiments, R 13 In certain embodiments, R 13 is C1-C6 alkylCOOH. In certain embodiments, R 13 is a C3-C6 cycloalkyl group. Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, R 13 is a C1-C6 alkyl group. Examples of C1-C6 alkyl groups may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R 13 is a haloalkyl group. Suitable examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl. 13 is a C1-C6 alkyl OH. Examples of suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol. In certain embodiments, R 13It is CON(R 7 )(R 8 In certain embodiments, R 13 It is N(R 7 )(R 8 In certain embodiments, R 13 Is C1-C6 alkyl N (R 7 )(R 8 ).
[0404] In certain embodiments, R 13 is hydrogen, methyl, ethyl, methoxy, OH or
[0405] In certain embodiments, R 13 is hydrogen or
[0406] In certain embodiments, R 12 and R 13 Independently selected from the group consisting of hydrogen, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkyl.
[0407] In the embodiments described herein, R 14 Each occurrence of is independently selected from the group consisting of hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C1-C6 alkyl N(R 7 )(R 8 In certain embodiments, R 14 is hydrogen. In certain embodiments, R 14 is a halogen. Suitable halogens include fluorine, chlorine, bromine and iodine. In certain embodiments, R 14 In certain embodiments, R 14 It's OH.
[0408] In certain embodiments, R 14 is C1-C6 alkoxy. Suitable alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy. In certain embodiments, R 14 is C1-C6 alkyl OC1-C6 alkyl. In certain embodiments, R 14 In certain embodiments, R 14is C1-C6 alkylCOOH. In certain embodiments, R 14 is a C3-C6 cycloalkyl group. Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, R 14 is a C1-C6 alkyl group. Examples of C1-C6 alkyl groups may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R 14 is a haloalkyl group. Suitable examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl. 14 is a C1-C6 alkyl OH. Examples of suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol. In certain embodiments, R 14 It is CON(R 7 )(R 8 In certain embodiments, R 14 It is N(R 7 )(R 8 In certain embodiments, R 14 Is C1-C6 alkyl N (R 7 )(R 8 ).
[0409] In certain embodiments, wherein X is C(R 14 )2,R 14 Independently selected from the group consisting of hydrogen, halogen, OH, C1-C6 alkylOH, C1-C6 alkoxy, C1-C6 alkylOC1-C6 alkyl and C1-C6 alkyl.
[0410] In certain embodiments, R 14 is hydrogen, methyl, ethyl, methoxy, OH or
[0411] In the embodiments described herein, R 15is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 ) and N(R 7 )(R 8 In certain embodiments, R 15 is hydrogen. In certain embodiments, R 15 is a halogen. Suitable halogens include fluorine, chlorine, bromine and iodine. In certain embodiments, R 15 In certain embodiments, R 15 It's OH.
[0412] In certain embodiments, R 15 is C1-C6 alkoxy. Suitable alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy. In certain embodiments, R 15 is C1-C6 alkyl OC1-C6 alkyl. In certain embodiments, R 15 In certain embodiments, R 15 is C1-C6 alkylCOOH. In certain embodiments, R 15 is a C3-C6 cycloalkyl group. Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, R 15 is a C1-C6 alkyl group. Examples of C1-C6 alkyl groups may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R 15 It's ethyl.
[0413] In certain embodiments, R 15 is a haloalkyl group. Suitable examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl. 15 is a C1-C6 alkyl OH. Examples of suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol. In certain embodiments, R15 It is CON(R 7 )(R 8 In certain embodiments, R 15 It is N(R 7 )(R 8 In certain embodiments, R 15 Is C1-C6 alkyl N (R 7 )(R 8 ).
[0414] In certain embodiments, R 15 It is a methyl or ethyl group.
[0415] In the embodiments described herein, R 16 is hydrogen, halogen, CN, OH, C1-C6 alkoxy, C1-C6 alkyl OC1-C6 alkyl, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylOH, CON(R 7 )(R 8 ) and N(R 7 )(R 8 In certain embodiments, R 16 is hydrogen. In certain embodiments, R 16 is a halogen. Suitable halogens include fluorine, chlorine, bromine and iodine. In certain embodiments, R 16 In certain embodiments, R 16 It's OH.
[0416] In certain embodiments, R 16 is C1-C6 alkoxy. Suitable alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy. In certain embodiments, R 16 is C1-C6 alkyl OC1-C6 alkyl. In certain embodiments, R 16 In certain embodiments, R 16 is C1-C6 alkylCOOH. In certain embodiments, R 16 is a C3-C6 cycloalkyl group. Suitable examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0417] In certain embodiments, R 16is a C1-C6 alkyl group. Examples of C1-C6 alkyl groups may include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, and 1-ethyl-1-methylpropyl. In certain embodiments, R 16 is a haloalkyl group. Suitable examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, and 2,2-difluoroethyl. 16 is a C1-C6 alkyl OH. Examples of suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol. In certain embodiments, R 16 It is CON(R 7 )(R 8 In certain embodiments, R 16 It is N(R 7 )(R 8 In certain embodiments, R 16 Is C1-C6 alkyl N (R 7 )(R 8 ).
[0418] In the compound embodiments described herein, l is 0 or 1. In certain embodiments, l is 0. In certain embodiments, l is 1.
[0419] In the compound embodiments described herein, m is 0 or 1. In certain embodiments, m is 0. In certain embodiments, m is 1.
[0420] In the compound embodiments described herein, p is 0 or 1. In certain embodiments, p is 0. In certain embodiments, p is 1.
[0421] In certain embodiments, m and p are 1, and X is O.
[0422] In certain embodiments, m and p are 1, and X is CH2.
[0423] In certain embodiments, m is 0, p is 1, and X is O.
[0424] In certain embodiments, m and p are 1, and X is SO2.
[0425] In certain embodiments, m is 0, p is 1, and X is C(R 14 )2, where R 14 Each occurrence of is independently selected from the group consisting of hydrogen, halogen, OH, C1-C6 alkoxy, and C1-C6 alkyl.
[0426] In certain embodiments, m is 1, and X is C(R 14 )2, where R 14 Each occurrence of is independently selected from the group consisting of hydrogen, halogen, OH, C1-C6 alkoxy, and C1-C6 alkyl.
[0427] For example, in certain embodiments of Formula (I), l is 0; m is 1; p is 1; X is O; V, Y, and Z are all CH; and Q is CH2, as shown in Formula (VII):
[0428]
[0429] For example, in certain embodiments of Formula (I), l, m, and p are all 1; X is O; V, Y, and Z are all CH; and Q is O, as shown in Formula (VIII):
[0430]
[0431] In the embodiments described herein, A is a linear or branched, saturated or unsaturated (C3-C 10 ) alkylene, phenyl (C3-C 10 ) alkylene or cycloalkyl (C3-C 10 )alkylene, and contains at least one -CH2- group, wherein one or more additional -CH2- groups in A may be optionally and independently substituted with a group selected from the group consisting of: O, S, NR, CONR, NRCO, SO2 and SO2NR, and one or more hydrogens in A may be independently substituted with a group selected from the group consisting of: hydroxy, halogen and C 1-3 In certain embodiments, A is a linear or branched, saturated or unsaturated (C3-C 10 ) alkylene or cycloalkyl (C3-C 10 )alkylene, wherein one or more -CH2- groups in A may be optionally and independently substituted with a group selected from the group consisting of O, S, and NH. In certain embodiments, A will always contain at least one -CH2- group.
[0432] In certain embodiments, A is a linear (C3-C 10 ) alkylene. Straight chain C3-C 10 ) Examples of alkylene groups include,
[0433]
[0434] In certain embodiments, A is a branched (C3-C 10 ) alkylene. Suitable branched chain (C3-C 10 ) Alkylene includes but is not limited to:
[0435]
[0436] In certain embodiments, A is saturated (C3-C 10 )alkylene. Examples include:
[0437]
[0438] In certain embodiments, A is unsaturated (C3-C 10 ) alkylene. Suitable unsaturated (C3-C 10 ) alkylene includes any saturated (C3-C 10 )alkylene, wherein hydrogen has been removed and one or more double or triple bonds exist between adjacent carbon atoms. Unsaturated (C3-C 10 ) Examples of alkylene groups include, but are not limited to:
[0439]
[0440] In other embodiments, A is a straight chain cycloalkyl (C3-C 10 Suitable straight chain cycloalkyl (C3-C 10 ) alkylene includes two carbon atoms in the chain contained in a (C3-C 10 ) Cycloalkyl in cycloalkyl (C3-C 10 ) alkylene. Straight chain cycloalkyl (C3-C 10 ) Examples of alkylene groups include, but are not limited to:
[0441]
[0442] In certain embodiments, A is a branched cycloalkyl (C3-C 10 Suitable branched cycloalkyl (C3-C 10 ) alkylene includes two carbon atoms in the chain contained in a (C3-C 10 ) Branched chain in cycloalkyl (C3-C 10 ) alkylene. Cycloalkyl (C3-C 10 ) Examples of alkylene groups include, but are not limited to:
[0443]
[0444] In certain embodiments, A is a saturated cycloalkyl (C3-C 10 ) alkylene. Saturated cycloalkyl (C3-C 10 ) Examples of alkylene groups include, but are not limited to:
[0445]
[0446] In certain embodiments, A is an unsaturated cycloalkyl (C3-C 10 ) alkylene. Unsaturated ring (C3-C 10 ) Examples of alkylene groups include, but are not limited to:
[0447]
[0448] In certain embodiments, A is an unsaturated or saturated phenyl group (C3-C 10 ) alkylene. Unsaturated and saturated phenyl (C3-C 10 ) Examples of alkylene groups include, but are not limited to:
[0449]
[0450] In other embodiments, one or more -CH2- groups in A may be optionally and independently substituted with a group selected from the group consisting of O, S, NR, CONR, NRCO, SO2, and SO2NR. In other embodiments, one or more -CH2- groups in A may be optionally and independently substituted with a group selected from the group consisting of O, S, and NH. In other embodiments, one or more -CH2- groups in A may be optionally and independently substituted with O. In other embodiments, one or more -CH2- groups in A may be optionally and independently substituted with S. In other embodiments, one or more -CH2- groups in A may be optionally and independently substituted with NR. In other embodiments, one or more -CH2- groups in A may be optionally and independently substituted with CONR. In other embodiments, one or more -CH2- groups in A may be optionally and independently substituted with NRCO. In other embodiments, one or more -CH2- groups in A may be optionally and independently substituted with SO2. In other embodiments, one or more -CH2- groups in A may be optionally and independently substituted with SO2NR. R will be described in further detail below.
[0451] In the embodiments described herein, R is hydrogen, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halo-C1-C6 alkyl, C1-C6 alkylOH, COC1-C6 alkyl, or COOC1-C6 alkyl. In certain embodiments, R is hydrogen, C1-C6 alkylCOOH, COOH, C3-C6 cycloalkyl, C1-C6 alkyl, halo-C1-C6 alkyl, or C1-C6 alkylOH.
[0452] In certain embodiments, R is hydrogen. In certain embodiments, R is C1-C6 alkyl, COOH. In certain embodiments, R is COOH. In certain embodiments, R is C3-C6 cycloalkyl. Suitable examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In certain embodiments, R is C1-C6 alkyl. The example of C1-C6 alkyl can include but is not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl and 1-ethyl-1-methylpropyl. In certain embodiments, R is a halo C1-C6 alkyl. Suitable examples of haloalkyl include but are not limited to fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl and 2,2-difluoroethyl. In certain embodiments, R is a C1-C6 alkyl OH. Examples of suitable alcohols include, but are not limited to, methanol, ethanol, propanol, butanol, and isobutanol.
[0453] In certain embodiments, R is COC1-C6 alkyl. Suitable examples include, but are not limited to, COCH3. In certain embodiments, R is COOC1-C6 alkyl. Suitable examples include, but are not limited to, COOCH3.
[0454] Examples of such implementations include, but are not limited to:
[0455]
[0456] In certain embodiments, A is:
[0457]
[0458] In certain embodiments, one or more hydrogen atoms on A may be substituted with a group independently selected from the group consisting of hydroxyl, halogen, and C 1-3Examples of suitable halogens include chlorine, bromine, fluorine, and iodine. In certain embodiments, A is:
[0459]
[0460] In the various embodiments of the invention, unless otherwise indicated, in the compounds used in the methods used herein, it is understood that each variable (including the variables in each of Formulas (I) to (VIII), and their various embodiments) is selected independently of the other variables.
[0461] In various embodiments of the present invention, the compounds described herein, including each of Formulas (I) to (VIII), and their various embodiments, may exist in different forms of compounds, for example, any solvates, hydrates, stereoisomers and tautomers of the compounds, and any pharmaceutically acceptable salts thereof.
[0462] In certain embodiments, the compounds described herein include:
[0463]
[0464]
[0465]
[0466]
[0467]
[0468]
[0469]
[0470] In certain embodiments, the compounds described herein include:
[0471]
[0472]
[0473]
[0474]
[0475]
[0476]
[0477]
[0478] or a pharmaceutically acceptable salt thereof.
[0479] Definitions and Abbreviations:
[0480] The terms used herein have their ordinary meanings, and the meanings of these terms are independent at each occurrence. Nevertheless, and unless otherwise indicated, the following definitions apply throughout the specification and claims. Chemical names, common names, and chemical structures are used interchangeably to describe the same structure. Unless otherwise indicated, these definitions apply to the terms themselves or in combination with other terms. Thus, the definition of "alkyl" applies to both "alkyl" and the "alkyl" portion of "hydroxyalkyl," "haloalkyl," aralkyl-, alkylaryl-, "alkoxy," etc.
[0481] It is to be understood that in the various embodiments of the invention described herein, unless any variable is explicitly defined in the context of that embodiment, the variable is as defined in Formula (I).
[0482] In the various embodiments described herein, each variable is selected independently of the other variables unless otherwise stated.
[0483] "Drug resistance" refers to a related strain of the Plasmodium parasite that is no longer susceptible to at least one previously effective drug; it has developed the ability to resist attack by at least one previously effective drug. Resistant strains may pass this resistance on to their offspring. This resistance may arise from random genetic mutations in the bacterial cell that alter its sensitivity to a single drug or to different drugs.
[0484] “Patient” includes humans and non-human animals. Non-human animals include research animals and companion animals, such as mice, rats, primates, monkeys, chimpanzees, gorillas, dogs, and domestic cats.
[0485] A "pharmaceutical composition" (or "pharmaceutically acceptable composition") refers to a composition suitable for administration to a patient. Such a composition may comprise a pure compound (or compounds) of the invention or a mixture thereof, or a salt, solvate, prodrug, isomer or tautomer thereof, and one or more pharmaceutically acceptable carriers or diluents. The term "pharmaceutical composition" is also intended to encompass the total composition and individual dosage units consisting of one or more (e.g., two) pharmaceutically active drugs (e.g., a compound of the invention and an additional drug selected from the list of additional drugs described herein) and any pharmaceutically inactive excipients. The total composition and each individual dosage unit may contain a fixed amount of the above-mentioned "more than one pharmaceutically active drugs". The total composition is a substance that has not yet been formulated into individual dosage units. An exemplary dosage unit is an oral dosage unit, such as a tablet, pill, etc. Similarly, the methods described herein for treating a patient by administering a pharmaceutical composition of the invention are also intended to include administering the above-mentioned total composition and individual dosage units.
[0486] "Halogen" and "halo" mean fluorine, chlorine, bromine or iodine. Preferred are fluorine, chlorine and bromine.
[0487] "Alkylene" by itself or as part of another substituent represents a divalent hydrocarbon chain group having the stated number of carbon atoms. For example, -(C1-C5)alkylene can include, for example, -CH2-, -CH2CH2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, -CH2CH(CH3)CH2-, or -CH2CH2CH2CH2CH2-. Straight-chain alkylene represents a divalent straight-chain hydrocarbon chain group having the stated number of carbon atoms. Branched-chain alkylene represents a divalent branched-chain hydrocarbon chain group having the stated number of carbon atoms. Saturated alkylene represents a divalent saturated hydrocarbon chain group having the stated number of carbon atoms. Unsaturated alkylene represents a divalent hydrocarbon chain group having the stated number of carbon atoms and having one or more double or triple bonds within the chain. Cycloalkylene represents a divalent hydrocarbon chain group having the stated number of carbon atoms and having a cycloalkyl portion within the chain.
[0488] "Alkyl" means an aliphatic hydrocarbon group that can be straight or branched, containing about 1 to about 20 carbon atoms in the chain. Preferred alkyl groups contain about 1 to about 12 carbon atoms in the chain. More preferred alkyl groups contain about 1 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups (such as methyl, ethyl or propyl) are attached to a linear alkyl chain. "Lower alkyl" means a group that contains about 1 to about 6 carbon atoms in the chain, which can be straight or branched. Non-limiting examples of suitable alkyl groups include methyl, ethyl, n-propyl, isopropyl and tert-butyl.
[0489] "Haloalkyl" means an alkyl group as defined above wherein one or more hydrogen atoms on the alkyl group is replaced by a halo group as defined above.
[0490] "Aryl" means an aromatic monocyclic or polycyclic ring system containing from about 6 to about 14 carbon atoms, preferably from about 6 to about 10 carbon atoms. An aryl group may be optionally substituted with one or more "ring system substituents," which may be the same or different, and are as defined herein. Non-limiting examples of suitable aryl groups include phenyl and naphthyl. "Monocyclic aryl" means phenyl.
[0491] "Cycloalkyl" refers to a non-aromatic monocyclic or polycyclic ring system containing from about 3 to about 12 carbon atoms, preferably from about 3 to about 10 carbon atoms. Preferred cycloalkyl rings contain from about 5 to about 10 ring atoms. The cycloalkyl group may optionally be substituted with one or more substituents, which may be the same or different, as described herein. Monocyclic cycloalkyl refers to a monocyclic form of the cycloalkyl moiety described herein. Non-limiting examples of suitable monocyclic cycloalkyls include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like. Polycyclic cycloalkyl refers to a polycyclic (including bicyclic) system containing a non-aromatic ring. Non-limiting examples of suitable polycyclic cycloalkyls include 1-decalinyl, norbornyl, adamantyl, and the like. In certain embodiments, the non-aromatic ring is fused to the aromatic ring.
[0492] "Heterocycloalkyl" (or "heterocyclyl") means a non-aromatic, saturated or partially saturated monocyclic or polycyclic ring system comprising from about 3 to about 10 ring atoms, preferably from about 5 to about 10 ring atoms, wherein one or more of the atoms in the ring system is an element other than carbon, such as nitrogen, oxygen, or sulfur, either alone or in combination. There are no adjacent oxygen and / or sulfur atoms in the ring system. Preferred heterocyclyl groups contain from about 5 to about 6 ring atoms. The prefix "aza," "oxa," or "thia" before the heterocyclyl root name indicates that at least one nitrogen, oxygen, or sulfur atom, respectively, is present in the ring. Any -NH group in a heterocyclyl ring may be protected, for example, as an -N(Boc), -N(CBz), -N(Tos), and the like; such protections are also considered part of this invention. The heterocyclyl group may be optionally substituted with one or more substituents, which may be the same or different, as described herein. The nitrogen or sulfur atom of the heterocyclyl group may be optionally oxidized to the corresponding N-oxide, S-oxide, or S,S-dioxide. Thus, when the term "oxide" appears in the definition of a variable in the general structures described herein, it refers to the corresponding N-oxide, S-oxide, or S,S-dioxide. "Heterocyclyl" also includes rings in which =O replaces two available hydrogen atoms on the same carbon atom (i.e., heterocyclyl includes rings having a carbonyl group in the ring). Such =O groups may be referred to herein as "oxo." An example of such a moiety is pyrrolidone (or pyrrolidone): As used herein, "monocyclic heterocycloalkyl" refers to monocyclic forms of heterocycloalkyl moieties described herein, including 4- to 7-membered monocyclic heterocycloalkyl groups containing 1 to 4 ring heteroatoms independently selected from the group consisting of N, N-oxide, O, S, S-oxide, S(O), and S(O)2. The point of attachment to the parent moiety is any available ring carbon atom or ring heteroatom. Non-limiting examples of monocyclic heterocycloalkyl groups include piperidinyl, oxetanyl, pyrrolyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, β-lactam, γ-lactam, δ-lactam, β-lactone, γ-lactone, δ-lactone, and pyrrolidone, and oxides thereof. A non-limiting example of a monocyclic heterocycloalkyl group includes the moiety:
[0493] Non-limiting examples of polycyclic heterocycloalkyl groups include bicyclic heterocycloalkyl groups. Specific examples include, but are not limited to
[0494]
[0495] "Alkoxy" means an alkyl-O- group, wherein the alkyl group is as described above. Non-limiting examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy. The bond to the parent group is through the ether oxygen atom.
[0496] The term "substituted" means that one or more hydrogen atoms on the designated atom are replaced with a substituent selected from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded and that the substitution results in the formation of a stable compound. Combinations of substituents and / or variables are permissible only if such combinations result in stable compounds. A "stable compound" or "stable structure" is intended to indicate a compound that is sufficiently stable to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
[0497] The term "optionally substituted" indicates optional substitution with the specified group, radical or moiety.
[0498] When a variable appears multiple times in a group, such as -N(R 8 )2 in R 8 , or when variables appear multiple times in the structures given in this article, these variables can be the same or different.
[0499] A solid line - as a bond - generally represents a mixture of possible isomers, or any one of them, such as isomers containing (R)- and (S)-stereochemistry. For example:
[0500]
[0501] The wavy lines used in this article Represents a crossover point on a chemical bond, indicating the point of attachment to the rest of the compound. Lines drawn into a ring system, such as The indicated line (bond) is connected to any substitutable ring atom.
[0502] "Oxo" is defined as an oxygen atom double-bonded to a ring carbon atom in a cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, or another ring described herein, e.g.
[0503] In the present specification, when a plurality of oxygen atoms and / or sulfur atoms are present in a ring system, adjacent oxygen atoms and / or sulfur atoms cannot be present in the ring system.
[0504] As is well known to those skilled in the art, a bond drawn from a particular atom, without a moiety depicted at the end of the bond, indicates a methyl group attached to the atom through the bond, unless otherwise indicated. For example:
[0505]
[0506] In another embodiment, the compounds useful in the methods of the present invention, and / or compositions comprising them useful in the methods, are present in isolated and / or purified form. With respect to a compound, "purified," "in purified form," or "in isolated and purified form" refers to the physical state of the compound after it has been isolated from a synthetic process (e.g., from a reaction mixture), a natural source, or a combination thereof. Thus, with respect to a compound, "purified," "in purified form," or "in isolated and purified form" refers to the physical state of the compound (or its tautomer or stereoisomer, or a pharmaceutically acceptable salt or solvate thereof, said stereoisomer, or said tautomer) obtained from one or more purification processes described herein or known to those skilled in the art (e.g., chromatography, recrystallization, etc.), in a purity sufficient to be suitable for in vivo or pharmaceutical use, and / or can be characterized by standard analytical techniques described herein or known to those skilled in the art.
[0507] It should be understood that any carbon atom and heteroatom in the text, schemes, examples and tables herein, if the valence is not full, is assumed to have a sufficient number of hydrogen atoms to satisfy the valence.
[0508] When a functional group in a compound is referred to as "protected," this means that the group is in modified form to prevent undesirable side reactions at the protected site when the compound is reacted. Suitable protecting groups will be recognized by those skilled in the art and by reference to standard textbooks (TW Greene et al., Protective Groups in Organic Synthesis (1991), Wiley, New York).
[0509] Another embodiment provides prodrugs and / or solvates of the compounds of the present invention. For a discussion of prodrugs, see T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems (1987). 14 of the A.C. S. Symposium Series, and Bioreversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press. The term "prodrug" refers to a compound (e.g., a drug precursor) that is converted in vivo to produce a compound of the invention or a pharmaceutically acceptable salt, hydrate, or solvate of the compound. The conversion can occur by various mechanisms (e.g., by metabolic or chemical processes), such as by hydrolysis in the blood. For a discussion of the use of prodrugs, see T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C. S. Symposium Series, and Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
[0510] For example, if the compound useful in the methods of the invention, or a pharmaceutically acceptable salt thereof, contains a carboxylic acid functional group, the prodrug may comprise an ester formed by replacing the hydrogen atom of the acid group with, for example, a (C1-C8)alkyl, (C2-C 12)alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having 4 to 9 carbon atoms, 1-methyl-1-(alkanoyloxy)ethyl having 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having 3 to 6 carbon atoms, 1-(alkoxycarbonyloxy)ethyl having 4 to 7 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)ethyl having 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having 3 to 9 carbon atoms, The alkyl group is substituted by 1-(N-(alkoxycarbonyl)amino)ethyl, 3-benzylidene, 4-crotonolactone, γ-butyrolactone-4-yl, di-N,N-(C1-C2)alkylamino(C2-C3)alkyl (such as β-dimethylaminoethyl), carbamoyl-(C1-C2)alkyl, N,N-di(C1-C2)alkylcarbamoyl-(C1-C2)alkyl and piperidinyl-, pyrrolidinyl- or morpholinyl(C2-C3)alkyl groups.
[0511] Similarly, if the compound used in the method of the invention contains an alcohol functional group, a prodrug can be formed by replacing the hydrogen atom of the alcohol group with a group such as (C1-C6)alkanoyloxymethyl, 1-((C1-C6)alkanoyloxy)ethyl, 1-methyl-1-((C1-C6)alkanoyloxy)ethyl, (C1-C6)alkoxycarbonyloxymethyl, N-(C1-C6)alkoxycarbonylaminomethyl, succinyl, (C1-C6)alkanoyl, α-amino(C1-C4)alkyl, aroyl and α-aminoacyl, or α-aminoacyl-α-aminoacyl (wherein each α-aminoacyl group is independently selected from naturally occurring L-amino acids), P(O)(OH)2, -P(O)(O(C1-C6)alkyl)2, or a glycosyl group (a group derived from the removal of a hydroxyl group from the hemiacetal form of a carbohydrate).
[0512] If the compound used in the method of the invention contains an amine functional group, a prodrug can be prepared by replacing the hydrogen atom in the amine group with, for example, R-carbonyl, RO-carbonyl, NRR'-carbonyl (wherein R and R' are each independently (C1-C 10 )alkyl, (C3-C7)cycloalkyl, benzyl, or R-carbonyl is a natural α-aminoacyl or a natural α-aminoacyl, -C(OH)C(O)OY 1 (where Y 1 is H, (C1-C6) alkyl or benzyl), C(OY 2 )Y 3 (where Y 2 is (C1-C4) alkyl and Y 3 (C1-C6) alkyl), carboxyl (C1-C6) alkyl, amino (C1-C4) alkyl or mono-N or di-N, N-(C1-C6) alkylaminoalkyl, -C(Y 4 )Y5 (where Y 4 is H or methyl and Y 5 It is formed by a group such as mono-N or di-N,N-(C1-C6)alkylaminomorpholinyl, piperidin-1-yl or pyrrolidin-1-yl).
[0513] One or more compounds used in the methods of the present invention may exist in an unsolvated form as well as in a solvated form with a pharmaceutically acceptable solvent (such as water, ethanol, etc.), and it is intended that the present invention include both solvated and unsolvated forms. "Solvate" refers to the physical combination between a compound of the present invention and one or more solvent molecules. This physical combination involves varying degrees of ionic and covalent bonds, including hydrogen bonds. In some cases, the solvate can be separated, for example, when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid. "Solvate" encompasses liquid phase and separable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, etc. "Hydrate" is a solvate in which the solvent molecule is H2O.
[0514] One or more compounds used in the method of the present invention may optionally be converted into solvates. The preparation of solvates is generally known. Thus, for example, M. Caira et al., J. Pharmaceutical Sci., 1993, 3, 601-611, describe the preparation of solvates of the antifungal drug fluconazole in ethyl acetate and water. EC van Tonder et al., AAPS PharmSciTech., 5(1) , article 12 (2004); and A.L. Bingham et al., Chem. Commun., 603-604 (2001) describe the preparation of similar solvates, hemisolvates, hydrates, etc. A typical, non-limiting process includes dissolving the compound of the present invention in a desired amount of a desired solvent (organic solvent or water or a mixture thereof) at a temperature above ambient temperature, and cooling the solution at a sufficient rate to form crystals, and then isolating the crystals by standard methods. Analytical techniques such as infrared spectroscopy show that the solvent (or water) is present in the crystals in the form of a solvate (or hydrate).
[0515] "Effective amount" or "therapeutically effective amount" refers to the amount of the compound or composition used in the method of the present invention, which effectively inhibits the above-mentioned disease or enzyme activity, thereby producing the desired treatment, improvement, inhibition or prevention effect.
[0516] Another embodiment provides a pharmaceutically acceptable salt of the compound used in the method of the present invention. Therefore, unless otherwise indicated, the compound used in the method of the present invention mentioned herein should be understood to include reference to its salt. The term "salt" used herein refers to an acidic salt formed with an inorganic and / or organic acid, and an alkaline salt formed with an inorganic and / or organic base. In addition, when the compound of the present invention comprises a basic moiety (such as, but not limited to, pyridine or imidazole) and an acidic moiety (such as, but not limited to, carboxylic acid) simultaneously, a zwitterion (inner salt) can be formed, and is included in the term "salt" used herein. Although other salts are also available, pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred. The salt of the compound used in the method of the present invention can be formed by, for example, reacting the compound of the present invention with a certain amount of acid or base (such as an equivalent) in a salt-precipitated medium or in an aqueous medium and then freeze-drying.
[0517] Exemplary acid addition salts include acetate, ascorbate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphorate, camphorsulfonate, fumarate, hydrochloride, hydrobromide, hydroiodide, lactate, maleate, methanesulfonate, naphthylsulfonate, nitrate, oxalate, phosphate, propionate, salicylate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate (also known as tosylate), and the like.
[0518] In addition, acids generally considered suitable for forming pharmaceutically useful salts from basic pharmaceutical compounds are described, for example, in P. Stahl et al., Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley-VCH; Zurich: Wiley-VCH; P. Gould, International J. of Pharmaceutics (1986) 33 Anderson et al., The Practice of Medicinal Chemistry (1996), Academic Press, New York; and The Orange Book (Food & Drug Administration, Washington, D.C., USA). The disclosures of these are incorporated herein by reference in their entirety.
[0519] Exemplary basic salts include ammonium salts, alkali metal salts such as sodium salts, lithium salts, potassium salts, alkaline earth metal salts such as calcium salts and magnesium salts, salts with organic bases (e.g., organic amines) such as dicyclohexylamine salts, tert-butylamine salts, and salts with amino acids such as arginine, lysine, etc. Nitrogen-containing basic groups can be quaternized using reagents such as lower alkyl halides (e.g., methyl, ethyl, and butyl chlorides, bromides, and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, and dibutyl sulfates), long-chain halides (e.g., decyl, lauryl, and stearyl chlorides, bromides, and iodides), aralkyl halides (e.g., benzyl and phenethyl bromides), and the like.
[0520] All such acid salts and base salts are intended as pharmaceutically acceptable salts of the invention and are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.
[0521] Another embodiment provides pharmaceutically acceptable esters of the compounds used in the methods of the present invention. These esters include the following groups: (1) carboxylic acid esters obtained by esterification of a hydroxyl group, wherein the non-carbonyl portion of the carboxylic acid moiety in the ester group is selected from a linear or branched alkyl group (e.g., acetyl, n-propyl, t-butyl, or n-butyl), an alkoxyalkyl group (e.g., methoxymethyl), an aralkyl group (e.g., benzyl), an aryloxyalkyl group (e.g., phenoxymethyl), an aryl group (e.g., halogen, C 1-4 Alkyl or C 1-4 (e.g., phenyl substituted with alkoxy or amino); (2) sulfonates, such as alkyl or aralkylsulfonyl (e.g., methylsulfonyl); (3) amino acid esters (e.g., L-valine ester or L-isoleucine ester); (4) phosphonates; (5) monophosphates, diphosphates, or triphosphates. Phosphates can also be further esterified, for example, with C 1-20 Alcohol or its reactive derivatives, or 2,3-di(C 6-24 ) Acylglycerol esterification.
[0522] As described herein, another embodiment provides tautomers of the compounds used in the methods of the present invention, as well as salts, solvates, esters, and prodrugs of these tautomers. It should be understood that all tautomeric forms of these compounds are within the scope of the compounds used in the methods of the present invention. For example, when present, all keto-enol and imine-enamine forms of these compounds are included in the present invention.
[0523] The compounds used in the methods of the present invention may contain asymmetric or chiral centers and therefore exist in different stereoisomeric forms. The present invention is intended to include all stereoisomeric forms of the compounds used in the methods of the present invention and mixtures thereof, including racemic mixtures as part of the present invention. In addition, the present invention also includes the use of all geometric isomers and positional isomers. For example, if the compound used in the methods of the present invention contains a double bond or a fused ring, then the cis and trans forms, (E) and (Z) forms, and mixtures thereof are all within the scope of the present invention.
[0524] Another embodiment provides a diastereomeric mixture and a single enantiomer of the compound used in the method of the invention. The diastereomeric mixture can be separated into a single diastereoisomer according to its physicochemical differences by methods well known to those skilled in the art, such as chromatography and / or fractional crystallization. Enantiomers can be converted into diastereomeric mixtures by reacting the enantiomer mixture with a suitable optically active compound (for example, a chiral auxiliary, such as chiral alcohol or Mosher acid chloride), then separating the diastereoisomers, and converting the single diastereoisomer into (for example, hydrolysis) the corresponding pure enantiomer to separate. In addition, some compounds used in the method of the invention may be atropisomers (for example, substituted biaryl) and are considered to be a part of the present invention. Enantiomers can also be separated by using a chiral HPLC column.
[0525] All stereoisomers (e.g., geometric isomers, optical isomers, etc.) of the compounds used in the methods of the present invention (including salts, solvates, esters and prodrugs of the compounds and stereoisomers of salts, solvates and esters of the prodrugs), such as stereoisomers that may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotational isomers, atropisomers and diastereomeric forms are considered to be embodiments within the scope of the present invention; as well as positional isomers (such as 4-pyridyl and 3-pyridyl) (for example, if the compounds of the present invention contain double bonds or fused rings, both the cis and trans forms and mixtures thereof are within the scope of the present invention. In addition, for example, all keto-enol and imine-enamine forms of the present invention are included in the methods of the present invention).
[0526] Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other or selected stereoisomers. The chiral centers of the invention may have the S or R configuration as defined in the IUPAC 1974 Recommendations. The use of the terms "salt," "solvate," "ester," "prodrug," and the like applies equally to salts, solvates, esters, and prodrugs of enantiomers, stereoisomers, rotational isomers, tautomers, positional isomers, racemates, or prodrugs of the compounds of the invention.
[0527] Another embodiment provides isotopically labeled compounds for use in the methods of the present invention. These compounds are identical to the compounds described herein except that one or more atoms have been replaced by an atom having an atomic mass or mass number different from that normally found in nature. Examples of isotopes that can be incorporated into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, such as 2 H. 3 H. 13 C. 14 C. 15 N. 18 O. 17 O. 31 P. 32 P. 35 S. 18 F and 36 Cl.
[0528] Certain isotopically labeled compounds of the present invention (e.g., 3 H and 14 C-labeled compounds) are useful in assays for the tissue distribution of compounds and / or substrates. 3 H) and carbon-14 (i.e. 14 C) isotopes are particularly popular because they are easy to prepare and detect. In addition, heavier isotopes such as deuterium (i.e. 2 H) substitution may offer certain therapeutic advantages due to greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and may therefore be preferred in certain circumstances. Isotopically labeled compounds of the present invention can generally be prepared by following procedures analogous to those disclosed in the schemes and / or embodiments herein below, i.e., substituting an appropriate isotopically labeled reagent for a non-isotopically labeled reagent.
[0529] In the compounds used in the methods of the present invention, atoms may exhibit their natural isotopic abundance, or one or more atoms may be artificially enriched in a particular isotope having the same atomic number but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. The present invention is intended to include all suitable isotopic variations of the compounds of the present invention. For example, different isotopic forms of hydrogen (H) include protium ( 1 H) and deuterium ( 2 H). The presence of deuterium in the compounds of the present invention is indicated by "D." Protium is the predominant hydrogen isotope found in nature. Deuterium enrichment may offer certain therapeutic advantages, such as increased in vivo half-life or reduced dosage requirements, or may provide a compound useful as a standard for characterizing biological samples. Isotopically enriched compounds of the present invention can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the schemes and embodiments herein using appropriate isotopically enriched reagents and / or intermediates.
[0530] The present invention is also intended to include polymorphic forms of the compounds used in the methods of the present invention, as well as polymorphic forms of the salts, solvates, esters, and prodrugs of these compounds.
[0531] Treatment
[0532] The present invention relates to a method for treating Plasmodium infection, comprising administering a compound as described herein or a pharmaceutically acceptable salt thereof to a subject in need of such treatment. More specifically, the method of the present invention comprises administering a compound of formula (I) or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in the form of a pharmaceutical composition containing a pharmaceutically acceptable carrier or excipient.
[0533] The present invention provides a method for treating Plasmodium infection, treating malaria, or inhibiting plasmepsin X, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, wherein the compound has structural formula (I) as described in the Summary of the Invention. In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered as a pharmaceutical composition together with a pharmaceutically acceptable carrier. Various embodiments of these methods are also provided herein, as described below.
[0534] The present invention also relates to the use of compounds of Formulas (I)-(VIII) or pharmaceutically acceptable salts thereof for inhibiting plasmepsin X activity, treating Plasmodium infection, or treating malaria. The present invention further relates to the use of compounds of Formulas (I)-(VIII) or pharmaceutically acceptable salts thereof for preparing medicaments for inhibiting plasmepsin X activity, treating Plasmodium infection, or treating malaria. The compounds of Formulas (I)-(VIII) or pharmaceutically acceptable salts thereof described in any embodiment of the present invention can be used for any of the above-mentioned uses.
[0535] The present invention provides a method for treating Plasmodium infection, treating malaria, or inhibiting plasmepsin IX, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, wherein the compound has structural formula (I) as described in the Summary of the Invention. In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered as a pharmaceutical composition together with a pharmaceutically acceptable carrier. Various embodiments of these methods are also provided herein, as described below.
[0536] The present invention also relates to the use of compounds of Formulas (I)-(VIII) or pharmaceutically acceptable salts thereof for inhibiting plasmepsin IX activity, treating Plasmodium infection, or treating malaria. The present invention further relates to the use of compounds of Formulas (I)-(VIII) or pharmaceutically acceptable salts thereof for preparing medicaments for inhibiting plasmepsin IX activity, treating Plasmodium infection, or treating malaria. The compounds of Formulas (I)-(VIII) or pharmaceutically acceptable salts thereof described in any embodiment of the present invention can be used for any of the above-mentioned uses.
[0537] The present invention provides a method for treating Plasmodium infection, treating malaria, or simultaneously inhibiting plasmepsin X and plasmepsin IX, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, wherein the compound has structural formula (I) as described in the Summary of the Invention. In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered as a pharmaceutical composition together with a pharmaceutically acceptable carrier. Various embodiments of these methods are also provided herein, as described below.
[0538] The present invention also relates to the use of compounds of formula (I)-(VIII) or pharmaceutically acceptable salts thereof for inhibiting the activity of plasmepsin X and plasmepsin IX, treating Plasmodium infection, or treating malaria. The present invention further relates to the use of compounds of formula (I)-(VIII) or pharmaceutically acceptable salts thereof for preparing medicaments for inhibiting the activity of plasmepsin X and plasmepsin IX, treating Plasmodium infection, or treating malaria. The compounds of formula (I)-(VIII) or pharmaceutically acceptable salts thereof described in any embodiment of the present invention can be used for any of the above-mentioned uses.
[0539] The methods of the present invention are useful in treating malaria because they can inhibit the onset, growth, or progression of the disease, alleviate the symptoms of the disease, cause regression of the disease, cure the disease, or otherwise improve the overall health of a subject suffering from or at risk of developing malaria. Thus, in accordance with the presently disclosed subject matter, the terms "treat," "treating," and grammatical variations thereof, as well as the phrase "therapeutic method," are intended to encompass any desired therapeutic intervention, including but not limited to methods for treating an existing infection in a subject, such as in a subject that has been exposed to a parasite as described herein.
[0540] Embodiments of the present invention also include one or more compounds of Formulae (I)-(VIII), or pharmaceutically acceptable salts thereof, for (i) use, (ii) use as a medicament or composition, or (iii) use in the preparation of a medicament for: (a) therapy (e.g., of a human); (b) medicine; (c) inhibition of parasite / malarial growth; (d) prevention or treatment of infection caused by a Plasmodium species; (e) reduction of the development, onset or severity of pathological symptoms associated with Plasmodium infection, or reduction of the likelihood of severe Plasmodium infection; or (f) treatment, prevention or delay of the onset, severity or progression of a malaria-related disease, including but not limited to malaria.
[0541] Thus, another embodiment provides a method for treating malaria or treating a Plasmodium infection, comprising administering a composition comprising an amount of at least one compound of Formula (I)-(VIII), or a pharmaceutically acceptable salt, solvate, ester, or prodrug thereof, and an effective amount of one or more other agents described below. In certain embodiments, the present invention describes a method for treating malaria or treating a Plasmodium infection, comprising administering a pharmaceutical composition comprising an amount of at least one compound of Formula (I)-(VIII), or a pharmaceutically acceptable salt, solvate, ester, or prodrug thereof, and an effective amount of one or more additional antimalarial drugs. In certain embodiments, the present invention also provides a method for treating malaria by inhibiting plasmepsin X, IX, and at least one other mechanism, comprising administering a pharmaceutical composition comprising an amount of at least one compound of Formula (I)-(VIII), or a pharmaceutically acceptable salt, solvate, ester, or prodrug thereof, and an effective amount of one or more additional antimalarial drugs, wherein the additional antimalarial drugs act by a mechanism other than inhibition of plasmepsin IX or plasmepsin X.
[0542] The pharmacological properties of the compounds of formula (I)-(VIII) or pharmaceutically acceptable salts thereof can be confirmed by various pharmacological assays.
[0543] Dosage and administration
[0544] Another embodiment provides suitable dosages and dosage forms for the compounds used in the methods of the present invention. The suitable dosage of the compound used in the methods of the present invention administered to a patient can be easily determined by a person skilled in the art, such as a primary physician, pharmacist, or other skilled staff member, and can vary depending on the patient's health, age, weight, frequency of administration, the situation of use in combination with other active ingredients, and the purpose of administration. The dosage range of the compound of the present invention can be from about 0.001 to 500 mg / kg body weight / day. In one embodiment, the dosage of a compound of the present invention or a pharmaceutically acceptable salt or solvate of the compound is from about 0.01 to about 25 mg / kg body weight / day. In another embodiment, the amount of active compound in the unit dose of the formulation can be varied or adjusted between about 1 mg to about 100 mg, in a specific embodiment, from about 1 mg to about 50 mg, and in another specific embodiment, from about 1 mg to about 25 mg. In another embodiment, the typical recommended daily dosage regimen for oral administration can be between about 1 mg / day to about 500 mg / day, in a specific embodiment, from 1 mg / day to 200 mg / day, administered in 2 to 4 divided doses.
[0545] As described above, the dosage and frequency of administration of the compounds of the present invention and / or pharmaceutically acceptable salts thereof will be adjusted according to the judgment of the attending clinician, taking into account factors such as the age, condition and size of the patient and the severity of the symptoms being treated.
[0546] Liquid form preparations include solutions, suspensions, and emulsions. For example, water or water-propylene glycol solutions may be mentioned for parenteral injection preparations, or sweeteners and opacifiers may be added to solutions, suspensions, and emulsions for oral administration. Liquid form preparations may also include solutions for intranasal administration.
[0547] Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas, eg nitrogen.
[0548] Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions, and emulsions.
[0549] Another embodiment provides the use of a composition comprising a compound of Formula (I)-(VIII) or a pharmaceutically acceptable salt thereof, formulated for transdermal delivery. The transdermal composition can be in the form of a cream, lotion, aerosol, and / or emulsion, and can be contained in a matrix or reservoir type transdermal patch, which is conventional in the art for this purpose.
[0550] Another embodiment provides the use of a composition comprising a compound of formula (I)-(VIII) or a pharmaceutically acceptable salt thereof, for subcutaneous administration. Another embodiment provides the use of a composition suitable for oral administration. In certain embodiments, it may be advantageous to prepare a pharmaceutical formulation comprising one or more compounds of formula (I)-(VIII) or a pharmaceutically acceptable salt thereof in unit dosage form. In this form, the formulation is subdivided into appropriately sized unit doses containing an appropriate amount of active ingredient, such as an effective amount to achieve the desired purpose. Each of the above alternatives is considered to be included in various embodiments of the present invention.
[0551] When used in combination with one or more other therapeutic agents ("combination therapy"), the compounds used in the methods of the present invention (i.e., compounds of Formula (I)-(VIII)) can be administered in combination or sequentially. When administered sequentially, the compounds of the present invention can be administered before or after the one or more other therapeutic agents, as determined by one skilled in the art or by patient preference.
[0552] If formulated as a fixed dose, such combination products employ a compound of Formula (I)-(VIII) of this invention, or a pharmaceutically acceptable salt thereof, within a dosage range as described herein, and the other pharmaceutically active agent or treatment within its dosage range.
[0553] Combination therapy
[0554] Another embodiment provides a method of treatment using a pharmaceutically acceptable composition comprising a compound of the present invention, which may be a pure chemical and may optionally further comprise other ingredients. Such compositions are believed to be capable of being prepared and used alone or in combination therapy. To prepare pharmaceutical compositions from the compounds of the present invention, the inert, pharmaceutically acceptable carrier may be a solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, dragees, and suppositories. Powders and tablets may contain from about 5% to about 95% active ingredient. Examples of suitable solid carriers are known in the art, such as magnesium carbonate, magnesium stearate, talc, sugar, or lactose. Tablets, powders, dragees, and capsules may be used as solid dosage forms suitable for oral administration. For examples of pharmaceutically acceptable carriers and methods of manufacture of various compositions, see A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18 th Edition, (1990), Mack Publishing Co., Easton, Pennsylvania.
[0555] Non-limiting examples of other drugs and active agents useful in combination therapies for treating malaria include: (Novartis International AG, Basel, Switzerland; artesunate + luminafine), (Sigma-Tau Pharmaceuticals, Inc, Rome, Italy; dihydroartemisinin-piperaquine), (Shin Poong Pharmaceutical Co, Ltd, Seoul, Korea; pyrrolidine + artesunate), ASAQ (Sanofi SA (Gentilly, France) / DNDi (Geneva, Switzerland; artesunate + amodiaquine), ASMQ (Cipla Limited (Mumbai, India) / DNDi, artesunate + mefloquine), SPAQ-CO TM(Guilin Pharmaceutical Co, Ltd. (Shanghai), amodiaquine + sulfadoxine, pyrimethamine), (Guilin Pharmaceutical, artesunate), artesunate, artesunate, dihydroartemisinin, luminafine, amodiaquine, mefloquine, piperaquine, quinine, chloroquine, atovaquone, artemether and sulfadoxine-pyrimethamine, Tafenoquine (Glaxosmithkline), OZ439 / PQP (Sanofi), OZ439 / FQ (Sanofi), KAE609 (Novartis), KAF156 (Novartis), DSM265 (NIH / Takeda) and MK-4815 (Merck & Co., Inc., Powles et al., Antimicrobial Agents and Chemotherapy 56(5):2414–2419 (2012)). The choice of such other active ingredients will be determined by the attending physician or other healthcare provider depending on the disease or condition to be treated.
[0556] Therefore, the present invention also provides a method of using a compound of Formula (I)-(VIII) or a pharmaceutically acceptable salt thereof to inhibit plasmepsin X, plasmepsin IX, or plasmepsin X and IX for treating Plasmodium infection or treating malaria, wherein the method further comprises administering one or more additional antimalarial drugs to a subject in need of such treatment. In certain embodiments, the one or more additional antimalarial drugs are selected from the group consisting of artemether, lumefantrine, dihydroartemisinin, piperaquine, pyrrolidine, artesunate, amodiaquine, mefloquine, sulfadoxine, pyrimethamine, lumefantrine, quinine, chloroquine, atovaquone, and proguanil.
[0557] Example
[0558] The meanings of the abbreviations in the examples are as follows.
[0559] ACN=MeCN=CH3CN=acetonitrile
[0560] AcOH = acetic acid
[0561] AIBN = azobisisobutyronitrile
[0562] Ar=Argon
[0563] BBr3=boron tribromide
[0564] BF3 Et2O=boron trifluoride etherate
[0565] Boc2O=di-tert-butyl dicarbonate
[0566] Cbz = benzyloxycarbonyl
[0567] CbzOSu=N-(benzyloxycarbonyloxy)succinimide
[0568] CBr4=tetrabromomethane
[0569] CCl4 = Carbon tetrachloride
[0570] CELITE = Diatomaceous earth Conc. = Concentrated
[0571] Cs2CO3=cesium carbonate
[0572] DBU=1,8-diazabicyclo[5.4.0]undec-7-ene
[0573] DCE = dichloroethane
[0574] DCM = dichloromethane
[0575] DDQ = 2,3-dichloro-5,6-dicyano-1,4-benzoquinone
[0576] DIBALH = Diisobutylaluminum hydride
[0577] DIPEA=DIEA=N,N-diisopropylethylamine, or Hünig's base
[0578] DMA = dimethylacetamide
[0579] DMAP = 4-dimethylaminopyridine
[0580] DMF=N,N-dimethylformamide
[0581] DMP = Dess-Martin Periodinane
[0582] DMSO = dimethyl sulfoxide
[0583] DPPE = 1,2-bis(diphenylphosphine)ethane
[0584] DPPF=1,1'-bis(diphenylphosphino)ferrocene
[0585] EDCI = EDC = 1-ethyl-(3-dimethylaminopropyl)carbodiimide
[0586] Et2O = diethyl ether
[0587] EtOAc = ethyl acetate
[0588] EtOH = ethanol
[0589] Et3SiH=triethylsilane
[0590] h = hours
[0591] H2=Hydrogen
[0592] HATU = 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate
[0593] HCl = hydrochloric acid
[0594] HFBA = heptafluorobutyric acid
[0595] HOAc = acetic acid
[0596] I2 = iodine
[0597] IPA = Isopropyl alcohol
[0598] [Ir(cod)Cl]2=cyclooctadiene iridium chloride dimer
[0599] K2CO3=potassium carbonate
[0600] K3PO4 = Potassium triphosphate
[0601] KF = Potassium Fluoride
[0602] KHMDS = Potassium bis(trimethylsilyl)amide
[0603] KOTMS = Potassium trimethylsilanol
[0604] LCMS = Liquid Chromatography-Mass Spectrometry
[0605] LDA = lithium diisopropylamide
[0606] LHMDS=LiHMDS=Lithium bis(trimethylsilyl)amide
[0607] LiAlH4=lithium aluminum hydride
[0608] LiOH = lithium hydroxide
[0609] min = minutes
[0610] Me = methyl
[0611] MeCN = acetonitrile
[0612] MeOH = CH3OH = methanol
[0613] MgSO4 = magnesium sulfate
[0614] MsCl = methanesulfonyl chloride
[0615] N2 = Nitrogen
[0616] NaBH4=Sodium borohydride
[0617] NaH = Sodium Hydride
[0618] NaHCO3 = Sodium bicarbonate
[0619] NaIO4 = sodium periodate
[0620] NaOH = Sodium Hydroxide
[0621] Na2CO3=sodium carbonate
[0622] Na2SO3=sodium sulfite
[0623] Na2SO4=Sodium sulfate
[0624] NH4Cl = ammonium chloride
[0625] NH4OH = ammonium hydroxide
[0626] NH4OAc = ammonium acetate
[0627] NaHMDS = Sodium bis(trimethylsilyl)amide
[0628] OMs = mesylate
[0629] OTs = tosylate
[0630] OTf = trifluoromethanesulfonyl
[0631] Pd(OH)2 / C=Pearlman's catalyst-palladium hydroxide on carbon
[0632] Pd-C = Palladium on Carbon
[0633] [Pd(C3H5)Cl2]=allylpalladium(II) chloride dimer
[0634] PdCl2(dppf)-CH2Cl2=[1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride
[0635] PPh3=triphenylphosphine
[0636] RuO2.H2O=Ruthenium(IV) oxide hydrate
[0637] RP-HPLC = Reversed-Phase High-Performance Liquid Chromatography
[0638] SFC = Supercritical Fluid Chromatography
[0639] TBDPS-Cl=TBSCl=tert-butyl(chloro)diphenylsilane
[0640] TEA=Et3N=triethylamine
[0641] TBAF = Tetra-n-butylammonium fluoride
[0642] TFA = trifluoroacetic acid
[0643] THF = Tetrahydrofuran
[0644] Ti(EtO)4=ethyl titanate
[0645] TMS = trimethylsilyl
[0646] TMSOTf = trimethylsilyl trifluoromethanesulfonate
[0647] TsOH = p-toluenesulfonic acid
[0648] CDCl3=heavy chloroform
[0649] CD3OD = heavy methanol
[0650] 1 standard atmosphere [atm] = 101325 Pascal [Pa] = 14.6959488 psi
[0651] The abbreviations used in NMR spectra are as follows:
[0652] s = singlet, d = doublet, dd = double of doublets, dt = double of triplets, ddd = double of doublets, Sept = septet, t = triplet, m = multiplet, br = broad, brs = broad singlet, q = quartet, J = coupling constant and Hz = Hertz.
[0653] Several methods for preparing the disclosed compounds are described in the following schemes and examples. Starting materials and intermediates were purchased from common commercial catalog sources, or prepared using known procedures, or otherwise described. Common preparation routes for some compounds of Formula I are described in the following schemes. In some cases, the order in which the reaction steps in the schemes are performed may be changed in order to promote the reaction or avoid unwanted reaction products.
[0654] Solution 1
[0655]
[0656] The compound of formula S-2 is prepared from S-1 by a macrolactamation reaction using an amide coupling reagent.
[0657] Option 2
[0658]
[0659] The intermediate compound of formula S-4 is prepared from S-3 using a catalyst such as the second generation Grubbs', Zhan', and Hoveyda / Grubbs' catalysts, after a ring-closing metathesis (RCM) reaction. The double bond in S-4 can be reduced, for example, under hydrogenation conditions, to give a product of formula S-5.
[0660] Option 3
[0661]
[0662] After a transition metal-catalyzed intramolecular cross-coupling reaction (e.g., Heck reaction), an intermediate compound of formula S-7 is prepared from S-6, wherein X is a halogen such as Cl, Br, and I. The double bond generated in S-7 can be reduced under, for example, hydrogenation conditions to give a product of formula S-8.
[0663] Option 4
[0664]
[0665] Products of formula S-10, where X is a halogen such as Cl, Br, and I, are prepared from S-9 following a transition metal-catalyzed intramolecular cross-coupling reaction such as a palladium-catalyzed CO coupling reaction.
[0666] Option 5
[0667]
[0668] Intramolecular S between alcohol and X N After the reaction of S-2, the product of formula S-12 is prepared from S-11, wherein X is a leaving group such as Cl, Br, I, OMs, OTs or OTf. The product of formula S-12 can also be prepared from the S-11 diol after dehydration conditions using acidic or other dehydrating agents.
[0669] Option 6
[0670]
[0671] Products of formula S-12 are prepared from intermediates S-13 or S-14 after intramolecular reductive etherification using conditions such as TMSOTf and Et3SiH.
[0672] Reactions sensitive to moisture or air were carried out in a glove box or under nitrogen or argon using anhydrous solvents and reagents. The progress of the reaction was determined by analytical thin layer chromatography (TLC) (typically using E. Merck pre-coated TLC plates, silica gel 60F-254, layer thickness 0.25 mm) or liquid chromatography-mass spectrometry (LC / MS).
[0673] Typically, the analytical LC-MS system used was a Waters ZQ ionizer with electrospray ionization in positive ion detection mode. TM The platform and Agilent 1100 series HPLC with autosampler. The column is usually Waters Xterra MS C18, 3.0×50mm, 5μm or Waters Acquity BEH C18 1.0 × 50 mm, 1.7 μm. The flow rate was 1 mL / min, and the injection volume was 10 μL. The UV detection range was 210–400 nm. The mobile phase consisted of solvent A (water with 0.05% TFA) and solvent B (MeCN with 0.05% TFA), with a gradient of 100% solvent A over 0.7 min, followed by a change to 100% solvent B over 3.75 min, a hold of 1.1 min, and then a return to 100% solvent A over 0.2 min.
[0674] Preparative HPLC purification is typically performed using either a mass spectrometry-guided system or a non-mass spectrometry-guided system. Purification is typically performed on a Waters Chromatography Workstation equipped with an LC-MS system consisting of a Waters ZQ TM The system consisted of a single quadrupole MS, a Waters 2525 gradient pump, a Waters 2767 injector / collector, and a Waters 996 PDA detector. The MS conditions were: 150-750 amu, positive electrospray, MS triggered collection, and a Waters C-18 5-micron, 30 mm (id) × 100 mm column. The mobile phase consisted of a mixture of acetonitrile (10-100%) and water containing 0.1% TFA. The flow rate was maintained at 50 mL / min, the injection volume was 1800 μL, and the UV detection range was 210-400 nm. Another preparative HPLC system was a Gilson Workstation, consisting of a Gilson GX-281 injector / collector, a Gilson UV / VIS-155 detector, a Gilson 333 and 334 pumps, and a Phenomenex Gemini-NX C-18 5-micron, 50 mm (id) × 250 mm column or a Waters XBridge TM C-18 5-micron OBD TM ,30mm(id)×250mm column. The mobile phase consisted of a mixture of acetonitrile (0-75%) and water containing 5mmol (NH4)HCO3. Waters Xbridge TMThe flow rate was maintained at 50 mL / min for the column and 90 mL / min for the Phenomenex Gemini column. The injection volume range was 1000-8000 μL, and the UV detection range was 210-400 nm. The mobile phase gradient was optimized for the specific compound. Reactions using microwave irradiation were typically performed in an Emrys Optimizer manufactured by Personal Chemistry or an Initiator manufactured by Biotage. Solution concentration was performed under reduced pressure on a rotary evaporator. Flash chromatography typically uses Flash chromatograph (Dyax Corp.), ISCO Rf meter or ISCO Companion XL is available in prepacked columns of the specified size (32-63 μM, Unless otherwise stated, 1 H NMR spectra were obtained in CDCl3 solution on a 500 MHz spectrometer. Chemical shifts are reported in parts per million (ppm). In CDCl3 solution, tetramethylsilane (TMS) was used as an internal reference; in CD3OD solution, the residual CH3OH peak or TMS was used as an internal reference. Coupling constants (J) are reported in Hertz (Hz). Chiral analytical chromatography is usually performed in AS, AD, OD, IA or Chiral preparative chromatography was performed on an OJ column (250×4.6 mm) (Daicel Chemical Industries, Ltd.) using the indicated percentages of ethanol in hexane (% Et / Hex) or isopropanol in n-heptane (% IPA / Hep) as isocratic solvent systems. OD, IA, OJ columns (20 x 250 mm) (Daicel Chemical Industries, Ltd.) were used with the desired isocratic solvent system as determined on chiral analytical chromatography or by supercritical fluid chromatography (SFC) conditions.
[0675] It is understood that chiral centers in a compound may exist in either the "S" or "R" stereoconfiguration, or as a mixture of both. Within a molecule, each bond drawn straight from a chiral center is intended to encompass both (R) and (S) stereoisomers, and mixtures thereof.
[0676] Intermediate 1
[0677] Preparation of intermediate 1-2
[0678]
[0679] To a mixture of a THF (80 mL) solution of (S)-6-methyl 4-hydroxychromene formate (INT1-1) (10 g, 48.0 mmol) was added DBU (21.72 mL, 144 mmol) and diphenylphosphonyl. Azide (35.0 g, 144 mmol) was added under N2. The mixture was stirred at 50 ° C for 12 h. The mixture was quenched with water (100 mL) and extracted with EtOAc (3×100 mL). The organic layer was washed with brine (80 mL), dried over Na2SO4, filtered and concentrated. The product was purified by flash silica gel chromatography ( 330g The crude product was purified by silica gel flash column (gradient elution with 15% EtOAc / petroleum ether @ 50 mL / min) to afford (R)-methyl 4-azidochromane-6-carboxylate (INT1-2).
[0680] MS (ESI) m / z 234.0 (M+H + )
[0681] 1 H NMR (500 MHz, chloroform-d) δ 7.93-7.96 (m, 2H), 6.91 (d, J = 8.5 Hz, 1H), 4.65 (t, J = 3.5 Hz, 1H), 4.29-4.35 (m, 2H), 3.90 (s, 3H), 2.14-2.26 (m, 1H), 2.06-2.12 (m, 1H)
[0682] Preparation of intermediate 1-3
[0683]
[0684] Under N2 atmosphere, to a THF (200mL) solution of (R)-4-azidochromane-6-formic acid methyl ester (INT1-2) (11g, 47.2mmol) was added Pd-C (2.510g, 4.72mmol). The mixture was degassed and backfilled with H2 (three times). The resulting mixture was stirred at 25 ° C for 12h under H2 (15psi) atmosphere. The catalyst was filtered off and the filtrate was concentrated under reduced pressure to obtain (R)-4-aminochromane-6-formic acid methyl ester (INT1-3).
[0685] MS (ESI) m / z: 191.1 (M-17+H + )
[0686] Preparation of intermediate 1
[0687]
[0688] Under N2, sodium hydride (3.77 g, 94 mmol) was added portionwise to a solution of N,N-bis-tert-butoxycarbonylthiourea (16.94 g, 61.3 mmol) in THF (250 mL). After 1 h at this temperature, 2,2,2-trifluoroacetic anhydride (8.82 mL, 61.3 mmol) was added dropwise. The mixture was stirred at 0 ° C for 1 h. A solution of (R)-4-aminochrome-6-carboxylic acid methyl ester (INT1-3) (9.77 g, 47.1 mmol) in THF (50 mL) was added dropwise at 0 ° C. The mixture was stirred at 0 ° C for 2 h. The reaction mixture was quenched with water (80 mL) and extracted with EtOAc (3×50 mL). The organic layer was washed with brine (40 mL), dried over Na2SO4, filtered and concentrated in vacuo. The product was purified by flash silica gel chromatography ( 220g The crude product was purified by silica gel flash column (gradient elution with 20% EtOAc / petroleum ether @ 50 mL / min) to afford (R)-methyl 4-(3-(tert-butoxycarbonyl)thioureido)chromane-6-carboxylate (INT-1).
[0689] MS (ESI) m / z 367.1 (M+H + )
[0690] 1 H NMR (500 MHz, chloroform-d) δ 8.01 (d, J = 1.5 Hz, 1H), 7.96 (s, 1H), 7.89 (dd, J = 2.0, 9.0 Hz, 1H), 6.89 (d, J = 9.0 Hz, 1H), 4.34-4.41 (m, 1H), 4.19-4.26 (m, 1H), 3.88 (s, 3H), 2.25-2.40 (m, 2H), 1.47 (s, 9H)
[0691] Intermediate 2
[0692] Preparation of intermediate 2-2
[0693]
[0694] To a solution of 4-pentenoic acid (INT2-1) (40 g, 400 mmol), EDCI (92 g, 479 mmol), 1H-benzo[d][1,2,3]triazole-1-ol (64.8 g, 479 mmol) and N-ethyl-N-isopropylpropane-2-amine (279 mL, 1598 mmol) in DCM (400 mL) was added N, O-dimethylhydroxylamine hydrochloride (54.6 g, 559 mmol). The reaction was stirred at 25 ° C for 12 h under N2 atmosphere. LCMS showed the desired mass. The mixture was quenched with water (300 mL) and extracted with DCM (3×100 mL). The organic layer was washed with brine (100 mL), dried over Na2SO4, filtered and concentrated in vacuo. The product was purified by flash silica gel chromatography ( The crude product was purified using a 220 g Agela silica flash column with a gradient of 8% EtOAc / petroleum ether at 50 mL / min to afford N-methoxy-N-methyl-4-pentenamide (INT2-2).
[0695] MS (ESI) m / z 144.1 (M+H) +
[0696] 1 H NMR (500 MHz, chloroform-d) δ 5.83-5.92 (m, 1H), 4.94-5.10 (m, 2H), 3.68 (s, 3H), 3.18 (s, 3H), 2.50-2.56 (m, 2H), 2.35-2.42 (m, 2H)
[0697] Preparation of intermediate 2-3
[0698]
[0699] To a solution of N-methoxy-N-methyl-4-penteneamide (INT2-2) (20 g, 140 mmol) in THF (200 mL) at 0 ° C under N2 atmosphere, ethylmagnesium bromide (69.8 mL, 210 mmol) was added dropwise at 0 ° C. The reaction was stirred at 25 ° C for 1 h under N2 atmosphere. TLC showed a new spot. The mixture was quenched with saturated NH4Cl aq (100 mL) and water (100 mL) and extracted with EtOAc (3×100 mL). The organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated in vacuo. The product was purified by flash silica gel chromatography ( The crude product was purified by 120 g Agela silica flash column, 5% EtOAc / petroleum ether gradient elution @ 40 mL / min) to give 6-hepten-3-one (INT2-3).
[0700] 1H NMR (500 MHz, chloroform-d) δ 5.78-5.83 (m, 1H), 4.92-5.07 (m, 2H), 2.48-2.54 (m, 2H), 2.43 (q, J = 7.0 Hz, 2H), 2.29-2.37 (m, 2H), 1.06 (t, J = 7.0 Hz, 3H)
[0701] Preparation of intermediate 2-4
[0702]
[0703] To a THF (100 mL) solution of 6-heptene-3-one (INT2-3) (10 g, 89 mmol) was added (R)-2-methylpropane-2-sulfinamide (12.97 g, 107 mmol), followed by Ti(EtO) (37.5 mL, 178 mmol). The reaction was then stirred at 75 ° C for 12 h under a N2 atmosphere. TLC showed new spots. The final mixture was cooled to room temperature, then diluted with DCM (200 mL), stirred for 15 min, and then ice-cold saturated sodium bicarbonate aqueous solution (50 mL) and Na2SO4 were added, filtered and concentrated in vacuo. The product was purified by flash silica gel chromatography ( The crude product was purified using a 120 g Agela silica flash column with a gradient of 8% EtOAc / petroleum ether at 40 mL / min to afford (R,E)-N-(6-hepten-3-ylidene)-2-methylpropane-2-sulfenamide (INT2-4).
[0704] MS (ESI) m / z 216.2 (M+H) +
[0705] 1 H NMR (500 MHz, chloroform-d) δ 5.73-5.88 (m, 1H), 4.94-5.10 (m, 2H), 2.64-2.87 (m, 2H), 2.31-2.58 (m, 4H), 1.22 (s, 9H), 1.05-1.20 (m, 3H)
[0706] Preparation of intermediate 2-5
[0707]
[0708] To a solution of diisopropylamine (19.64 mL, 139 mmol) in anhydrous THF (40 mL) was added n-butyl lithium (55.7 mL, 139 mmol) dropwise at -78 ° C under N2 atmosphere. The reaction was stirred at 0 ° C for 30 min to prepare LDA. Methyl acetate (7.48 mL, 93 mmol) and Ti(OiPr)3Cl (116 mL, 116 mmol) were added to anhydrous THF (90 mL). Then, at -78 ° C, LDA (76 mL, 93 mmol) was added dropwise to the mixture. After 1 h, a solution of (R, E)-N-(6-heptene-3-ylidene)-2-methylpropane-2-sulfenamide (INT2-4) (10 g, 46.4 mmol) in anhydrous THF (20 mL) was added dropwise, and the mixture was stirred at -78 ° C for 3 h. The color did not change and was yellow. LCMS showed the main DP mass. The mixture was quenched with ice-cold half-saturated aqueous ammonium chloride solution (60 mL). The slurry was diluted with EtOAc (200 mL), then filtered and rinsed with EtOAc and water. The organic layer was washed with salt water (50 mL), dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash silica gel chromatography ( The residue was purified on a 120 g Agela silica flash column, 25% EtOAc / petroleum ether gradient @ 40 mL / min) to afford methyl 3-(((R)-tert-butylsulfinyl)amino)-3-ethyl-6-heptenoate (INT2-5).
[0709] MS (ESI) m / z 290.1 (M+H) +
[0710] 1 H NMR (500MHz, chloroform-d) δ5.76-5.82(m,1H),5.01-5.05(m,1H),4.97(dd,J=1.0,10.0Hz,1H),4.63(br d,J=17.0Hz,1H),3.68(s,3H),2.72(dd,J=5.0,16.0Hz,1H),2.52(dd,J=2.5,16.0Hz,1H),2.07-2.13(m,1H), 1.82-1.91(m,1H),1.76-1.81(m,1H),1.71-1.75(m,1H),1.26(t,J=7.0Hz,2H),1.24(s,9H),0.87-0.95(m,3H)
[0711] Preparation of intermediate 2-6
[0712]
[0713] The SFC column DAICEL CHIRALPAK AD (250 mm × 50 mm, 10 μm) (condition 0.1% NH3·H2O IPA, start B15, end B15, gradient time (min) 100% B, hold time (min), flow rate (mL / min) 200, injection 200) and column DAICEL CHIRALPAK AD (250 mm × 50 mm, 10 μm) (condition 0.1% NH3·H2O IPA, start B12, stop B12, gradient time (min) 100% B, hold time (min), flow rate (mL / min) 200, injection 240) separated methyl 3-(((R)-tert-butylsulfinyl)amino)-3-ethyl-6-heptenoate (INT2-5) (12 g, 41.5 mmol) to give methyl (R)-3-(((R)-tert-butylsulfinyl)amino)-3-ethyl-6-heptenoate (INT2-6_P1, desired product) (t R = 1.978 min, UV = 220 nm) and methyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-ethyl-6-heptenoate (INT2-6_P2) (t R =2.132min, UV=220nm).
[0714] MS (ESI) m / z 290.1 (M+H) +
[0715] INT2-6_P1: 1 H NMR (500 MHz, chloroform-d) δ 5.79 (tdd, J = 6.56, 10.32, 16.99 Hz, 1H), 4.93-5.09 (m, 2H), 3.62-3.73 (m, 3H), 2.72 (d, J = 15.87 Hz, 1H), 2.52 (d, J = 15.87 Hz, 1H), 2.48 (s, 1H), 2.00-2.09 (m, 2H), 1.76-1.88 (m, 2H), 1.68-1.74 (m, 2H), 1.23 (s, 9H), 0.86-0.95 (m, 3H). INT2-6_P2: 1H NMR (500 MHz, chloroform-d) δ 5.71-5.87 (m, 1H), 4.94-5.07 (m, 2H), 3.65-3.73 (m, 3H), 2.72 (d, J = 16.02 Hz, 1H), 2.52 (d, J = 16.02 Hz, 1H), 2.00-2.14 (m, 2H), 1.83-1.91 (m, 1H), 1.74-1.80 (m, 1H), 1.67-1.74 (m, 2H), 1.20-1.25 (m, 8H), 0.83-0.89 (m, 3H).
[0716] Preparation of intermediate 2-7
[0717]
[0718] Methyl (R)-3-(((R)-tert-butylsulfinyl)amino)-3-ethyl-6-heptenoate (INT2-6_P1) (20 g, 69.1 mmol) was dissolved in HCl-dioxane (4N) (100 mL) and MeOH (200 mL) and stirred at 25 ° C for 2 h. LCMS showed that the reaction was complete. The solvent was evaporated under reduced pressure to give the product (R)-3-amino-3-ethyl-6-heptenoate hydrochloride methyl ester (INT2-7).
[0719] MS (ESI) m / z 186.3 (M+H) +
[0720] 1 H NMR (500 MHz, methanol-d4) δ 5.80-5.87 (m, 1H), 5.07-5.15 (m, 1H), 5.02-5.04 (m, 1H), 3.73 (s, 3H), 2.71-2.79 (m, 2H), 2.07-2.18 (m, 2H), 1.75-1.85 (m, 4H), 0.99 (t, J = 7.6 Hz, 3H)
[0721] Preparation of intermediate 2-8
[0722]
[0723] To a solution of DMB-BOC-THIOUREA (5 g, 15.32 mmol), (R)-3-amino-3-ethyl-6-heptenoate hydrochloride methyl ester (INT2-7) (3.74 g, 16.85 mmol) and EDC (7.34 g, 38.3 mmol) in acetonitrile (100 mL) was added DIEA (12.04 mL, 68.9 mmol). The reaction was stirred at 15 ° C for 12 h under N2 atmosphere. LCMS showed the desired mass and some ring-opening by-product ester. The temperature was then raised to 50 ° C and stirring was continued at 50 ° C for 2 h. LCMS showed only the desired product mass. The mixture was concentrated in vacuo. The crude product was dissolved in EtOAc (100 mL) and water (100 mL) and the organic layer was separated. The aqueous layer was extracted with EtOAc (2×50 mL). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered and concentrated in vacuo. The product was purified by flash silica gel chromatography ( The crude product was purified using an 80 g Agela silica gel flash column (15% EtOAc / petroleum ether gradient elution @ 30 mL / min) to afford tert-butyl (R,E)-(4-(but-3-en-1-yl)-1-(2,4-dimethoxybenzyl)-4-ethyl-6-oxotetrahydropyrimidin-2(1H)-ylidene)carbamate (INT2-8). MS (ESI) m / z 390.1 (M+H-56) +
[0724] 1 H NMR(400MHz,chloroform-d)δ9.92(br s,1H),7.10(br d,J=8.8Hz,1H),6.33-6.50(m,2H),5.63-5.83(m,1H),5.09(s,2H),4.96-5.06(m,2H),3.78(dd,J=1 .6,4.4Hz,6H),2.61(s,2H),1.98-2.12(m,2H),1.59-1.70(m,4H),1.49(s,9H),0.92(t,J=7.6Hz,3H)
[0725] Preparation of intermediate 2-9
[0726]
[0727] A solution of tert-butyl (R,E)-(4-(but-3-en-1-yl)-1-(2,4-dimethoxybenzyl)-4-ethyl-6-oxotetrahydropyrimidin-2(1H)-ylidene)carbamate (INT2-8) (1.0 g, 2.244 mmol) in TFA (10 mL) was stirred at 60°C for 16 h. LCMS showed the desired mass. The mixture was concentrated in vacuo. The residue was partitioned between petroleum ether / EtOAc (v / v=4:1, 10 mL) and water (10 mL). LCMS showed that the product was only in the aqueous phase and was very pure. A solution of (R)-6-(but-3-en-1-yl)-6-ethyl-2-iminotetrahydropyrimidin-4(1H)-one (INT2-9) in water (10 mL) was used directly in the next reaction. MS (ESI) m / z 196.0 (M+H) +
[0728] Preparation of intermediate 2
[0729]
[0730] To a solution of (R)-6-(but-3-ene-1-yl)-6-ethyl-2-iminotetrahydropyrimidin-4(1H)-one (INT2-9) (438 mg, 2.243 mmol) in water (10 mL) and THF (3 mL) was added NaHCO (942 mg, 11.22 mmol) and (BOC) O (1.042 mL, 4.49 mmol) in portions at 0 ° C. The reaction was stirred at 25 ° C for 16 h. LCMS showed the desired mass. The mixture was extracted with EtOAc (3×10 mL). The organic layer was washed with brine (10 mL), dried over Na SO, filtered and concentrated in vacuo. The product was purified by flash silica gel chromatography ( The crude product was purified by 12 g Agela silica gel flash column, eluted with 20% EE (EtOAC / EtOH=3:1) / petroleum ether @30 mL / min) to give tert-butyl (R,E)-(4-(but-3-en-1-yl)-4-ethyl-6-oxotetrahydropyrimidin-2(1H)-ylidene)carbamate (Intermediate 2).
[0731] MS (ESI) m / z 296.2 (M+H) +
[0732] 1 H NMR (400 MHz, chloroform-d) δ 9.37 (br s, 1H), 5.74-5.81 (m, 1H), 4.90-5.17 (m, 2H), 2.59 (s, 2H), 2.07-2.10 (m, 2H), 1.62-1.78 (m, 4H), 1.51 (s, 9H), 0.97 (t, J = 7.2 Hz, 3H)
[0733] Example 1
[0734]
[0735] (1R,5R,15R,16R)-5-Ethyl-15-hydroxy-3-imino-9-methyl-23-oxa-2,4,17-triazahexacyclo[17.6.2.22,5.210,13.012,16.022,26]triundecano-10,12,19,21,26,28-hexaene
[0736] -18,31-dione
[0737] Preparation of compound 1-2
[0738]
[0739] To a solution of (1R,2R)-1-amino-2,3-dihydro-1H-indene-2-ol (1-1) (500 mg, 3.35 mmol) in DCM (10 mL) was added trifluoromethanesulfonic acid (503 mg, 3.35 mmol) and N-bromosuccinimide (596 mg, 3.35 mmol) at 0 ° C. Under an N2 atmosphere, the reaction was stirred at 18 ° C for 1 h. The mixture was quenched with saturated sodium bicarbonate solution (10 mL) at 0 ° C and extracted with DCM (1×10 mL) and then with EtOAc (3×10 mL). The organic layer was washed with brine (10 mL), dried over Na2SO4, filtered and concentrated in vacuo. The product was purified by flash silica gel chromatography ( 12g The crude product was purified by silica gel flash column with a gradient of 10% MeOH / DCM (with 1% ammonium hydroxide added) at 50 mL / min to afford (1R,2R)-1-amino-6-bromo-2,3-dihydro-1H-inden-2-ol (1-2).
[0740] MS (ESI) m / z: 228.1, 230.1 (M+H + )
[0741] 1 H NMR (400MHz, methanol-d4) δ7.50(s,1H),7.33(dd,J=1.6,8.0Hz,1H),7.10(d,J=8.0Hz,1H),4.10(q ,J=6.8Hz,1H),4.01-4.05(m,1H),3.15(dd,J=6.8,15.6Hz,1H),2.68(dd,J=7.2,15.6Hz,1H)
[0742] Preparation of Compounds 1-3
[0743]
[0744] To a solution of (R)-4-((R,E)-2-((tert-butoxycarbonyl)imino)-4-ethyl-6-oxo-4-(pent-4-en-1-yl)tetrahydropyrimidin-1(2H)-yl)chromene-6-carboxylic acid (1-2) (96 mg, 0.198 mmol), EDC (189 mg, 0.989 mmol), 1H-benzo[d][1,2,3]triazol-1-ol (134 mg, 0.989 mmol), and (1R,2R)-1-amino-6-bromo-2,3-dihydro-1H-inden-2-ol (45.1 mg, 0.198 mmol) in THF (5 mL) was added DIEA (0.276 mL, 1.582 mmol). The reaction was stirred at 18° C. for 2 h. The reaction mixture was quenched with water (5 mL) and extracted with EtOAc (3×5 mL). The organic layer was washed with brine (5 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude product was purified by prep-TLC (petroleum ether / EtOAc=1:1) to give tert-butyl ((R,E)-1-((R)-6-(((1R,2R)-6-bromo-2-hydroxy-2,3-dihydro-1H-inden-1-yl)carbamoyl)chroman-4-yl)-4-ethyl-6-oxo-4-(pent-4-en-1-yl)tetrahydropyrimidin-2(1H)-ylidene)carbamate (1-3).
[0745] MS (ESI) m / z: 695.1, 697.1 (M+H + )
[0746] Preparation of compounds 1-4A, 1-4B and 1-4C
[0747]
[0748] In a glove box, to a solution of tert-butyl ((R,E)-1-((R)-6-(((1R,2R)-6-bromo-2-hydroxy-2,3-dihydro-1H-inden-1-yl)carbamoyl)chromen-4-yl)-4-ethyl-6-oxo-4-(pent-4-en-1-yl)tetrahydropyrimidin-2(1H)-ylidene)carbamate (1-3) (100 mg, 0.144 mmol) in dioxane (1.5 mL) were added [tri(o-tolyl)phosphine]chloro[2-(2'-amino-1,1'-biphenyl)]palladium(II) (8.83 mg, 0.014 mmol) and N,N-dicyclohexylmethylamine (140 mg, 0.719 mmol) at 25° C. The reaction was stirred at 70° C. for 16 h. The mixture was quenched with water (3 mL) and extracted with EtOAc (3 x 5 mL).The organic layer was washed with brine (5 mL), dried over Na2SO4, filtered and concentrated in vacuo.The crude product was purified by reverse phase preparative HPLC (instrument ED; method: column Boston Prime C18 150×30 mm, 5 μm; conditions: water (0.04% NH3H2O+10 mM NH4HCO3)-ACN, start B 65; end B 95, gradient time (min) 10 100% B; hold time (min) 2, flow rate (mL / min) 25; injection 5) to give: ((4aR,8R,12E,18R,18aR,28E)-8-ethyl-18-hydroxy-6,20-dioxo-4,4a,7,8,9,10,11,17,18,18a,19,20-dodecahydro-3H,6H-1,21-(epiethane[1,2]diylidene)-8,5-(amino-bridged) ... tert-Butyl ((4aR,8R,12Z,18R,18aR,28E)-8-ethyl-18-hydroxy-6,20-dioxo-4,4a,7,8,9,10,11,17,18,18a,19,20-dodecahydro-3-nitropropane)carbamate; ((4aR,8R,12Z,18R,18aR,28E)-8-ethyl-18-hydroxy-6,20-dioxo-4,4a,7,8,9,10,11,17,18,18a,19,20-dodecahydro-3-nitropropane)carbamate; tert-Butyl H,6H-1,21-(epiethane[1,2]diylidene)-8,5-(imidomethylidene)-14,16-vinylidenecyclopenta[h]pyrano[4,3-b][1,7]diazacyclononadecin-28-ylidene)carbamate (1-4B); and ((4aR,8R,17R,17aR,E)-8-ethyl-17-hydroxy-12-methylene-6,19 Tert-butyl-4,4a,6,7,8,9,10,11,12,16,17,17a,18,19-tetradecahydro-3H-1,20-(epiethane[1,2]diylidene)-8,5-(imidomethylidene)-13,15-vinylidenecyclopenta[h]pyrano[4,3-b][1,7]diazacyclooctadecin-27-ylidene)carbamate (1-4C).
[0749] MS (ESI) m / z: 486.2 (M+H + )
[0750] 1-4A: 11H NMR (500 MHz, chloroform-d) δ 10.09 (s, 1H), 7.93 (dd, J = 1.5, 8.50 Hz, 1H), 7.21 - 7.26 (m, 2H), 7.14 (d, J = 8.0 Hz, 1H), 6.91 - 6.98 (m, 2H), 6.42 - 6.54 (m, 3H), 5.82 - 5.92 (m, 1H), 5.25 (t, J = 5.5 Hz, 1H), 4.94 (s, 1H), 4.40 - 4.50 (m, 2H), 4.25 - 4.35 (m, 1H), 3.34 (dd, J = 8.0, 15.5 Hz, 1H), 2.99 - 3.05 (m, 1H), 2.67 - 2.86 (m, 2H), 2.57 (d, J = 13.5 Hz, 1H), 2.40 (d, J = 15.5 Hz, 1H), 2.07 (s, 2H), 1.82 (d, J = 11.0 Hz, 2H), 1.62 - 1.67 (m, 4H), 1.49 (s, 9H), 0.96 (t, J = 7.5 Hz, 3H)
[0751] 1-4B: 1 1H NMR (500 MHz, chloroform-d) δ 10.13 (s, 1H), 7.90 (dd, J = 2.0, 8.50 Hz, 1H), 7.37 (s, 1H), 7.25 (d, J = 7.5 Hz, 1H), 7.17 (s, 1H), 7.12 (d, J = 7.5 Hz, 1H), 6.96 (d, J = 8.50 Hz, 1H), 6.41 - 6.48 (m, 2H), 6.26 (dd, J = 7.0, 9.0 Hz, 1H), 5.60 - 5.70 (m, 1H), 5.34 (t, J = 6.5 Hz, 1H), 4.60 (s, 1H), 4.46 - 4.54 (m, 1H), 4.42 (td, J = 4.0, 11.0 Hz, 1H), 4.21 (dt, J = 2.5, 11.0 Hz, 1H), 3.34 (dd, J = 7.5, 16.0 Hz, 1H), 2.97 (dd, J = 7.5, 16.0 Hz, 1H), 2.60 - 2.72 (m, 2H), 2.49 - 2.53 (m, 2H), 2.22 - 2.30 (m, 1H), 2.13 - 2.18 (m, 1H), 2.03 - 2.12 (m, 2H), 1.72 - 1.82 (m, 4H), 1.49 (s, 9H), 1.00 (t, J = 7.5 Hz, 3H)
[0752] 1-4C: 1H NMR (500MHz, chloroform-d) δ10.04(s,1H),7.81(dd,J=2.0,8.5Hz,1H),7.52(d,J=8.0Hz,1H),7.24(d,J=8.0Hz,1H),6.99-7.16(m,2H) ,6.91(d,J=8.50Hz,1H),6.38-6.50(m,2H),5.44(s,1H),5.31(t,J=6.5Hz,1H),5.13(s,1H),4.41-4.57(m,2H),4.36(s,1H),4 .23 (dt, J = 2.0, 11.50 Hz, 1H), 3.34 (dd, J = 8.0, 16.0 Hz, 1H), 2.98 (dd, J = 8.0, 16.0 Hz, 1H), 2.69-2.79 (m, 1H), 2.59-2.63 (m, 1H), 2.45-2.52 (m, 2H), 1.93-2.09 (m, 2H), 1.86 (d, J = 12.0 Hz, 2H), 1.53-1.65 (m, 4H), 1.45 (s, 9H), 0.98 (t, J = 7.5 Hz, 3H) Preparation of compound 1-5
[0753]
[0754] To a solution of tert-butyl ((4aR,8R,17R,17aR,E)-8-ethyl-17-hydroxy-12-methylene-6,19-dioxo-4,4a,6,7,8,9,10,11,12,16,17,17a,18,19-tetradecahydro-3H-1,20-(epiethane[1,2]diylidene)-8,5-(imidomethylidene)-13,15-vinylidenecyclopenta[h]pyrano[4,3-b][1,7]diazacyclooctadecin-27-ylidene)carbamate (1-4C) (10 mg, 0.016 mmol) in MeOH (2 ml) was added Pd—C (1.731 mg, 3.25 μmol) under N₂ atmosphere. The mixture was degassed and backfilled with H₂ (three times). The reaction mixture was stirred at 25° C. for 12 h under H2 (15 psi). The catalyst was filtered off and the filtrate was concentrated under reduced pressure to afford tert-butyl ((4aR,8R,17R,17aR,E)-8-ethyl-17-hydroxy-12-methyl-6,19-dioxo-4,4a,6,7,8,9,10,11,12,16,17,17a,18,19-tetradecahydro-3H-1,20-(epiethane[1,2]diylidene)-8,5-(imidomethylidene)-13,15-vinylidenecyclopenta[h]pyrano[4,3-b][1,7]diazacyclooctadecin-27-ylidene)carbamate (1-5).
[0755] MS (ESI) m / z: 617.3 (M+H + )
[0756] Preparation of Example 1
[0757]
[0758] To a solution of tert-butyl ((4aR,8R,17R,17aR,E)-8-ethyl-17-hydroxy-12-methyl-6,19-dioxo-4,4a,6,7,8,9,10,11,12,16,17,17a,18,19-tetradecahydro-3H-1,20-(epiethane[1,2]diylidene)-8,5-(imidomethylidene)-13,15-vinylidenecyclopenta[h]pyrano[4,3-b][1,7]diazacyclooctadecin-27-ylidene)carbamate (1-5) (8 mg, 0.013 mmol) in DCM (3 ml) was added zinc(II) bromide (29.2 mg, 0.130 mmol) under N2 atmosphere at 22°C. The mixture was stirred at 22°C for 16 h. The mixture was cooled and the solvent was evaporated under reduced pressure to give a crude product. The residue was purified by reverse phase preparative HPLC (instrument EJ, method: column Boston Green ODS 150 x 30 mm, 5 μm; conditions: water (TFA)-ACN, start B 22, end B 52, gradient time (min) 10, 100% B; hold time (min) 2, flow rate (ml / min) 25, injection 1) to give Example 1. MS (ESI) m / z: 517.2 (M+H + )
[0759] 1 H NMR (500MHz, methanol-d4) δ8.49(d,J=9.0Hz,1H),7.72(dd,J=2.0,8.5Hz,1H),7.39(d,J=1.0Hz,1H),7.19-7.24 (m,1H),7.14-7.19(m,1H),6.91-6.96(m,2H),5.30-5.39(m,2H),4.38-4.53(m,2H),4.13-4.15(m,1H),3. 18-3.29(m,1H),2.75-2.94(m,3H),2.61-2.72(m,2H),2.20-2.30(m,1H),1.74-1.85(m,3H),1.58-1.68(m ,2H),1.50-1.57(m,1H),1.31(d,J=7.0Hz,3H),1.24-1.29(m,1H),1.11-1.20(m,1H),0.97(t,J=7.5Hz,3H)
[0760] Example 2
[0761]
[0762] (1R,5R,16R,17R)-5-Ethyl-16-hydroxy-3-imino-24-oxa-2,4,18-triazahexacyclo[18.6.2.22,5.211,14.013,17.023,27]triacontria-11,13,20,22,27,29-hexaene-19,32-dione
[0763] Preparation of compound 2-1
[0764]
[0765] To a solution of tert-butyl ((4aR,8R,12E,18R,18aR,28E)-8-ethyl-18-hydroxy-6,20-dioxo-4,4a,7,8,9,10,11,17,18,18a,19,20-dodecahydro-3H,6H-1,21-(epiethane[1,2]diylidene)-8,5-(imidomethyl)-14,16-vinylidenecyclopenta[h]pyrano[4,3-b][1,7]diazacyclononadecin-28-ylidene)carbamate (2-1) (13 mg, 0.021 mmol) in MeOH (4 mL) was added Pd—C (2.250 mg, 4.23 μmol) under N₂ atmosphere. The mixture was degassed and backfilled with H₂ (three times). The resulting mixture was stirred at 20° C. for 2 h under H2 (15 psi). The catalyst was filtered off, and the filtrate was concentrated under reduced pressure to give tert-butyl ((4aR,8R,18R,18aR,E)-8-ethyl-18-hydroxy-6,20-dioxo-4,4a,7,8,9,10,11,12,13,17,18,18a,19,20-tetradecahydro-3H,6H-1,21-(epiethane[1,2]diylidene)-8,5-(imidomethylidene)-14,16-vinylidenecyclopenta[h]pyrano[4,3-b][1,7]diazacyclononadecin-28-ylidene)carbamate (2-1).
[0766] MS (ESI) m / z: 617.2 (M+H + )
[0767] Preparation of Example 2
[0768]
[0769] To a solution of tert-butyl ((4aR,8R,18R,18aR,E)-8-ethyl-18-hydroxy-6,20-dioxo-4,4a,7,8,9,10,11,12,13,17,18,18a,19,20-tetradecahydro-3H,6H-1,21-(epiethane[1,2]diylidene)-8,5-(imidomethylidene)-14,16-vinylidenecyclopenta[h]pyrano[4,3-b][1,7]diazacyclononadecin-28-ylidene)carbamate (2-1) (3 mg, 0.021 mmol) in DCM (3 mL) was added zinc(II) bromide (47.5 mg, 0.211 mmol) under N2 atmosphere. The mixture was stirred at 22 °C for 16 h. The mixture was concentrated under reduced pressure to give a crude product. The crude product was purified by reverse phase preparative HPLC (instrument EJ; method column Boston Green ODS 150 x 30 mm, 5 μm, conditions water (TFA)-ACN starting B 22; end B 52 gradient time (min) 10; 100% B retention time (min) 2 flow rate (mL / min) 25; injection 1) The residue was purified to obtain (4aR,8R,18R,18aR)-8-ethyl-18-hydroxy-28-imino-4,4a,8,9,10,11,12,13,17,18,18a,19-dodecahydro-3H,6H-1,21-(epiethane[1,2]diylidene)-8,5-(iminodimethyl)-14,16-vinylidenecyclopenta[h]pyrano[4,3-b][1,7]diazacyclononadecine-6,20(7H)-dione (Example 2).
[0770] MS (ESI) m / z: 517.2 (M+H + )
[0771] 1H NMR(500MHz,METHANOL-d4)δ7.76(dd,J=2.0,8.5Hz,1H),7.46(d,J=1.5Hz,1H),7.13(d,J=8.0Hz,1H),6.99-7.06(m,2 H),6.93(d,J=8.5Hz,1H),5.21(t,J=7.5Hz,1H),5.07(d,J=5.5Hz,1H),4.54-4.62(m,1H),4.38-4.49(m,1H),4.09-4. 19(m,1H),3.23-3.28(m,1H),2.90(d,J=16.5Hz,1H),2.79(dd,J=6.0,16.0Hz,1H),2.62-2.74(m,2H),2.50-2.61(m,2 H),2.20-2.34(m,1H),1.81(s,1H),1.62-1.76(m,3H),1.49(t,J=11.5Hz,1H),1.12-1.44(m,6H),0.95(t,J=7.5Hz,3H)
[0772] Example 3A
[0773]
[0774] (1R,5R,17S)-5-ethyl-3-imino-15,15-dimethyl-14,24-dioxa-2,4,18-triazahexacyclo[18.6.2.22,5.210,13.012,17.023,27]triacontria-10,12,20,22,27,29-hexaene-19,32-dione
[0775] Preparation of compound 3-2
[0776]
[0777] To a solution of pent-4-enoic acid (40 g, 400 mmol), EDC (92 g, 479 mmol), 1H-benzo[d][1,2,3]triazole-1-ol (3-1) (64.8 g, 479 mmol) and N-ethyl-N-isopropylpropane-2-amine (279 mL, 1598 mmol) in DCM (400 mL) was added N,O-dimethylhydroxylamine hydrochloride (54.6 g, 559 mmol). Under N2 atmosphere, the reaction mixture was stirred at 25 ° C for 12 h. The mixture was quenched with water (300 mL) and extracted with DCM (3×100 mL). The organic layer was washed with brine (100 mL), dried over Na2SO4, filtered and concentrated in vacuo. The product was purified by flash silica gel chromatography ( The crude product was purified by 220 g Agela silica flash column, 8% EtOAc / petroleum ether gradient elution @ 50 mL / min) to afford N-methoxy-N-methylpent-4-enamide (3-2).
[0778] MS (ESI) m / z 144.1 (M+H + )
[0779] 1 H NMR (500 MHz, chloroform-d) δ 5.83-5.92 (m, 1H), 4.94-5.10 (m, 2H), 3.68 (s, 3H), 3.18 (s, 3H), 2.50-2.56 (m, 2H), 2.35-2.42 (m, 2H)
[0780] Preparation of compound 3-3
[0781]
[0782] To a solution of N-methoxy-N-methylpent-4-eneamide (3-2) (20 g, 140 mmol) in THF (200 mL) was added ethylmagnesium bromide (69.8 mL, 210 mmol) dropwise under N2 atmosphere at 0 ° C. Under N2 atmosphere, the reaction mixture was stirred at 25 ° C for 1 h. The mixture was quenched with saturated NH4Cl (100 mL) and water (100 mL) and extracted with EtOAc (3 × 100 mL). The organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated in vacuo. The product was purified by flash silica gel chromatography ( The crude product was purified using a 120 g Agela silica flash column (5% EtOAc / petroleum ether gradient elution @ 40 mL / min) to afford 6-hepten-3-one (3-3).
[0783] 1 H NMR (500 MHz, chloroform-d) δ 5.78-5.83 (m, 1H), 4.92-5.07 (m, 2H), 2.48-2.54 (m, 2H), 2.43 (q, J = 7.0 Hz, 2H), 2.29-2.37 (m, 2H), 1.06 (t, J = 7.0 Hz, 3H)
[0784] Preparation of compound 3-4
[0785]
[0786] To a THF (100 mL) solution of 6-heptene-3-one (3-3) (10 g, 89 mmol) was added (R)-2-methylpropane-2-sulfinamide (12.97 g, 107 mmol). Subsequently, Ti(EtO) 4 (37.5 mL, 178 mmol) was added, and the reaction mixture was stirred at 75 ° C for 12 h under an N 2 atmosphere. The mixture was cooled to room temperature, diluted with DCM (200 mL) and stirred for 15 min. Ice-cold saturated aqueous sodium bicarbonate solution (50 mL) and Na 2 SO 4 were added, the mixture was filtered and concentrated in vacuo. The residue was purified by flash silica gel chromatography ( The crude product was purified using a 120 g Agela silica flash column (8% EtOAc / petroleum ether gradient @ 40 mL / min) to afford (R,E)-N-(6-hepten-3-ylidene)-2-methylpropane-2-sulfenamide (3-4).
[0787] MS (ESI) m / z 216.2 (M+H + )
[0788] 1 H NMR (500 MHz, chloroform-d) δ 5.73-5.88 (m, 1H), 4.94-5.10 (m, 2H), 2.64-2.87 (m, 2H), 2.31-2.58 (m, 4H), 1.22 (s, 9H), 1.05-1.20 (m, 3H)
[0789] Preparation of compound 3-5
[0790]
[0791] To a solution of diisopropylamine (19.64 mL, 139 mmol) in anhydrous THF (40 mL) was added n-butyl lithium (55.7 mL, 139 mmol) dropwise at -78 ° C under N2 atmosphere. The reaction was stirred at 0 ° C for 30 min to prepare LDA. The generated LDA (76 mL, 93 mmol) was added dropwise to a mixture of EtOAc (7.48 mL, 93 mmol) and Ti(OiPr)3Cl (116 mL, 116 mmol) in anhydrous THF (90 mL) at -78 ° C. After 1 h, a solution of (R, E)-N-(6-heptene-3-ylidene)-2-methylpropane-2-sulfinamide (3-4) (10 g, 46.4 mmol) in anhydrous THF (20 mL) was added dropwise, and the mixture was stirred at -78 ° C for 3 h. The reaction mixture was quenched with ice-cold half-saturated NH4Cl aqueous solution (60 mL). The slurry was diluted with EtOAc (200 mL), then filtered and rinsed with EtOAc and water. The organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated in vacuo. The product was purified by flash silica gel chromatography ( The residue was purified using a 120 g Agela silica flash column, 25% EtOAc / petroleum ether gradient @ 40 mL / min) to afford methyl 3-(((R)-tert-butylsulfinyl)amino)-3-ethylhept-6-enoate (3-5).
[0792] MS (ESI) m / z 290.1 (M+H + )
[0793] 1 H NMR (500MHz, chloroform-d) δ5.76-5.82(m,1H),5.01-5.05(m,1H),4.97(dd,J=1.0,10.0Hz,1H),4.63(br d,J=17.0Hz,1H),3.68(s,3H),2.72(dd,J=5.0,16.0Hz,1H),2.52(dd,J=2.5,16.0Hz,1H),2.07-2.13(m,1H), 1.82-1.91(m,1H),1.76-1.81(m,1H),1.71-1.75(m,1H),1.26(t,J=7.0Hz,2H),1.24(s,9H),0.87-0.95(m,3H)
[0794] Preparation of Compound 3-6
[0795]
[0796] A solution of methyl 3-(((R)-tert-butylsulfinyl)amino)-3-ethylhept-6-enoate (3-5) (9 g, 31.1 mmol) in HCl-dioxane (4N) (20 mL) and MeOH (20.00 mL) was stirred at 25° C. under N atmosphere for 1 hour. The solvent was evaporated under reduced pressure to give a crude product, methyl 3-amino-3-ethylhept-6-enoate hydrochloride (3-6), which was used directly in the next step.
[0797] MS (ESI) m / z 186.2 (M+H + )
[0798] 1 H NMR (500 MHz, chloroform-d) δ 5.75-5.80 (m, 1H), 5.08 (dd, J = 1.0, 18.0 Hz, 1H), 4.98 (d, J = 10.22 Hz, 1H), 3.72-3.75 (m, 3H), 2.78-2.85 (m, 2H), 2.21-2.29 (m, 2H), 1.84-2.00 (m, 4H), 1.06 (t, J = 7.5 Hz, 3H)
[0799] Preparation of compound 3-7
[0800]
[0801] To a solution of EDC (9.08 g, 47.4 mmol), 3-amino-3-ethylhept-6-enoic acid methyl ester hydrochloride (3-6) (3.5 g, 15.79 mmol) and (R)-4-(3-(tert-butoxycarbonyl)thioureido)chromane-6-carboxylic acid methyl ester (INT-1) (5.78 g, 15.79 mmol) in ACN (30 mL) was added N-ethyl-N-isopropylpropane-2-amine (13.79 mL, 79 mmol). Under N2 atmosphere, the reaction mixture was stirred at 25 ° C for 12 h. The mixture was quenched with water (50 mL) and extracted with EtOAc (3×50 mL). The organic layer was washed with brine (30 mL), dried over Na2SO4, filtered and concentrated in vacuo to give methyl (4R)-4-((Z)-2-(tert-butoxycarbonyl)-3-(3-ethyl-1-methoxy-1-oxohept-6-en-3-yl)guanidino)chromene-6-carboxylate (3-7), which was used directly in the next step.
[0802] MS (ESI) m / z 518.2 (M+H + )
[0803] Preparation of compound 3-8
[0804]
[0805] To a solution of (4R)-4-((Z)-2-(tert-butyloxycarbonyl)-3-(3-ethyl-1-methoxy-1-oxohept-6-en-3-yl)guanidino)chromane-6-carboxylic acid methyl ester (3-7) (8.17 g, 15.78 mmol) in THF (50 mL) was added DBU (11.90 mL, 79 mmol). Under N2 atmosphere, the mixture was stirred at 50 ° C for 16 h. The mixture was quenched with water (50 mL) and extracted with EtOAc (3×50 mL). The organic layer was washed with brine (30 mL), dried over Na2SO4, filtered and concentrated in vacuo. The product was purified by flash silica gel chromatography ( The crude product was purified using a 120 g Agela silica flash column with a 25% EtOAc / petroleum ether gradient at 40 mL / min to afford methyl (4R)-4-((E)-4-(but-3-en-1-yl)-2-((tert-butoxycarbonyl)imino)-4-ethyl-6-oxotetrahydropyrimidin-1(2H)-yl)chromane-6-carboxylate (3-8).
[0806] MS (ESI) m / z 486.2 (M+H + )
[0807] 1 H NMR (500 MHz, chloroform-d) δ 7.77 (td, J = 2.0, 8.5 Hz, 1H), 7.62 (s, 1H), 6.84 (dd, J = 2.0, 8.5 Hz, 1H), 6.33-6.42 (m, 1H), 5.76-5.90 (m, 1H), 5.00-5.14 (m, 2H), 4.42-4.49 (m, 1H) ,4.22-4.23(m,1H),3.81-3.86(m,3H),2.70-2.81(m,1H),2.51-2.60(m,2H),2.03 -2.16(m,4H),1.75-1.84(m,2H),1.65-1.73(m,4H),1.52(s,9H),0.98-1.04(m,3H)
[0808] Preparation of compounds 3-9A and 3-9B
[0809]
[0810] The results were analyzed by SFC (column Boston Green ODS 150x30mm, 5um; conditions: water (TFA)-ACN, starting B 48, ending B 78, gradient time (min) 10, 100% B, hold time (min) 2, flow rate (mL / min) 25, injection 1) (4R)-4-((E)-4-(but-3-en-1-yl)-2-((tert-butoxycarbonyl)imino)-4-ethyl-6-oxotetrahydropyrimidin-1(2H)-yl)chromane-6-carboxylic acid methyl ester (3-8) (4 g, 8.24 mmol) was separated to give P1 (4R)-4-((E)-4-(but-3-en-1-yl)-2-((tert-butoxycarbonyl)imino)-4-ethyl-6-oxotetrahydropyrimidin-1(2H)-yl)chromane-6-carboxylic acid methyl ester (3-9A) (t R = 2.105 min, UV = 220 nm) and P2(4R)-4-((E)-4-(but-3-en-1-yl)-2-((tert-butoxycarbonyl)imino)-4-ethyl-6-oxotetrahydropyrimidin-1(2H)-yl)chromane-6-carboxylic acid methyl ester (3-9B) (t R =2.251 min, UV=220 nm).
[0811] MS (ESI) m / z 486.2 (M+H + )
[0812] 3-9A: 1 H NMR (500MHz, chloroform-d) δ7.77(dd,J=1.5,8.5Hz,1H),7.62(s,1H),6.84(d,J=9.0Hz,1H),6.37(br dd,J=7.0,10.0Hz,1H),5.81-5.86(m,1H),5.00-5.12(m,2H),4.42-4.45(m,2H),4.21-4.24(m,1H),3. 83(s,3H),2.68-2.78(m,1H),2.07-2.16(m,3H),1.66-1.83(m,5H),1.51(s,9H),0.96(t,J=7.5Hz,3H)
[0813] 3-9B: 1H NMR (500MHz, chloroform-d) δ7.77(br d,J=8.70Hz,1H),7.62(s,1H),6.84(d,J=8.5Hz,1H),6.39(br dd,J=7.0,10.0Hz,1H),5.74-5.86(m,1H),5.00-5.10(m,2H),4.41-4.50(m,1H),4.21-4.25(m,1H), 3.83(s,3H),2.73-2.81(m,1H),2.06-2.12(m,3H),1.68-1.83(m,5H),1.52(s,9H),0.98-1.04(m,3H)
[0814] Preparation of compound 3-10
[0815]
[0816] To a solution of methyl (4R)-4-((E)-4-(but-3-en-1-yl)-2-((tert-butoxycarbonyl)imino)-4-ethyl-6-oxotetrahydropyrimidin-1(2H)-yl)chromene-6-carboxylate (3-9A) (550 mg, 1.133 mmol) in THF (5 mL) was added potassium trimethylsilanol (872 mg, 6.80 mmol). The reaction was stirred at 25° C. for 0.5 h. The solution of (R)-4-((R,E)-4-(but-3-en-1-yl)-2-((tert-butoxycarbonyl)imino)-4-ethyl-6-oxotetrahydropyrimidin-1(2H)-yl)chromene-6-carboxylic acid (3-10) was used directly in the next step without further treatment or purification.
[0817] MS (ESI) m / z 472.2 (M+H + ).
[0818] Preparation of compound 3-11
[0819]
[0820] To a solution of (R)-4-((R,E)-4-(but-3-en-1-yl)-2-((tert-butoxycarbonyl)imino)-4-ethyl-6-oxotetrahydropyrimidin-1(2H)-yl)chromene-6-carboxylic acid (3-10) (534 mg, 1.132 mmol), EDC (1085 mg, 5.66 mmol), 1H-benzo[d][1,2,3]triazol-1-ol (765 mg, 5.66 mmol), and (S)-2,2-dimethyl-6-vinylchromene-4-amine (253 mg, 1.246 mmol) in THF (50 mL) was added DIEA (1.582 mL, 9.06 mmol). The reaction was stirred at 25° C. for 12 h. The mixture was quenched with water (20 mL) and extracted with EtOAc (3×20 mL). The organic layer was washed with brine (15 mL), dried over Na2SO4, filtered, and concentrated in vacuo. The crude product was purified by prep-TLC (petroleum ether / EtOAc ester = 2:1) to give tert-butyl ((R,E)-4-(but-3-en-1-yl)-1-((R)-6-(((S)-2,2-dimethyl-6-vinylchroman-4-yl)carbamoyl)chroman-4-yl)-4-ethyl-6-oxotetrahydropyrimidin-2(1H)-ylidene)carbamate (3-11).
[0821] MS (ESI) m / z 657.3 (M+H + )
[0822] Preparation of compound 3-12
[0823]
[0824] To a solution of tert-butyl ((R,E)-4-(but-3-en-1-yl)-1-((R)-6-(((S)-2,2-dimethyl-6-vinylchroman-4-yl)carbamoyl)chroman-4-yl)-4-ethyl-6-oxotetrahydropyrimidin-2(1H)-ylidene)carbamate (3-11) (500 mg, 0.761 mmol) in DCE (500 mL) was added (1,3-bis-(2,4,6-trimethylphenyl)-2-imidazolidinylidene)dichloro(o-isopropoxyphenylmethylene)ruthenium (95 mg, 0.152 mmol). The reaction was stirred at 50° C. under N atmosphere for 5 h. The mixture was concentrated in vacuo and the crude product was purified by flash column chromatography (petroleum ether / EtOAc / EtOH=8:3:1) to give tert-butyl ((4aR,8R,11E,18aS,28E)-8-ethyl-17,17-dimethyl-6,20-dioxo-4,4a,7,8,9,10,18,18a,19,20-decahydro-3H,6H,17H-8,5-(imidomethyl)-1,21:13,15-divinylidenedipyrano[4,3-b:4',3'-h][1,7]diazacyclooctadecin-28-ylidene)carbamate (3-12).
[0825] MS (ESI) m / z 629.3 (M+H + )
[0826] 1 H NMR (500MHz, chloroform-d) δ7.67(dd,J=1.5,8.5Hz,1H),7.36(s,1H),7.19(s,1H),7.05-7.10(m,1H),6.91(d,J=8.5Hz,1H),6.69(d,J= 8.5Hz,1H),6.37(d,J=15.5Hz,1H),6.09-6.22(m,2H),5.92-5.93(m,1H),5.40-5.42(m,1H),4.49(td,J=4.0,11.5Hz,1H),2.93- 3.04(m,2H),2.46-2.53(m,2H),2.35-2.41(m,1H),2.29(dd,J=6.5,13.0Hz,1H),1.91-1.99(m,1H),1.71-1.78(m,2H),1.66-1.7 1(m,4H),1.61-1.66(m,1H),1.50-1.53(m,1H),1.46-1.50(m,1H),1.43(s,3H),1.37(s,3H),1.26(s,9H),0.95(t,J=7.48Hz,3H)
[0827] Preparation of compound 3-13
[0828]
[0829] To a solution of tert-butyl ((4aR,8R,11E,18aS,28E)-8-ethyl-17,17-dimethyl-6,20-dioxo-4,4a,7,8,9,10,18,18a,19,20-decahydro-3H,6H,17H-8,5-(imidomethyl)-1,21:13,15-divinylidenedipyrano[4,3-b:4',3'-h][1,7]diazacyclooctadecin-28-ylidene)carbamate (3-12) (300 mg, 0.477 mmol) in MeOH (10 mL) was added Pd-C (50.8 mg, 0.048 mmol) under N2 atmosphere. The mixture was degassed and backfilled with H2 (three times). The reaction mixture was stirred at 25°C for 0.5 h under a H2 atmosphere (15 psi). The catalyst was filtered off, and the filtrate was concentrated under reduced pressure to obtain tert-butyl ((4aR,8R,18aS,E)-8-ethyl-17,17-dimethyl-6,20-dioxo-4,4a,7,8,9,10,11,12,18,18a,19,20-dodecahydro-3H,6H,17H-8,5-(imidomethyl)-1,21:13,15-divinylidenedipyrano[4,3-b:4',3'-h][1,7]diazacyclooctadecin-28-ylidene)carbamate (3-13), which was used directly in the next reaction.
[0830] MS (ESI) m / z 631.3 (M+H + )
[0831] Preparation of Example 3A
[0832]
[0833] Tert-butyl ((4aR,8R,18aS,E)-8-ethyl-17,17-dimethyl-6,20-dioxo-4,4a,7,8,9,10,11,12,18,18a,19,20-dodecahydro-3H,6H,17H-8,5-(imidomethyl)-1,21:13,15-divinylidenedipyrano[4,3-b:4',3'-h][1,7]diazacyclooctadecin-28-ylidene)carbamate (3-13) (280 mg, 0.444 mmol) was dissolved in HCl-dioxane (4N) (30 mL) and stirred at 25°C for 16 h. The solvent was evaporated under reduced pressure to give a crude product. The residue was purified by reverse phase preparative HPLC (column Boston Green ODS 150x30 mm, 5 um; conditions: water (HCl)-ACN, start B 30, stop B 50, gradient time (min) 10, 100% B, hold time (min) 2, flow rate (mL / min) 25, injection 6) to give (4aR,8R,18aS)-8-ethyl-28-imino-17,17-dimethyl-4,4a,7,8,9,10,11,12,17,18,18a,19-dodecahydro-3H,6H,20H-8,5-(imidomethyl)-1,21:13,15-divinylidenedipyrano[4,3-b:4',3'-h][1,7]diazacyclooctadecine-6,20-dione (Example 3A).
[0834] MS (ESI) m / z 531.2 (M+H + )
[0835] 1 H NMR (500MHz, methanol-d4) δ7.73 (dd, J = 2.0, 8.5Hz, 1H), 7.45 (s, 1H), 7.02 (s, 1H), 6.92-6.99 (m, 2H), 6. 70(d,J=8.5Hz,1H),5.37-5.44(m,2H),4.44-4.47(m,1H),4.12-4.17(m,1H),2.93(d,J=16.5Hz,1 H),2.55-2.70(m,4H),2.23-2.31(m,1H),2.12(dd,J=6.5,13.0Hz,1H),1.81-1.87(m,1H),1.66-1 .80(m,5H),1.49-1.59(m,1H),1.42(s,3H),1.34-1.40(m,2H),1.32(s,3H),0.98(t,J=7.5Hz,3H)
[0836] Example 4
[0837]
[0838] (1R,5R,18S)-5-ethyl-3-imino-16,16-dimethyl-10,15,25-trioxa-2,4,19-triazahexacyclo[19.6.2.22,5.211,14.013,18.024,28]tritrioxa-11,13,21,23,28,30-
[0839] Hexaene-20,33-dione
[0840] Preparation of compound 4-2
[0841]
[0842] To a solution of hex-5-enoic acid (4-1) (8 g, 70.1 mmol), EDC (20.15 g, 105 mmol), 1H-benzo[d][1,2,3]triazole-1-ol (14.21 g, 105 mmol) and N,O-dimethylhydroxylamine hydrochloride (7.52 g, 77 mmol) in THF (100 mL) was added DIEA (36.7 mL, 210 mmol). The reaction was stirred at 25 ° C for 5 h. The mixture was quenched with water (150 mL) and extracted with EtOAc (3×50 mL). The organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated in vacuo. The product was purified by flash silica gel chromatography ( 80g The crude product was purified by silica gel flash column (5% EtOAc / petroleum ether gradient elution @ 80 mL / min) to give N-methoxy-N-methylhex-5-enamide (4-2).
[0843] MS (ESI) m / z 157.7 (M+H + )
[0844] Preparation of compound 4-3
[0845]
[0846] To a solution of N-methoxy-N-methylhex-5-enamide (4-2) (9 g, 57.2 mmol) in THF (120 mL) was added ethylmagnesium bromide (38.2 mL, 114 mmol) dropwise under N2 atmosphere at 0°C. The mixture was then stirred at 20°C for 2 h. The mixture was quenched with saturated aqueous NH4Cl solution (25 mL). The mixture was quenched with water (150 mL) and extracted with EtOAc (3×100 mL). The combined organic layers were washed with brine (80 mL), dried over Na2SO4, and then filtered. The solvent was removed under reduced pressure to obtain a crude product, which was purified by column chromatography (SiO2, petroleum ether: EtOAc = 100:1 to 10:1) to give oct-7-ene-3-one (4-3).
[0847] 1 H NMR (500 MHz, chloroform-d) δ 5.76 (m, 1H), 4.93-5.04 (m, 2H), 2.38-2.44 (m, 4H), 2.05 (q, J = 7.0 Hz, 2H), 1.68 (m, 2H), 1.04 (t, J = 7.5 Hz, 3H). Preparation of compound 4-4
[0848]
[0849] To a THF (80 mL) solution of oct-7-ene-3-one (4-3) (5.5 g, 43.6 mmol) was added 2-methylpropane-2-sulfinamide (6.34 g, 52.3 mmol), followed by Ti(EtO) (18.31 ml, 87 mmol). The reaction mixture was stirred at 75 ° C for 16 h under an N2 atmosphere. The final mixture was cooled to 0 ° C, diluted with DCM (100 mL) and stirred for 15 min. An ice-cold saturated aqueous sodium bicarbonate solution (15 mL) was added, the solution was filtered and concentrated in vacuo. The crude product was purified by flash column chromatography (SiO2, petroleum ether / EtOAc=100:1 to 5:1) to give ((E)-2-methyl-N-(oct-7-ene-3-ylidene)propane-2-sulfinamide (4-4).
[0850] MS (ESI) m / z 230.2 (M+H + )
[0851] 1 H NMR (500 MHz, chloroform-d) δ 5.78-5.80 (m, 1H), 4.96-5.07 (m, 2H), 2.62-2.76 (m, 2H), 2.39-2.50 (m, 2H), 2.04-2.17 (m, 2H), 1.67-1.76 (m, 2H), 1.23 (s, 9H), 1.06-1.21 (m, 3H)
[0852] Preparation of compound 4-5
[0853]
[0854] To anhydrous THF (35mL) solution of LiHMDS (22.67ml, 22.67mmol) at -78 ° C under N2 atmosphere, methyl acetate (1.545ml, 19.18mmol) was added. The reaction was stirred at -78 ° C for 15 minutes. Then, a THF (15mL) solution of (E)-2-methyl-N-(oct-7-ene-3-ylidene)propane-2-sulfinamide (4-4) (4g, 17.44mmol) was added dropwise, and the mixture was stirred at -78 ° C for 3h. The mixture was quenched with ice-cold half-saturated aqueous ammonium chloride solution (30mL). The slurry was diluted with EtOAc (50mL), then filtered, and rinsed with EtOAc and water. The organic layer was washed with brine (50mL), dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash column chromatography (SiO 2 , petroleum ether / EtOAc=100:0 to 10:1) to give methyl 3-((tert-butylsulfinyl)amino)-3-ethyloct-7-enoate (4-5).
[0855] MS (ESI) m / z 304.3 (M+H + ).
[0856] 1 H NMR (500 MHz, chloroform-d) δ 5.72-5.86 (m, 1H), 4.91-5.06 (m, 2H), 4.59-4.61 (m, 1H), 3.63-3.76 (m, 3H), 2.68-2.71 (m, 1H), 2.42-2.55 (m, 1H), 1.99-2.13 (m, 2H), 1.58-1.91 (m, 5H), 1.31-1.48 (m, 2H), 1.16-1.24 (m, 9H), 0.80-0.93 (m, 3H)
[0857] Preparation of Compound 4-6
[0858]
[0859] Methyl 3-((tert-butylsulfinyl)amino)-3-ethyloct-7-enoate (4-5) (2 g, 6.59 mmol) was dissolved in HCl-dioxane (4N) (5 mL) and MeOH (5 mL) under N2 atmosphere at 15°C and stirred for 1 h at 15°C. The solution was concentrated in vacuo to give the crude product, methyl 3-amino-3-ethyloct-7-enoate hydrochloride (4-6), which was used in the next step without further purification.
[0860] 1 H NMR (500 MHz, chloroform-d) δ 5.77 (m, 1H), 4.93-5.06 (m, 2H), 3.73 (s, 3H), 2.72-2.88 (m, 2H), 2.02-2.14 (m, 2H), 1.70-2.00 (m, 5H), 1.56 (m, 2H), 1.04 (t, J = 7.50 Hz, 3H)
[0861] Preparation of Compound 4-7
[0862]
[0863] To a solution of (R)-4-(3-(tert-butoxycarbonyl)thioureido)chromane-6-carboxylic acid methyl ester (INT-1) (1.5 g, 4.09 mmol), 3-amino-3-ethyloct-7-enoic acid methyl ester hydrochloride (4-6) (1.448 g, 6.14 mmol) and N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (2.354 g, 12.28 mmol) in acetonitrile (30 mL) was added N-ethyl-N-isopropylpropan-2-amine (4.37 ml, 24.56 mmol). The mixture was stirred at 15° C. for 10 h. The mixture was quenched with water (50 mL) and extracted with EtOAc (3×40 mL). The organic layer was washed with brine (20 mL), dried over Na2SO4, filtered and concentrated in vacuo to give (4R)-4-((Z)-2-(tert-butoxycarbonyl)-3-(3-ethyl-1-methoxy-1-oxooct-7-en-3-yl)guanidino)chromane-6-carboxylic acid methyl ester (4-7), which was used directly in the next step as a crude product.
[0864] MS (ESI) m / z 532.3 (M+H + ).
[0865] Preparation of Compound 4-8
[0866]
[0867] To a solution of (4R)-4-((Z)-2-(tert-butyloxycarbonyl)-3-(3-ethyl-1-methoxy-1-oxooct-7-en-3-yl)guanidino)chromane-6-carboxylic acid methyl ester (4-7) (2.0 g, 3.76 mmol) in THF (20 mL) was added DBU (2.84 mL, 18.81 mmol). The mixture was stirred at 50 ° C for 10 h. The mixture was quenched with water (40 mL) and extracted with EtOAc (3×40 mL). The organic layer was washed with brine (20 mL), dried over Na2SO4, filtered and concentrated in vacuo. The product was purified by flash silica gel chromatography ( The crude product was purified using a 20 g Agela silica flash column with a 15% EtOAc / petroleum ether gradient at 60 mL / min to afford methyl (4R)-4-((E)-2-((tert-butoxycarbonyl)imino)-4-ethyl-6-oxo-4-(pent-4-en-1-yl)tetrahydropyrimidin-1(2H)-yl)chromane-6-carboxylate (4-8).
[0868] MS (ESI) m / z: 500.6 (M+H + ).
[0869] 1 H NMR (400 MHz, chloroform-d) δ 10.10 (s, 1H), 7.75 (d, J = 8.8 Hz, 1H), 7.61 (s, 1H), 6.83 (dd, J = 0.8, 8.8 Hz, 1H), 6.31-6.46 (m, 1H), 5.77 (m, 1H), 4.97-5.10 (m, 2H), 4.43 (d, J = 11.2 Hz, 1H), 4.17-4.29 (m, 1H), 3.82 (s, 3H), 2.68-2.86 (m, 1H), 2.47-2.59 (m, 2H), 2.06-2.18 (m, 2H), 1.56-1.81 (m, 5H), 1.51 (s, 9H), 1.45 (s, 3H), 1.40 (s, 1H)
[0870] Preparation of compounds 4-9A and 4-9B
[0871]
[0872] Methyl (4R)-4-((E)-2-((tert-Butoxycarbonyl)imino)-4-ethyl-6-oxo-4-(pent-4-en-1-yl)tetrahydropyrimidin-1(2H)-yl)chromane-6-carboxylate (4-8) (1.8 g, 3.60 mmol) was purified by SFC (instrument SFC-22, method column DAICEL CHIRALPAK AD (250 mm x 30 mm, 10 μm), condition: 0.1% NH 3 H 2 O IPA, starting B 10%, ending B 10%, gradient time (min) 100% B, holding time (min), flow rate (mL / min) 50, injection 60) was used for separation to obtain the products (R)-4-((R,E)-2-((tert-butoxycarbonyl)imino)-4-ethyl-6-oxo-4-(pent-4-en-1-yl)tetrahydropyrimidin-1(2H)-yl)chromene-6-carboxylic acid methyl ester (4-9A) (peak 1, Rt = 0.816) and (E)-4-(2-((tert-butoxycarbonyl)imino)-4-ethyl-6-oxo-4-(pent-4-en-1-yl)tetrahydropyrimidin-1(2H)-yl)chromene-6-carboxylic acid methyl ester (4-9B) (peak 2, Rt = 0.879).
[0873] MS (ESI) m / z: 500.2 (M+H + )
[0874] Preparation of compound 4-10
[0875]
[0876] To a solution of (R)-4-((R,E)-2-((tert-butoxycarbonyl)imino)-4-ethyl-6-oxo-4-(pent-4-en-1-yl)tetrahydropyrimidin-1(2H)-yl)chromane-6-carboxylic acid methyl ester (4-9A) (100 mg, 0.200 mmol) in 1,4-dioxane (4 mL) and water (1 mL) were added 2,6-lutidine (42.9 mg, 0.400 mmol) and osmium (VIII) oxide (5.09 mg, 0.020 mmol). The resulting solution was stirred at 25° C. for 0.2 h. Sodium periodate (1 mL) was added. The product was concentrated into 4- ((R, E)-2- (tert-butyloxycarbonyl) imino) -4-ethyl -6- oxo -4- (4- oxobutyl) tetrahydropyrimidin-1 (2H) -yl) chromane -6- carboxylic acid methyl ester (4-10), which was used as a crude product in the next step.
[0877] MS (ESI) m / z: 502.3 (M+H + )
[0878] Preparation of compound 4-11
[0879]
[0880] To a solution of (R)-4-((R,E)-2-((tert-butoxycarbonyl)imino)-4-ethyl-6-oxo-4-(4-oxobutyl)tetrahydropyrimidin-1(2H)-yl)chromane-6-carboxylic acid methyl ester (4-10) (95 mg, 0.189 mmol) in MeOH (2 mL) was added NaBH4 (10.75 mg, 0.284 mmol) in portions at 0°C. The mixture was stirred at 0°C for 1 h. LCMS showed the mass of the major desired product. The mixture was quenched with water (5 mL) and extracted with EtOAc (4×5 mL). The combined organic layers were washed with brine (5 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude product was purified by prep-TLC (petroleum ether / EtOAc=3:1) to give (R)-4-((R,E)-2-((tert-butyloxycarbonyl)imino)-4-ethyl-4-(4-hydroxybutyl)-6-oxotetrahydropyrimidin-1(2H)-yl)chromane-6-carboxylic acid methyl ester (4-11). MS (ESI) m / z: 504.4 (M+H + )
[0881] 1 H NMR (400 MHz, chloroform-d) δ 10.14 (s, 1H), 7.76 (dd, J = 2.0, 8.4 Hz, 1H), 7.65 (s, 1H), 6.84 (d, J = 8.4 Hz, 1H), 6.36 (dd, J = 7.2, 10.0 Hz, 1H), 4.43-4.46 (m, 1H), 4.22-4.26 (m, 1H) ,3.84(s,3H),3.68(t,J=6.4Hz,2H),2.69-2.78(m,1H),2.51-2.62(m,2H),1.95-2. 24(m,2H),1.64-1.69(m,6H),1.52(s,9H),1.43-1.49(m,2H),0.97(t,J=7.6Hz,3H)
[0882] Preparation of compound 4-12
[0883]
[0884] To a solution of (R)-4-((R,E)-2-((tert-butoxycarbonyl)imino)-4-ethyl-4-(4-hydroxybutyl)-6-oxotetrahydropyrimidin-1(2H)-yl)chromene-6-carboxylic acid methyl ester (4-11) (53 mg, 0.105 mmol) in THF (1 mL) was added potassium trimethylsilanol (81 mg, 0.631 mmol). The reaction mixture was stirred at 25° C. for 0.5 h. LCMS showed a major mass of the desired product. The resulting solution of (R)-4-((R,E)-2-((tert-butoxycarbonyl)imino)-4-ethyl-4-(4-hydroxybutyl)-6-oxotetrahydropyrimidin-1(2H)-yl)chromene-6-carboxylic acid (4-12) was used directly in the next step without further treatment or purification.
[0885] MS (ESI) m / z: 490.2 (M+H + )
[0886] Preparation of compound 4-13
[0887]
[0888] To a solution of (R)-4-((R,E)-2-((tert-butoxycarbonyl)imino)-4-ethyl-4-(4-hydroxybutyl)-6-oxotetrahydropyrimidin-1(2H)-yl)chromene-6-carboxylic acid (4-12) (50 mg, 0.102 mmol), EDC (98 mg, 0.511 mmol), 1H-benzo[d][1,2,3]triazol-1-ol (69.0 mg, 0.511 mmol), and (S)-6-bromo-2,2-dimethylchromen-4-amine (28.8 mg, 0.112 mmol) in THF (5 mL) was added DIEA (0.143 mL, 0.817 mmol). The reaction was stirred at 25° C. for 3 h. The mixture was quenched with water (5 mL) and extracted with EtOAc (3×5 mL). The organic layer was washed with brine (5 mL), dried over Na2SO4, filtered, and concentrated in vacuo. The crude product was purified by prep-TLC (petroleum ether / EtOAc=3:1) to give tert-butyl ((R,E)-1-((R)-6-(((S)-6-bromo-2,2-dimethylchroman-4-yl)carbamoyl)chroman-4-yl)-4-ethyl-4-(4-hydroxybutyl)-6-oxotetrahydropyrimidin-2(1H)-ylidene)carbamate (4-13).
[0889] MS (ESI) m / z: 727.2, 729.2 (M+H + )
[0890] Preparation of compound 4-14
[0891]
[0892] In a glove box, to a solution of tert-butyl ((R,E)-1-((R)-6-(((S)-6-bromo-2,2-dimethylchroman-4-yl)carbamoyl)chroman-4-yl)-4-ethyl-4-(4-hydroxybutyl)-6-oxotetrahydropyrimidin-2(1H)-ylidene)carbamate (4-13) (70 mg, 0.096 mmol) in dioxane (3 mL) was added [(2-di-tert-butylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)-2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate (7.64 mg, 9.62 μmol) and CsCO (37.1 mg, 0.192 mmol). The reaction mixture was stirred at 70° C. for 3 h. The mixture was diluted with water (10 mL) and extracted with EtOAc (3 x 10 mL).The organic layer was washed with brine (5 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude product was purified by prep-TLC (petroleum ether / EtOAc=2:1) to give tert-butyl ((4aR,5R,8R,19aS,E)-8-ethyl-18,18-dimethyl-6,21-dioxo-4,4a,7,8,9,10,11,12,19,19a,20,21-dodecahydro-3H,6H,18H-1,22-(epiethane[1,2]diylidene)-8,5-(imidomethyl)-14,16-vinylidenedipyrano[3,4-d:3',4'-j][1]oxa[6,12]diazacyclononadecin-29-ylidene)carbamate (4-14).
[0893] MS (ESI) m / z: 647.3 (M+H + )
[0894] 1H NMR (500MHz, chloroform-d) δ7.81(dd,J=2.0,8.5Hz,1H),7.01(s,1H),6.93(d,J=8.5Hz,1H),6.88(d,J=1.0Hz,1H),6.78(s,2 H),6.40(dd,J=7.0,10.0Hz,1H),6.13(d,J=8.50Hz,1H),5.37-5.44(m,1H),4.44(td,J=3.5,11.5Hz,1H),4.17-4.23 (m,2H),3.82(dt,J=5.0,9.5Hz,1H),2.71-2.79(m,2H),2.53(d,J=16.0Hz,1H),2.35(dd,J=6.5,13.0Hz,1H),2.07-2 .14(m,2H),1.78(dd,J=7.50,10.50Hz,4H),1.52(s,2H),1.49(s,9H),1.42(s,3H),1.37(s,3H),0.95(t,J=7.5Hz,3H)
[0895] Preparation of Example 4
[0896]
[0897] To a solution of tert-butyl((4aR,5R,8R,19aS,E)-8-ethyl-18,18-dimethyl-6,21-dioxo-4,4a,7,8,9,10,11,12,19,19a,20,21-dodecahydro-3H,6H,18H-1,22-(epiethane[1,2]diylidene)-8,5-(imidomethyl)-14,16-vinylidenedipyrano[3,4-d:3',4'-j][1] was added zinc(II) bromide (104 mg, 0.464 mmol) and oxa[6,12]diazacyclononadecin-29-ylidene)carbamate (4-14) (30 mg, 0.046 mmol) in DCM (3 mL) at 25 °C under N2 atmosphere. The mixture was stirred at 25° C. for 16 h. The solvent was evaporated under reduced pressure to give a crude product, and the residue was purified by reverse phase preparative HPLC (instrument, for example, column Welch Xtimate C18, 150 x 25 mm, 5 μm; conditions water (TFA)-ACN, starting B 25; stop B55, gradient time (min) 11; 100% B hold time (min) 2, flow rate (mL / min) 25, injection 1), to obtain (4aR,5R,8R,19aS)-8-ethyl-29-imino-18,18-dimethyl-4,4a,7,8,9,10,11,12,18,19,19a,20-dodecahydro-3H,6H,21H-1,22-(epiethane[1,2]diylidene)-8,5-(bridged iminobridged methylene)-14,16-bridged vinylidenedipyrano[3,4-d:3',4'-j][1]oxa[6,12]diazacyclononadecin-6,21-dione (Example 4).
[0898] MS (ESI) m / z: 547.2 (M+H + )
[0899] 1H NMR (500MHz, methanol-d4) δ8.55(d,J=8.5Hz,1H),7.73(dd,J=2.0,8.5Hz,1H),7.45(d,J=1.5Hz,1H),6.94(d,J=8.50Hz,1 H),6.86(d,J=2.5Hz,1H),6.76-6.82(m,1H),6.70(d,J=9.0Hz,1H),5.35-5.40(m,1H),5.24-5.32(m,1H),4.47(td, J=4.5,11.50Hz,1H),4.13-4.21(m,2H),3.90-3.92(m,1H),2.75-2.88(m,2H),2.60-2.72(m,1H),2.22-2.31(m,1H) ,2.15(dd,J=6.5,13.0Hz,1H),1.66-1.85(m,7H),1.47-1.60(m,2H),1.40(s,3H),1.33(s,3H),0.97(t,J=7.5Hz,3H)
[0900] Example 5
[0901]
[0902] (11R,14R,14aR,21aS)-11-ethyl-16,16-difluoro-24-imino-2,2-dimethyl-1,2,7,8,9,10,11,12,15,16,21,21a-dodecahydro-13H-11,14-(imidomethyl)-4,6:17,19-diavinylidenecyclopenta[b]pyrano[4,3-h][1,7]diazacyclooctadecene-13,20(14aH)-dione
[0903] Preparation of compound 5-2
[0904]
[0905] A solution of 5-bromo-2,3-dihydro-1H-indene-1-one (50 g, 237 mmol), ethane-1,2-dithiol (5-1) (26.6 mL, 317 mmol) and 4-methylbenzenesulfonic acid (8.16 g, 47.4 mmol) in toluene (500 mL) was heated to 130 ° C for 16 h using a Dean-Stark apparatus. TLC showed that the reaction was complete. The cooled solution was washed with 10% NaOH (600 mL) and the aqueous layer was extracted with DCM (3×600 mL). The combined organic layers were washed with brine (300 mL), dried over Na2SO4, filtered and the solvent was evaporated under reduced pressure to give the crude product. The product was purified by flash silica gel chromatography ( 330g The crude product was purified by silica gel flash column (gradient elution with 10% EtOAc / petroleum ether @ 60 mL / min) to afford 5-bromo-2,3-dihydrospiro[indene-1,2'-[1,3]dithiolane] (5-2).
[0906] MS (ESI) m / z 286.9, 288.9 (M+H) +
[0907] 1 H NMR (500 MHz, chloroform-d) δ 7.40-7.44 (m, 1H), 7.31-7.38 (m, 2H), 3.50-3.56 (m, 2H), 3.40-3.47 (m, 2H), 2.96 (t, J = 6.5 Hz, 2H), 2.69 (t, J = 6.5 Hz, 2H)
[0908] Preparation of compound 5-3
[0909]
[0910] A solution of 1,3-dibromo-5,5-dimethylhydantoin (194 g, 679 mmol) in anhydrous CHCl (700 mL) was cooled to -70°C in a dry ice-acetone bath. Pyridine hydrofluoride (57.4 mL, 226 mmol) was added dropwise under an N atmosphere while the temperature was below -65°C, and the mixture was stirred at -70°C for 30 min. A solution of 5-bromo-2,3-dihydrospiro[indene-1,2'-[1,3]dithiolane](5-2) (65 g, 226 mmol) in CHCl (200 mL) was then added dropwise, and the mixture was stirred at -70°C for 4 h and then at 25°C overnight. TLC indicated the reaction was complete. The mixture was poured into a solution of 39% NaHSO (600 mL) in NaOH (2 M, 300 mL). The aqueous layer was extracted with CH2Cl2 (2×600 mL), the combined organic layers were washed with brine (300 mL), dried over Na2SO4, filtered and the solvent was evaporated under reduced pressure to give the crude product. The crude product was purified by flash silica gel chromatography ( 220g The crude product was purified by silica gel flash column (gradient elution with 100% petroleum ether @ 60 mL / min) to afford 2,5-dibromo-1,1-difluoro-2,3-dihydro-1H-indene (5-3).
[0911] No LCMS signal.
[0912] 1 H NMR (500 MHz, chloroform-d) δ 7.52-7.58 (m, 1H), 7.47 (d, J = 6.5 Hz, 2H), 4.57 (tt, J = 7.0, 10.5 Hz, 1H), 3.57 (ddd, J = 2.0, 7.5, 16.5 Hz, 1H), 3.27 (dd, J = 7.0, 16.5 Hz, 1H)
[0913] Preparation of compound 5-4
[0914]
[0915] To a solution of 2,5-dibromo-1,1-difluoro-2,3-dihydro-1H-indene (5-3) (60 g, 192 mmol) in DCM (600 mL) was added DBU (43.5 mL, 289 mmol). The mixture was stirred at 25 ° C for 16 h. LCMS showed the desired product mass. Water (600 mL) was added and the mixture was acidified to pH = 7 with concentrated hydrochloric acid. The mixture was filtered through celite, the aqueous layer was extracted with CH2Cl2 (2×600 mL), the combined organic layers were washed with brine (300 mL), dried over Na2SO4, filtered and the solvent was evaporated under reduced pressure to give the crude product. The product was purified by flash silica gel chromatography ( 330g The crude product was purified by silica gel flash column (gradient elution with 100% petroleum ether @ 50 mL / min) to afford 5-bromo-1,1-difluoro-1H-indene (5-4).
[0916] No LCMS signal.
[0917] 1 H NMR (500 MHz, chloroform-d) δ 7.41 (dd, J = 1.5, 8.0 Hz, 1H), 7.29-7.35 (m, 2H), 6.75 (d, J = 6.0 Hz, 1H), 6.22 (d, J = 6.0 Hz, 1H)
[0918] Preparation of compound 5-5
[0919]
[0920] To a solution of 5-bromo-1,1-difluoro-1H-indene (5-4) (15 g, 64.9 mmol) in iPrOH (250 mL) bubbling with oxygen for 1 h was added phenylsilane (14.05 g, 130 mmol) and Mn(TMHD) 3 (3.93 g, 6.49 mmol) and stirred at 0 ° C for 2 h under oxygen (15 psi). TLC showed that the reaction was complete. The mixture was quenched with water (300 mL) and extracted with EtOAc (3×300 mL). The organic layer was washed with brine (300 mL), dried over Na2SO4, filtered and the solvent was evaporated under reduced pressure to give the crude product. The product was purified by flash silica gel chromatography ( 40g The crude product was purified by silica gel flash column (gradient elution with 17% EtOAc / petroleum ether @ 50 mL / min) to give a mixture of 6-bromo-3,3-difluoro-2,3-dihydro-1H-inden-1-ol (5-5) and 5-bromo-1,1-difluoro-2,3-dihydro-1H-inden-2-ol (5-5a) (5-5:5-5a=7:2).
[0921] 1 H NMR (500 MHz, chloroform-d) δ 7.68 (s, 1H), 7.59-7.62 (m, 1H), 7.43-7.46 (m, 1H), 5.31 (q, J = 6.0 Hz, 1H), 3.01-3.12 (m, 1H), 2.49 (dq, J = 5.0, 14.5 Hz, 1H)
[0922] Preparation of compound 5-6
[0923]
[0924] To a solution of a mixture of 6-bromo-3,3-difluoro-2,3-dihydro-1H-inden-1-ol and 5-bromo-1,1-difluoro-2,3-dihydro-1H-inden-2-ol (11.56 g, 47.3 mmol) (5-5:5-5a=7:2) in MeOH (150 mL) and DMSO (15 mL) was added [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (2.64 g, 3.61 mmol) and triethylamine (15.67 mL, 108 mmol) at 20° C. under an Ar atmosphere, and the mixture was stirred at 80° C. under a CO (3.5 mbar) atmosphere for 48 h. TLC showed that the reaction was complete. After cooling, the mixture was filtered through celite and diluted with water (200 mL), extracted with EtOAc (3×200 mL), dried over Na 2 SO 4 , filtered and the solvent evaporated under reduced pressure to give the crude product. The product was purified by flash chromatography on silica gel ( 120g The crude product was purified by silica gel flash column, 17% EtOAc / petroleum ether gradient elution @ 80 mL / min) to give a mixture of 1,1-difluoro-3-hydroxy-2,3-dihydro-1H-indene-5-carboxylic acid methyl ester (5-6) and 1,1-difluoro-2-hydroxy-2,3-dihydro-1H-indene-5-carboxylic acid methyl ester (5-6a) (5-6:5-6a=3:1).
[0925] 1 H NMR (500 MHz, chloroform-d) δ 8.21 (s, 1H), 8.14 (d, J = 8.0 Hz, 1H), 7.65 (d, J = 8.0 Hz, 1H), 5.37 (quin, J = 6.0 Hz, 1H), 3.96 (s, 3H), 3.05-3.17 (m, 1H), 2.54 (dq, J = 5.0, 14.5 Hz, 1H)
[0926] Preparation of compound 5-7_P1
[0927]
[0928] A mixture of 1,1-difluoro-3-hydroxy-2,3-dihydro-1H-indene-5-carboxylic acid methyl ester and 1,1-difluoro-2-hydroxy-2,3-dihydro-1H-indene-5-carboxylic acid methyl ester (8.3 g, 36.36 mmol) (5-6:27-6a=3:1) was separated by SFC (column: Chiralpak AD-3 150× 4.6 mm ID, 3 μm, mobile phase: A: CO2 B: isopropanol (0.05% DEA), gradient: from 5% to 40% B in 5 min and from 40% to 5% B in 0.5 min, then kept at 5% B for 1.5 min, flow rate: 2.5 mL / min, column temperature: 35° C.) to give the product (S)-1,1-difluoro-3-hydroxy-2,3-dihydro-1H-indene-5-carboxylic acid methyl ester. Methyl difluoro-3-hydroxy-2,3-dihydro-1H-indene-5-carboxylate (5-7_P1, desired product) (peak 1, Rt = 2.577), methyl (R)-1,1-difluoro-3-hydroxy-2,3-dihydro-1H-indene-5-carboxylate (5-7_P2) (peak 2, Rt = 2.944) and a mixture of (5-7_P2 and 5-6a) (2 g, 8.77 mmol). The mixture (5-7_P2 and 5-6a) was separated by SFC (column: Cellulose 2150x 4.6mm ID, 5μm, mobile phase: A: CO2 B: MeOH (0.05% DEA), gradient: from 5% to 40% B in 5 min and from 40% to 5% B in 0.5 min, then kept at 5% B for 1.5 min, column temperature: 35°C) to give 1,1-difluoro-2-hydroxy-2,3-dihydro-1H-indene-5-carboxylate (5-6a).
[0929] (5-7_P1): 1 H NMR (500 MHz, chloroform-d) δ 8.21 (s, 1H), 8.15 (d, J = 8.0 Hz, 1H), 7.65 (d, J = 8.0 Hz, 1H), 5.37 (q, J = 6.0 Hz, 1H), 3.96 (s, 3H), 3.06-3.17 (m, 1H), 2.54 (dq, J = 5.0, 14.5 Hz, 1H)
[0930] (5-7_P2): 1 H NMR (500 MHz, chloroform-d) δ 8.20 (s, 1H), 8.13 (d, J = 8.0 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 5.36 (q, J = 5.5 Hz, 1H), 3.95 (s, 3H), 3.05-3.17 (m, 1H), 2.54 (dq, J = 5.0, 14.5 Hz, 1H)
[0931] (5-6a): 1H NMR (500 MHz, chloroform-d) δ 8.05 (d, J = 8.0 Hz, 1H), 7.98 (s, 1H), 7.64 (d, J = 8.0 Hz, 1H), 4.53-4.68 (m, 1H), 3.95 (s, 3H), 3.40 (dd, J = 7.0, 16.0 Hz, 1H), 2.95 (dd, J = 5.0, 16.5 Hz, 1H)
[0932] Preparation of Compound 5-8
[0933]
[0934] To a solution of (S)-1,1-difluoro-3-hydroxy-2,3-dihydro-1H-indene-5-carboxylic acid methyl ester (5-7_P1) (585 mg, 2.56 mmol), (R,E)-(4-(but-3-en-1-yl)-4-ethyl-6-oxotetrahydropyrimidin-2(1H)-ylidene)carbamic acid tert-butyl ester (INT-2) (757 mg, 2.56 mmol) and Ph3P (1009 mg, 3.85 mmol) in THF (10 mL) was added DIAD (0.997 mL, 5.13 mmol) dropwise at 0 ° C under N2 atmosphere, and the mixture was stirred at 18 ° C for 2 h. TLC showed no SM. The mixture was concentrated in vacuo and purified by flash silica gel chromatography ( 20g The residue was purified by silica gel flash column (20% EtOAc / petroleum ether gradient elution @ 60 mL / min) to give the crude product. 20g The crude product was then purified using a silica gel flash column with a DCM gradient elution @ 60 mL / min to afford the product (R)-3-((R,E)-4-(but-3-en-1-yl)-2-((tert-butoxycarbonyl)imino)-4-ethyl-6-oxotetrahydropyrimidin-1(2H)-yl)-1,1-difluoro-2,3-dihydro-1H-indene-5-carboxylic acid methyl ester (5-8).
[0935] MS (ESI) m / z 506.2 (M+H) +
[0936] 1H NMR(400MHz,chloroform-d)δ10.08(br s,1H),8.07(d,J=8.0Hz,1H),7.78(s,1H),7.66(d,J=8.0Hz,1H),6.74(q,J=7.2Hz,1H),5.80-5.87(m,1H),4.95-5.21(m,2H),4.05 -4.19(m,1H),3.91(s,3H),2.92-3.14(m,2H),2.58(s,2H),2.07-2.19(m,2H),1.63-1.78(m,4H),1.52(s,9H),0.97(t,J=7.6Hz,3H)
[0937] Preparation of Compound 5-9
[0938]
[0939] To a solution of (R)-3-((R,E)-4-(but-3-en-1-yl)-2-((tert-butoxycarbonyl)imino)-4-ethyl-6-oxotetrahydropyrimidin-1(2H)-yl)-1,1-difluoro-2,3-dihydro-1H-indene-5-carboxylic acid methyl ester (5-8) (900 mg, 1.780 mmol) in THF (9 mL) was added potassium trimethylsilanol (1370 mg, 10.68 mmol). The reaction was stirred at 18°C for 0.5 h. LCMS showed the desired mass. H3PO4 (0.1 g / mL in water) was added to adjust the pH to approximately 6-7, and the mixture was then quenched with water (10 mL) and extracted with EtOAc (3 x 10 mL). The organic layer was washed with brine (10 mL), dried over Na2SO4, filtered and concentrated in vacuo to give the product (R)-3-((R,E)-4-(but-3-en-1-yl)-2-((tert-butoxycarbonyl)imino)-4-ethyl-6-oxotetrahydropyrimidin-1(2H)-yl)-1,1-difluoro-2,3-dihydro-1H-indene-5-carboxylic acid (5-9).
[0940] MS (ESI) m / z 492.1 (M+H) +
[0941] 1H NMR(400MHz,chloroform-d)δ10.08(br s,1H),8.06(d,J=8.0Hz,1H),7.82(s,1H),7.65(d,J=8.0Hz,1H),6.72-6.77(m,1H),5.80-5.89(m,1H),4.99-5.1 6(m,2H),2.98-3.14(m,2H),2.59(s,2H),2.11-2.13(m,2H),1.64-1.83(m,4H),1.53(s,9H),0.98(t,J=7.6Hz,3H)
[0942] Preparation of Compound 5-10
[0943]
[0944] To a solution of (R)-3-((R,E)-4-(but-3-en-1-yl)-2-((tert-butoxycarbonyl)imino)-4-ethyl-6-oxotetrahydropyrimidin-1(2H)-yl)-1,1-difluoro-2,3-dihydro-1H-indene-5-carboxylic acid (5-9) (0.87 g, 1.770 mmol), EDC (1.697 g, 8.85 mmol), and 1H-benzo[d][1,2,3]triazol-1-ol (0.718 g, 5.31 mmol) in THF (15 mL) was added DIEA (2.473 mL, 14.16 mmol) and (S)-2,2-dimethyl-6-vinylchroman-4-amine (0.396 g, 1.947 mmol). The reaction was stirred at 18° C. for 12 h. LCMS showed the desired mass. The mixture was quenched with water (15 mL) and extracted with EtOAc (3×15 mL). The organic layer was washed with brine (10 mL), dried over Na 2 SO 4 , filtered and concentrated in vacuo. The product was purified by flash chromatography on silica gel ( 12g The crude product was purified by silica gel flash column (gradient elution with 17% EtOAc / petroleum ether @ 60 mL / min) to afford the product tert-butyl ((R,E)-4-(but-3-en-1-yl)-1-((R)-6-(((S)-2,2-dimethyl-6-vinylchroman-4-yl)carbamoyl)-3,3-difluoro-2,3-dihydro-1H-inden-1-yl)-4-ethyl-6-oxotetrahydropyrimidin-2(1H)-ylidene)carbamate (5-10).
[0945] MS (ESI) m / z 677.4 (M+H) +
[0946] 1H NMR (400 MHz, chloroform-d) δ 10.08 (br s,1H),7.72-7.78(m,1H),7.61-7.69(m,2H),7.28-7.34(m,2H),6.81(d,J=8. 4Hz,1H),6.76-6.77(m,1H),6.58-6.62(m,1H),6.22(brd,J=8.8Hz,1H),5.72 -5.77(m,1H),5.46-5.61(m,2H),5.11(d,J=11.2Hz,1H),5.06-5.08(m,1H),4 .97-5.00(m,1H),2.96-3.14(m,2H),2.58(s,2H),2.29-2.34(m,1H),2.10(br d,J=6.0Hz,2H),1.71-1.81(m,1H),1.63-1.74(m,4H),1.52(s,9H),1.46(s,3H),1.38(s,3H),0.96(t,J=7.6Hz,3H).
[0947] Preparation of compound 5-11
[0948]
[0949] To a solution of tert-butyl ((R,E)-4-(but-3-en-1-yl)-1-((R)-6-(((S)-2,2-dimethyl-6-vinylchroman-4-yl)carbamoyl)-3,3-difluoro-2,3-dihydro-1H-inden-1-yl)-4-ethyl-6-oxotetrahydropyrimidin-2(1H)-ylidene)carbamate (5-10) (1 g, 1.478 mmol) in DCE (500 mL) was added [1,3-bis(2,6-isopropylphenyl)-2-imidazolidinylidene]dichloro(2-isopropoxyphenylmethylene)ruthenium(II) (0.105 g, 0.148 mmol). The reaction mixture was stirred at 50 ° C for 4 h under N2 atmosphere. LCMS showed the desired mass. The mixture was concentrated in vacuo and purified by flash silica gel chromatography ( 12g The crude product was purified by silica gel flash column with 15% EtOAc / petroleum ether gradient elution @ 60 mL / min to give tert-butyl ((7Z,11R,14R,14aR,21aS,24E)-11-ethyl-16,16-difluoro-2,2-dimethyl-13,20-dioxo-1,2,10,11,12,13,14a,15,16,20,21,21a-dodecahydro-9H-11,14-(imidomethyl)-4,6:17,19-divinylidenecyclopenta[b]pyrano[4,3-h][1,7]diazacyclooctadecin-24-ylidene)carbamate (5 -11a, cis-olefin; minor product) and tert-butyl ((7E,11R,14R,14aR,21aS,24E)-11-ethyl-16,16-difluoro-2,2-dimethyl-13,20-dioxo-1,2,10,11,12,13,14a,15,16,20,21,21a-dodecahydro-9H-11,14-(imidomethyl)-4,6:17,19-diavinylidenecyclopenta[b]pyrano[4,3-h][1,7]diazacyclooctadecin-24-ylidene)carbamate (5-11, trans-olefin; major product).
[0950] (5-11a, cis-olefin): MS (ESI) m / z 649.3 (M+H) +
[0951] 1 H NMR (400 MHz, chloroform-d) δ 10.12 (s, 1H), 8.06 (d, J = 7.6 Hz, 1H), 7.73 (d, J = 8.0 Hz, 1H), 7.17 (s, 1H), 6.99-7.01 (m, 1H), 6.84 (d, J = 8.4 Hz, 1H), 6.64-6.76 (m, 1H), 6.39 (d, J = 11.2 Hz, 1H), 6.28 (br d, J = 8.8 Hz, 1H), 5.58-5.61 (m, 1H), 5.41-5.45 (m, 1H), 3.01-3.13 (m, 2H), 2.66 (d, J = 16.4 Hz, 1H), 2.42-2.45 (m, 2H), 2.20-2.30 (m, 1H), 1.96-2.04 (m, 1H), 1.63-1.86 (m, 5H), 1.51 (s, 9H), 1.46 (s, 3H), 1.39 (s, 3H), 1.02 (t, J = 7.2 Hz, 3H) (5-11, trans olefin): MS (ESI) m / z 649.3 (M+H) +
[0952] 1 H NMR (400 MHz, chloroform-d) δ 10.15 (s, 1H), 7.90 (d, J = 8.0 Hz, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.35 (s, 1H), 7.23 (s, 1H), 7.06 (dd, J = 2.0, 8.4 Hz, 1H), 6.73 (d, J = 8.4 Hz, 1H), 6.61-6.70 (m, 1H), 6.39 (d, J = 15.6 Hz, 1H), 6.06 (d, J = 9.2 Hz, 1H), 5 .68-5.89(m,1H),5.47-5.50(m,1H),2.95-3.14(m,2H),2.68(d,J=16.4Hz,1H),2.55(d,J=16.4Hz,1H),2.32-2. 35(m,3H),1.85-1.97(m,1H),1.64-1.76(m,4H),1.47(s,3H),1.41(s,9H),1.40(brs,3H),0.97(t,J=7.6Hz,3H)
[0953] Preparation of compound 5-12
[0954]
[0955] To a solution of tert-butyl ((7E,11R,14R,14aR,21aS,24E)-11-ethyl-16,16-difluoro-2,2-dimethyl-13,20-dioxo-1,2,10,11,12,13,14a,15,16,20,21,21a-dodecahydro-9H-11,14-(imidomethyl)-4,6:17,19-diavinylidenecyclopenta[b]pyrano[4,3-h][1,7]diazacyclooctadecin-24-ylidene)carbamate (5-11) (780 mg, 1.202 mmol) in MeOH (10 mL) was added 10% Pd—C (128 mg, 0.120 mmol) under N2 atmosphere. The mixture was degassed and backfilled with H2 (three times). Under an atmosphere of H2 (15 psi), the reaction mixture was stirred at 18 ° C for 10 min. LCMS showed that the reaction was complete. The mixture was filtered and the concentrated filtrate was removed to obtain tert-butyl ((11R,14R,14aR,21aS,E)-11-ethyl-16,16-difluoro-2,2-dimethyl-13,20-dioxo-1,2,8,9,10,11,12,13,14a,15,16,20,21,21a-tetradecahydro-7H-11,14-(imidomethyl)-4,6:17,19-divinylenecyclopenta[b]pyrano[4,3-h][1,7]diazacyclooctadecin-24-ylidene)carbamate (5-12), which was used directly in the next step.
[0956] MS (ESI) m / z 651.4 (M+H) +
[0957] Preparation of Example 5
[0958]
[0959] A solution of tert-butyl ((11R,14R,14aR,21aS,E)-11-ethyl-16,16-difluoro-2,2-dimethyl-13,20-dioxo-1,2,8,9,10,11,12,13,14a,15,16,20,21,21a-tetradecahydro-7H-11,14-(imidomethyl)-4,6:17,19-divinylidenecyclopenta[b]pyrano[4,3-h][1,7]diazacyclooctadecin-24-ylidene)carbamate (5-12) (700 mg, 1.076 mmol) in HCl-dioxane (4N, 10 mL) was stirred at 18 ° C for 12 h. LCMS showed that the reaction was complete. The solvent was evaporated under reduced pressure to give the crude product. The precipitate was separated by reverse phase preparative HPLC (instrument: 3-101 (EK); method: phase separation column Boston Uni C18 150 x 40 mm, 5 μm; conditions: water (0.04% HCl)-ACN, starting B 33, ending B 63, gradient time (min) 10, 100% B hold time (min) 2, flow rate (mL / min) 60, injection 2) The residue was purified to give (11R,14R,14aR,21aS)-11-ethyl-16,16-difluoro-24-imino-2,2-dimethyl-1,2,7,8,9,10,11,12,15,16,21,21a-dodecahydro-13H-11,14-(imidomethyl)-4,6:17,19-diazovinylcyclopenta[b]pyrano[4,3-h][1,7]diazacyclooctadecine-13,20(14aH)-dione Example 5.
[0960] MS (ESI) m / z 551.3 (M+H) +
[0961] 1H NMR (400 MHz, methanol-d4) δ 7.98 (d, J = 8.0 Hz, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.62 (s, 1H), 7.03 (s, 1H), 6.97-7.00 (m, 1H), 6.70 (d, J = 8.0 Hz, 1H), 5.72 (br d,J=6.4Hz,1H),5.42(dd,J=6.4,11.6Hz,1H),3.22-3.31(m,1H),2.95-3.15(m,2H),2.46-2.63(m,3H),2.1 4-2.17(m,1H),1.73-1.91(m,5H),1.55-1.72(m,2H),1.39-1.51(m,5H),1.33(s,3H),0.98(t,J=7.2Hz,3H)
[0962] The compounds in Table 1 were prepared in an analogous manner to that described in Example 1 and / or Example 5. The isomers were separated by preparative HPLC and / or preparative chiral SFC.
[0963] In chemical structure diagrams, an asterisk (*) may be used to indicate the position of a chiral center.
[0964] Table 1
[0965]
[0966]
[0967]
[0968]
[0969]
[0970]
[0971]
[0972]
[0973]
[0974]
[0975]
[0976]
[0977]
[0978]
[0979]
[0980]
[0981]
[0982]
[0983]
[0984]
[0985]
[0986]
[0987]
[0988]
[0989]
[0990]
[0991]
[0992]
[0993]
[0994]
[0995]
[0996]
[0997]
[0998]
[0999]
[1000]
[1001]
[1002]
[1003]
[1004]
[1005]
[1006]
[1007]
[1008]
[1009]
[1010]
[1011]
[1012]
[1013]
[1014]
[1015]
[1016]
[1017]
[1018]
[1019]
[1020]
[1021]
[1022]
[1023]
[1024]
[1025]
[1026]
[1027]
[1028]
[1029]
[1030]
[1031]
[1032]
[1033]
[1034]
[1035]
[1036]
[1037]
[1038]
[1039]
[1040]
[1041]
[1042]
[1043]
[1044]
[1045]
[1046]
[1047]
[1048]
[1049]
[1050]
[1051]
[1052]
[1053]
[1054]
[1055]
[1056]
[1057]
[1058]
[1059]
[1060]
[1061]
[1062]
[1063] Evaluation of antiparasitic efficacy in the parasite LDH growth assay (parasite assay)
[1064] Parasite stocks were maintained at a hematocrit of 4% in RPMI-Hepes medium 30 buffered with sodium bicarbonate and supplemented with 5% heat-inactivated human serum and 0.5% albumin.
[1065] Approximately 42 hours before the start of the potency assay, parasites were synchronized with 5% sorbitol to select for ring-stage parasites. On the day of the assay, blood smears from the parasite culture were Giemsa-stained and counted. The parasitemia was 35, adjusted to 0.7% ring, and the hematocrit was diluted to 2% using sodium bicarbonate-buffered RPMI-Hepes medium supplemented with 5% heat-inactivated human serum and 0.5% albumin. Then, 30 μL of the diluted parasites were added to 10 μL of medium plus compound in a pre-prepared Greiner TC assay plate. The parasite assay plate was placed in a single-layer, aerated humidified chamber and incubated at 37°C for 72 hours. After 72 hours of growth, the assay plate was sealed with parafilm and frozen flat in a single row at -80°C overnight. The next day, the assay plate was thawed at room temperature for 4 hours before the LDH assay was performed to measure parasite growth.
[1066] The EC50 results are shown in Table 2.
[1067] Table 2
[1068]
[1069]
[1070]
[1071]
[1072]
[1073]
[1074]
[1075]
Claims
1. A compound having structural formula (I): or a pharmaceutically acceptable salt thereof, in: A is a straight chain or branched chain, saturated or unsaturated (C 3 -C 10 ) alkylene, phenyl (C 3 -C 10 ) alkylene or cycloalkyl (C 3 -C 10 ) alkylene, which contains at least one –CH 2 -group, in which one or more additional –CH 2 - groups are optionally and independently selected from O, S, NR, CONR, NRCO, SO 2 and SO 2 NR, and one or more hydrogen atoms along A may be independently selected from hydroxyl, halogen and C 1-3 Group substitution of haloalkyl; X is a bond, C(R 14 ) 2 , O, S, SO, SO 2 or NH; Y is CR 9 or N, where when Y is N, Z is CR 11 And V is CR 10 ; V is CR 10 or N, where when V is N, Z is CR 11 And Y is CR 9 ; Z is CR 11 or N, where when Z is N, V is CR 10 And Y is CR 9 ; R is hydrogen, C 1 -C 6 AlkylCOOH, COOH, C 3 -C 6 Cycloalkyl, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 1 -C 6 Alkyl OH, COC 1 -C 6 Alkyl or COOC 1 -C 6 alkyl; R a For hydrogen, halogen, CN, OH, C 1 -C 6 Alkoxy, C 1 -C 6 Alkyl OC 1 -C 6 Alkyl, C 1 -C 6 AlkylCOOH, COOH, oxo, COOC 1 -C 6 Alkyl, C 1 -C 6 Alkyl COOC 1 -C 6 Alkyl, C 3 -C 6 Cycloalkyl, C 1 -C 6 Alkyl C 3 -C 6 Cycloalkyl, C 1 -C 6 Alkyl, -C 1 -C 6 Alkyl O halide C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 1 -C 6 Alkyl OH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C 1 -C 6 Alkyl N(R 7 )(R 8 ), or when with R b Together, they form C 3 -C 6 Cycloalkyl or heterocycloalkyl, wherein the C 3 -C 6 The cycloalkyl or heterocycloalkyl group is unsubstituted or substituted with one or two substituents selected from the group consisting of halogen, CN, OH, C 1 -C 6 Alkoxy, C 1 -C 6 Alkyl OC 1 -C 6 Alkyl, C 1 -C 6 AlkylCOOH, COOH, oxo, COOC 1 -C 6 Alkyl, C 1 -C 6 Alkyl COOC 1 -C 6 Alkyl, C 3 -C 6 Cycloalkyl, C 1 -C 6 Alkyl C 3 -C 6 Cycloalkyl, C 1 -C 6 Alkyl, -C 1 -C 6 Alkyl O halide C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 1 -C 6 Alkyl OH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) and C 1 -C 6 Alkyl N(R 7 )(R 8 ); R b For hydrogen, halogen, CN, OH, C 1 -C 6 Alkoxy, C 1 -C 6 Alkyl OC 1 -C 6 Alkyl, C 1 -C 6 AlkylCOOH, COOH, oxo, COOC 1 -C 6 Alkyl, C 1 -C 6 Alkyl COOC 1 -C 6 Alkyl, C 3 -C 6 Cycloalkyl, C 1 -C 6 Alkyl C 3 -C 6 Cycloalkyl, C 1 -C 6 Alkyl, -C 1 -C 6 Alkyl O halide C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 1 -C 6 Alkyl OH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C 1 -C 6 Alkyl N(R 7 )(R 8 ), or when with R a Together, they form C 3 -C 6 Cycloalkyl or heterocycloalkyl, wherein the C 3 -C 6 The cycloalkyl or heterocycloalkyl group is unsubstituted or substituted with one or three substituents selected from the group consisting of halogen, CN, OH, C 1 -C 6 Alkoxy, C 1 -C 6 Alkyl OC 1 -C 6 Alkyl, C 1 -C 6 AlkylCOOH, COOH, oxo, COOC 1 -C 6 Alkyl, C 1 -C 6 Alkyl COOC 1 -C 6 Alkyl, C 3 -C 6 Cycloalkyl, C 1 -C 6 Alkyl C 3 -C 6 Cycloalkyl, C 1 -C 6 Alkyl, -C 1 -C 6 Alkyl O halide C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 1 -C 6 Alkyl OH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) and C 1 -C 6 Alkyl N(R 7 )(R 8 ); R 3 For hydrogen, halogen, CN, OH, C 1 -C 6 Alkoxy, C 1 -C 6 Alkyl OC 1 -C 6 Alkyl, C 1 -C 6 AlkylCOOH, COOH, C 3 -C 6 Cycloalkyl, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 1 -C 6 Alkyl OH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ), C 1 -C 6 Alkyl N(R 7 )(R 8 ), C 1 -C 6 Alkyl (OCH 2 CH 2 ) n N(R 7 )(R 8 ) or C 1 -C 6 Alkyl O halide C 1 -C 6 Alkyl, or when with R 4 Together, they form C 3 -C 6 Cycloalkyl or C 3 -C 6 Heterocycloalkyl; R 4 For hydrogen, halogen, CN, OH, C 1 -C 6 Alkoxy, C 1 -C 6 Alkyl OC 1 -C 6 Alkyl, C 1 -C 6 AlkylCOOH, COOH, C 3 -C 6 Cycloalkyl, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 1 -C 6 Alkyl OH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ), C 1 -C 6 Alkyl N(R 7 )(R 8 ), C 1 -C 6 Alkyl (OCH 2 CH 2 ) n N(R 7 )(R 8 ) or C 1 -C 6 Alkyl O halide C 1 -C 6 Alkyl, or when with R 3 Together, they form C 3 -C 6 Cycloalkyl or C 3 -C 6 Heterocycloalkyl; R 7 For hydrogen, C 1 -C 6 AlkylCOOH, COOH, C 3 -C 6 Cycloalkyl, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 1 -C 6 Alkyl OH, COC 1 -C 6 Alkyl or COOC 1 -C 6 alkyl; R 8 For hydrogen, C 1 -C 6 AlkylCOOH, COOH, C 3 -C 6 Cycloalkyl, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 1 -C 6 Alkyl OH, COC 1 -C 6 Alkyl or COOC 1 -C 6 alkyl; R 9 For hydrogen, halogen, CN, OH, C 1 -C 6 Alkoxy, C 1 -C 6 Alkyl OC 1 -C 6 Alkyl, C 1 -C 6 AlkylCOOH, COOH, C 3 -C 6 Cycloalkyl, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 1 -C 6 Alkyl OH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C 1 -C 6 Alkyl N(R 7 )(R 8 ); R 10 For hydrogen, halogen, CN, OH, C 1 -C 6 Alkoxy, C 1 -C 6 Alkyl OC 1 -C 6 Alkyl, C 1 -C 6 AlkylCOOH, COOH, C 3 -C 6 Cycloalkyl, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 1 -C 6 Alkyl OH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C 1 -C 6 Alkyl N(R 7 )(R 8 ); R 11 For hydrogen, halogen, CN, OH, C 1 -C 6 Alkoxy, C 1 -C 6 Alkyl OC 1 -C 6 Alkyl, C 1 -C 6 AlkylCOOH, COOH, C 3 -C 6 Cycloalkyl, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 1 -C 6 Alkyl OH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C 1 -C 6 Alkyl N(R 7 )(R 8 ); R 12 For hydrogen, halogen, CN, OH, C 1 -C 6 Alkoxy, C 1 -C 6 Alkyl OC 1 -C 6 Alkyl, C 1 -C 6 AlkylCOOH, COOH, C 3 -C 6 Cycloalkyl, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 1 -C 6 Alkyl OH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C 1 -C 6 Alkyl N(R 7 )(R 8 ); R 13 For hydrogen, halogen, CN, OH, C 1 -C 6 Alkoxy, C 1 -C 6 Alkyl OC 1 -C 6 Alkyl, C 1 -C 6 AlkylCOOH, COOH, C 3 -C 6 Cycloalkyl, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 1 -C 6 Alkyl OH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C 1 -C 6 Alkyl N(R 7 )(R 8 ); R 14 Each occurrence of is independently selected from the group consisting of hydrogen, halogen, CN, OH, C 1 -C 6 Alkoxy, C 1 -C 6 Alkyl OC 1 -C 6 Alkyl, C 1 -C 6 AlkylCOOH, COOH, C 3 -C 6 Cycloalkyl, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 1 -C 6 Alkyl OH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) and C 1 -C 6 Alkyl N(R 7 )(R 8 ); R 15 For hydrogen, halogen, CN, OH, C 1 -C 6 Alkoxy, C 1 -C 6 Alkyl OC 1 -C 6 Alkyl, C 1 -C 6 AlkylCOOH, COOH, C 3 -C 6 Cycloalkyl, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 1 -C 6 Alkyl OH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) or C 1 -C 6 Alkyl N(R 7 )(R 8 ); R 16 Each occurrence of is independently selected from the group consisting of hydrogen, halogen, CN, OH, C 1 -C 6 Alkoxy, C 1 -C 6 Alkyl OC 1 -C 6 Alkyl, C 1 -C 6 AlkylCOOH, COOH, C 3 -C 6 Cycloalkyl, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 1 -C 6 Alkyl OH, CON(R 7 )(R 8 )、N(R 7 )(R 8 ) and C 1 -C 6 Alkyl N(R 7 )(R 8 ); m is 0 or 1; n is 1, 2, 3 or 4; and p is 0 or 1. 2 . The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 1, p is 1, and X is O.
3. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein m is 1, p is 1, and X is a bond.
4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R a With R b Together they form a heterocycloalkyl.
5. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R a With R b and together form a heterocycloalkyl group, wherein the heterocycloalkyl group is and wherein the heterocycloalkyl group is separated by two C 1 -C 6 Alkyl group substitution.
6. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R a With R b Together they form C 3 -C 6 Cycloalkyl.
7. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R a With R b Together they form C 3 -C 6 Cycloalkyl, wherein the cycloalkyl is And wherein the C 3 -C 6 The cycloalkyl groups are unsubstituted or substituted with OH.
8. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 3 For hydrogen, C 1 -C 6 Alkyl OC 1 -C 6 Alkyl or C 1 -C 6 Alkyl, or when with R 4 Together, they form C 3 -C 6 Heterocycloalkyl.
9. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 3 is hydrogen or C 1 -C 6 Alkyl, or when with R 4 Together, they form C 3 -C 6 Heterocycloalkyl.
10. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 All are halogen.
11. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 15 is hydrogen or C 1 -C 6 alkyl.
12. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 independently selected from the group consisting of hydrogen, halogen, OH, C 1 -C 6 Alkyl OH, C 1 -C 6 Alkyl alkoxy, C 1 -C 6 Alkyl OC 1 -C 6 Alkyl, C 1 -C 6 Alkyl, C 1 -C 6 Alkyl O halide C 1 -C 6 Alkyl, CON(C 1 -C 6 alkyl) 2 , C 1 -C 6 Alkyl N(R 7 )(R 8 ) and C 1 -C 6 Alkyl (OCH 2 CH 2 ) n N(R 7 )(R 8 ); R 7 For hydrogen, C 1 -C 6 AlkylCOOH, COOH, C 3 -C 6 Cycloalkyl, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 1 -C 6 Alkyl OH, COC 1 -C 6 Alkyl or COOC 1 -C 6 alkyl; R 8 For hydrogen, C 1 -C 6 AlkylCOOH, COOH, C 3 -C 6 Cycloalkyl, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 1 -C 6 Alkyl OH, COC 1 -C 6 Alkyl or COOC 1 -C 6 alkyl; and n is 3.
13. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 12 and R 13 independently selected from the group consisting of hydrogen, halogen, OH, C 1 -C 6 Alkyl OH, C 1 -C 6 Alkyl alkoxy and C 1 -C 6 Alkyl OC 1 -C 6 Alkyl and C 1 -C 6 alkyl.
14. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein X is C(R 14 ) 2 , R 14 independently selected from the group consisting of hydrogen, halogen, OH, C 1 -C 6 Alkyl OH, C 1 -C 6 Alkyl alkoxy, C 1 -C 6 Alkyl OC 1 -C 6 Alkyl and C 1 -C 6 alkyl.
15. The compound according to claim 1-14 or a pharmaceutically acceptable salt thereof, wherein Y is CH.
16. The compound according to claim 1-14, or a pharmaceutically acceptable salt thereof, wherein Z is CH.
17. The compound according to claim 1-14 or a pharmaceutically acceptable salt thereof, wherein V is CH.
18. The compound according to claim 1-14 or a pharmaceutically acceptable salt thereof, wherein A is a linear, saturated or unsaturated (C 3 -C 10 )alkylene.
19. The compound according to claim 1-14 or a pharmaceutically acceptable salt thereof, wherein A is a branched, saturated or unsaturated (C 3 -C 10 )alkylene.
20. The compound according to claim 1-14 or a pharmaceutically acceptable salt thereof, wherein A is 21. A compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof.
22. With style or a pharmaceutically acceptable salt thereof.
23. With style or a pharmaceutically acceptable salt thereof.
24. With style or a pharmaceutically acceptable salt thereof.
25. A method of treating Plasmodium infection or treating malaria, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound according to any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof.
26. A method of inhibiting plasmepsin X comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound according to any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof.
27. A method of inhibiting plasmepsin IX comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound according to any one of claims 1 to 24 or a pharmaceutically acceptable salt thereof.
28. A method for dual inhibition of plasmepsin X and plasmepsin IX, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound according to any one of claims 1 to 24 or a pharmaceutically acceptable salt thereof.
29. Use of a compound according to any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, for treating Plasmodium infection or malaria in a patient in need thereof.
30. Use of a compound according to any one of claims 1 to 24 or a pharmaceutically acceptable salt thereof for inhibiting plasmepsin X in a patient in need thereof.
31. Use of a compound according to any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, for inhibiting plasmepsin IX in a patient in need thereof.
32. Use of a compound according to any one of claims 1 to 24 or a pharmaceutically acceptable salt thereof for inhibiting plasmepsin IX and plasmepsin X in a patient in need thereof.
33. A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
34. A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier.
35. A method of treating Plasmodium infection or treating malaria comprising administering a compound according to claim 1 or a pharmaceutically acceptable salt thereof, and an effective amount of one or more additional anti-malarial drugs.
36. A method of treating malaria by inhibiting plasmepsin X, IX and at least one other mechanism, comprising administering a compound according to claim 1 or a pharmaceutically acceptable salt thereof, and an effective amount of an additional anti-malarial drug, wherein the additional anti-malarial drug acts by a mechanism other than inhibition of plasmepsin IX or plasmepsin X.
